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INTRODUCTION 
Infectious bovine keratoconjunctivitis (IBK) is an eye disease of cattle. It is of 
major economic importance for the cattle industry worldwide. Currently available 
topical antibiotic preparations do not maintain therapeutic levels for sufficient time 
to cure the disease with one application of drug. For this reason, repeated 
applications of drug are necessary for a period from 5 to 7 days (Slatter et al., 
1982c). 
Hughes and Pugh (1980) used plastic tubing to develop a ring device suitable 
for prolonged retention in the bovine eye. They suggested that if a suitable 
biodegradable matrix which released antibiotics for a prolonged period could be 
developed, this system would offer a method of treatment for IBK. The major 
advantages were that only one treatment would be necessary and if the device 
eroded and dissolved, no further handling of the cattle would be required. 
Sodium alginate has been investigated as a bioerodible material for ocular 
inserts for the delivery of various drugs (Michaels, 1975). The (alginate) ocular 
inserts in the form of an elliptical disc when inserted in a monkey's eye and a 
human eye released a drug (hydrocortisone) at a controlled rate and completely 
bioeroded in the eye at the termination of the therapeutic program. Hydrogel (a 
copolymer of hydroxyethyl methacrylate (HEMA) and methyl methacrylate 
(MMA)) has been used by Ryoo (1989) to develop an ocular controlled released 
system, and it has been shown to be a biocompatible material in the eye. Tylosin 
tartrate is commercially available as an agricultural antibiotic and is effective in the 
control of IBK in calves. It is a salt of tylosin which is a nontoxic antibiotic, 
nonirritating to the eye and conjunctival sac, stable and readily soluble in water 
(Ellis and Barnes, 1961). 
In this study, the objectives were (1) to develop an erodible ocular insert using 
the above materials for the controlled release of antibiotic (tylosin tartrate) in the 
period of one day to several days, (2) to evaluate the retention characteristics of 
such insert in the bovine eye, (3) to determine the degradation characteristics of 
the insert in vitro, (4) to evaluate the drug release properties of the insert in vitro, 
and (5) to evaluate the therapeutic effects of the insert on IBK using Holstein 
calves. 
In order to achieve maximum retention of the ocular insert in bovine eye, 
various formulations of sodium alginates were used to alter the physical properties 
of the insert (e.g., stiffness and flexibility). 
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Statement of the Problem 
Nature of the problem 
Infectious bovine keratoconjunctivitis (IBK) is commonly called pinkeye. The 
disease occurs perennially in all areas where cattle are raised. Pinkeye is rarely 
fatal, but it may result in a major economic loss associated with weight loss in beef 
herds and with a reduction in milk production in dairy cattle. 
Known conventional methods of treatment for IBK range from a topical 
application of eye drops, ointment, or spray to parenteral injection of a variety of 
antibiotics and sulfonamide. A disadvantage of such treatment methods has been 
the difficulty of both obtaining and maintaining a therapeutic concentration of the 
drug in the tears and the affected tissues, and therefore repeated applications are 
necessary. 
In recent years, significant advances have been made in the field of ocular 
drug delivery systems. Several ocular inserts were investigated as an alternative 
method to treat pinkeye (Hughes and Pugh, 1980; Ryoo, 1989). These devices have 
the added advantage of permitting slow release of drug over prolonged periods of 
time. A single such ocular insert can provide the complete ophthalmic dosage 
regimen for a particular time period, on the order of 24 hours or longer. More 
frequent repeated applications which are necessary with conventional methods are 
thus avoided. 
f 
4 
While the drug dispensing ocular inserts mentioned above have proved to be 
markedly superior to the conventional treatment methods, improvements need to 
be made. In general, these ocular inserts are fabricated of materials that are 
biologically inert and non-bioerodible in tear liquid. They remain intact during the 
course of therapy and have to be removed on termination of the treatment. This 
may be difficult or time-consuming. 
Approach to the problem 
Hughes and Pugh (1980) suggested that if an erodible ocular insert could be 
developed, this system would offer several advantages over those non-erodible 
devices previously tried in that only one treatment would be necessary, and if the 
device eroded and dissolved, no further handling of the cattle would be required. 
Recent work by Ryoo (1989) on a polyvinyl chloride (PVC) ring-shaped device, 
coated with hydrogel (a copolymer of hydroxyethyl methacrylate (HEMA) and 
methyl methacrylate (MMA)) containing tylosin tartrate (an antibiotic), indicated 
that ocular devices with an outside diameter in the range between 1.18 to 1.23 
times the eye size, and a thickness less than 2 mm, tended to be retained in the 
eyes of cattle for a period of several days or more. The hydrogel material used in 
the ring did not cause any eye irritation and was capable of sustaining the drug 
release of the antibiotic for the required period of interest for the IBK treatment. 
The drug release characteristics of tylosin tartrate from hydrogel particles confined 
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within an erodible crosslinked calcium alginate have been studied by Mahmoud 
(1988). After 5 days, the drug release rate still ranged from 15 to 29 Mg/hr. This 
was above the minimum therapeutic level of 1.3 Mg/hr required for the treatment 
of BBK (Ryoo, 1986). Crosslinked alginates have been used in the development of 
ocular inserts, and have shown to be capable of bioeroding in the eye within one 
day to several days (Michaels, 1975). In addition, these materials were harmless to 
the tissues of the eye. 
Based on the results of these previous investigations, the present research was 
designed to carry out a development task to produce and to evaluate the retention 
characteristics and treatment characteristics of the device. Along with these 
studies, degradation and drug release characteristics were determined. 
The ocular insert is in the form of a ring-shaped device to accommodate to the 
shape of the bovine eye. It consists of an outer crosslinked alginate membrane and 
a hydrogel-drug inner core. The hydrogel-dmg core is held in place by the alginate 
membrane. The outer membrane is a bioerodible rate-controlling barrier 
constructed of polyvalent metal ion crosslinked sodium alginate. The polyvalent 
metal ions used in this research are Ca.*^ and Al^\ The inner drug core consists of 
hydrogel particles (< 150 iim) having the antibiotic confined inside the 
hydrogel particles. The ocular insert is formulated to contain an initial drug load 
of 50 mg of antibiotic (tylosin tartrate) and is designed so that it is capable of 
eroding in the environment of the eye during the treatment period. Both the 
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hydrogel matrix and the alginate membrane are permeable to the passage of drug 
by diffusion, that is, molecules of drug can dissolve in and diffuse through these 
materials. However, like other membrane devices, the permeability of the 
membrane to the drug is expected to be lower than from the hydrogel matrix so 
that release of drug through the membrane is the drug release rate controlling 
factor from the ocular insert. When placed in an environment such as the bovine 
eye, the ocular insert disintegrates due to the displacement process of the 
polyvalent metal ions in the crosslinked alginate by the monovalent sodium ions in 
the tear solution. In this design, the crosslinked alginate membrane erodes and 
only the hydrogel-drug particles are left behind which can be washed away by tears. 
The finished ring devices were evaluated in calves eyes to determine their 
retention characteristics. The best prototype was then used for other studies such 
as the degradation study of the ocular insert, the in vitro drug release study, and 
the efficacy test of the ocular insert in treating IBK. 
In the retention study, the ocular devices were evaluated for the ease of 
insertion, amount of local reaction, and period of retention. Six Holstein calves 
were used and they were monitored twice daily for signs of irritation to the eye that 
might be caused by the inserts and for retention of the inserts. Various 
formulations of sodium alginates (based on mixtures of components of different 
degrees of polymerization) and various crosslinking times (using Ca^^ and/or Al^^ 
ions to replace Na"^ ions) were employed to produce inserts with different 
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mechanical properties in order to achieve a retention time long enough for the 
device to be elective in the treatment of IBK. A retention period from one day to 
several day was desirable. The formulation that produced ocular inserts with best 
retention charateristics was then used to fabricate ring-shaped devices for use in the 
efficacy test in treating bovine infected eyes, and for both the drug release study 
and the degradation test of the ocular insert. 
Since is was desired to develop an ocular drug delivery system that is capable 
of eroding in the environment of the eye, and does not have to be removed from 
the eye at the termination of treatment, the in vitro degradation study of the ocular 
insert was performed in order to determine whether the treatment device could 
erode within the given treatment period or at a point in time after the required 
therapy has been completed. The rate of biodégradation of the insert was 
determined by placing an ocular insert of known weight into a 0.9% by weight 
sodium chloride solution, shaking the solution and ocular insert in a heated water 
bath at 37° C, renewing the saline solution every 24 hours, and then weighing the 
sample (after drying) to obtain the weight loss, and hence obtain the erosion rate. 
The erosion rate and change in physical appearance of the eroded ocular insert 
form a basis for evaluating the degradation time of the bioerodible ocular device. 
The degradation time of the ocular insert was taken as the time for complete 
breakdown, fragmentation, or dissolution. 
In order to design an optimum release device for treating eye infections in 
cattle, it is very important to determine the drug release charateristics of the 
device. The variables influencing the release profile are the duration of the 
treatment of drug and minimum and maximum concentrations required in treating 
the disease within a given period, lyiosin has an inhibitory concentration of 0.63 
jLig/ml against Moraxella bovis (Leytem, 1984). If a tear flow rate of 2.0 ± 1.84 
ml/hr (Slatter and Edwards, 1982) is assumed, a minimum drug release rate of the 
order of 1.2 to 2.4 /ig/hr of tylosin tartrate is required (Ryoo, 1986). To ensure 
that a minimum release rate of the order of 1.2 to 2.4 fig/hr of tylosin tartrate is 
achieved for a duration of about 5 to 7 days, the overall rate of drug release from 
several ocular inserts with best retention characteristics was determined using an 
elution system. Mammalian Ringer's solution was used as elution medium to 
simulate the tear fluid. Samples of elution medium were collected every one hour 
for seven consecutive days. The amount of tylosin tartrate in the collected samples 
was analyzed by thin layer chromatography (TLC) technique. From the results of 
drug analysis, the release profile was obtained. This release profile determined the 
minimum concentration (or steady state concentration) and the optimum duration 
provided by the ocular device. 
In the infection study, eight Holstein calves were used. Four calves were used 
for the ocular insert study, and the other four calves were used for subconjunctival 
injection of antibiotic (Azimycin®) so that a comparison could be made between 
the new ring device method and a commonly used method of treatment of severe 
f  . . .  
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IBK infections in cattle. The eyes of all calves were preconditioned using 
ultraviolet radiation, followed by instillation of a Moraxella bovis inoculum. After 
inoculation, the build-up of the number of bacteria in the eyes was monitored 
by sampling the mucosal surface and tear fluid from the infected eyes. Samples 
were obtained twice during the first five days after inoculation (2 days apart). Also, 
clinical observations of the eyes were recorded on a daily basis. Five days after 
instilling the bacteria, the two groups of animals were treated as follows. For 
calves that were designated for the ring studies, both infected eyes received an 
ocular insert: one eye was treated with a medicated ring, and the other eye was 
used as a control which received a non-medicated ring. For the subconjunctival 
injection group, the treated eye was injected with 1 ml of Azimycin®, while the 
control eye was injected with 1 ml of sterile saline. After ring insertion or 
subconjunctival injection, samples were obtained for 3 consecutive days and then 
every two days for the next 4 days. Also, the clinical signs of the eyes were 
recorded on a daily basis for a period of five days and then on the seventh day. In 
addition, the presence of the ocular insert in the eyes of each of the four calves 
used for the ring study was monitored every day to obtain retention data of the 
device in infected animals. The ability of each treatment method to cure the 
infections completely or to reduce the number of bacteria to a negligible level 
determined the effectiveness of that treatment method. Also, the degree of 
effectiveness between the two treatment methods used in this present work were 
compared. 
10 
Significance of the research 
The present work discloses a new ocular insert containing an antibiotic which 
is capable of bioeroding in the environment of the bovine eye. The device 
retention characteristics and drug release capacity are sufficient to treat pinkeye 
infections in cattle. In addition, the effectiveness of this type of device in treating 
infections in cattle has been evaluated for the first time and in parallel with a 
conventional treament method. 
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LITERATURE REVIEW 
Nature of Infectious Bovine Keratoconjunctivitis (IBK) 
Infectious bovine keratoconjunctivitis (IBK) is an ocular disease of worldwide 
distribution occurring wherever cattle are raised. The disease is rarely fatal, but 
because of the nature of the ocular defects it produces and the magnitude of 
susceptible populations, IBK causes major economic losses. In 1976, the U.S. 
Department of Agriculture estimated that 20% of the 48 million calves born 
annually in USA and 10% of the 30 million head of feedlot cattle developed IBK. 
It was estimated that the total loss (production cost plus treatment cost) due to this 
disease amounted to $150 million annually. This figure was for beef cattle only and 
did not include an estimate for loss of production in dairy cattle, decreased value of 
exhibition stock, or weight losses and injuries which may occur during the treatment 
period. 
Many organisms have been proposed as causes of IBK but it is now accepted 
that the agent is Moraxella bovis (Punch and Slatter, 1984). Moraxella bovis is a 
short, gram-negative, non-motile rod which is usually hemolytic (Punch and Slatter, 
1984). The cells are from 0.5 ixm to 1.0 fim in width and from 1.0 to 2.0 Aim in 
length (Hughes, 1981). The bacterium possesses pili which assist in its adherence 
to epithelial cells, in this case those of the cornea and conjunctiva. It has been 
shown to dissociate to virulent and nonvirulent forms. The virulent forms always 
possess pili and hemolysins whereas the nonvirulent forms do not (Punch and 
Slatter, 1984). Virulent M. bovis is considered to produce endotoxins, exotoxins 
and perhaps oculopathogenic substances (Pugh et al., 1973). These substances may 
cause degeneration of the epithelium, ulceration, and deep invasion by the 
organism. 
The early signs of IBK are photophobia (sensitivity to light), blepharospasm 
(blinking or closing the eye) and lacrimation, accompanied by hyperemia of the 
bulbar and palpebral conjunctiva. Within one to two days, a small corneal ulcer 
becomes visible and immediately afterwards, corneal edema develops and 
progresses to keratitis as the ulcer enlarges. This ulcer usually involves the 
epithelium and adjacent anterior stroma (Gelatt, 1981). Unless spontaneous 
healing or successful treatment intervenes, a corneal ulcer will progress in severity. 
If the ulcerative process is severe, the cornea may perforate so that the infection is 
carried into the interior of the eye. Occasionally, the iris may protrude through the 
perforation. In both situations, blindness may be the result. Throughout this time, 
infected animals may be reluctant to move about and eat due to inflammation and 
pain. As a result, milk production and weight gains are suppressed. Following 
deep ulceration, healing of the cornea commences. The cornea will vascularize 
eventually. Vascularization of the cornea proceeds rapidly toward the primary 
lesion. As the vascularization process continues, acute signs subside. When 
neovascularization reaches the center of the cornea, the opacity begins to clear 
from the periphery to the center, and the transparency of the cornea is restored as 
part of the repair process. The entire process of healing may take two to six weeks, 
leaving a small scar that is visible for several months. In mild cases, healing occurs 
without scarring. The disease process is usually more severe in young animals than 
in old animals, and a long repair period is also needed (Gelatt, 1981). Several 
investigators have developed their own clinical grading scales to describe the 
various stages of IBK (Jackson, 1953; Pugh et al., 1982a; Killinger et al., 1976). 
These are shown in Table 1. 
Several predisposing factors are considered necessary for M. hovis to cause the 
disease. A major factor appears to be ultraviolet (UV) radiation, the annual peak 
of which is positively correlated with the peak incidence of IBK in the field 
(Hughes and Pugh, 1970). A heavy dose of UV radiation is thought to alter the 
ocular cell surface so that intercellular spaces are widened and less completely 
sealed. This permits the microorganism to invade the eye more easily. 
Experimentally, IBK can be produced by direct exposure of the eye to UV light, 
followed by the instillation of M- bovis (Hughes et al., 1968). 
Cattle that lack pigment around their eyes also have a higher incidence of 
IBK. Because of their unpigmented eyelids, Herefords appear to be the most 
susceptible to IBK (Ward and Nielson, 1979; Caspari et al., 1980). There is also 
individual variation of susceptibility within a breed, and some other unspecified 
inheritance factor has been suggested. Regardless of the amount of eyelid 
pigmentation present, Bqs taurus breeds are more susceptible to IBK than Bos 
indicus cattle (Frisch, 1975). It has been suggested that this may be due to the 
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TABLE 1. Various clinical scales of IBK 
Author Type Description of clinical signs 
Jackson 
(1953) 
Acute form 
Subacute form 
Chronic form 
Fulminating 
form 
Carrier form 
• a comparative mild conjunctivitis and keratitis 
- more severe form with some corneal ulceration 
severe keratoconjunctivitis with formation of 
descemetocele and possible loss of the eye due to 
rupture of the anterior chamber 
severe ulceration, panophthalmitis, general bilateral, 
blindness, occasional death due to an ascending 
infection 
persistent lacrimination in some cases but the 
majority show no signs of infection 
Pugh et al. 
(1982a) 
grade 1 - small ulcer (1-2 mm) healed without corneal 
vascularization 
grade 2 - ulcer (3-4 nun) healed without corneal 
vascularization 
grade 3 - corneal change from permanent scar; healed 
with corneal vascularization 
grade 4 - more severe than grade 3 
Killinger score 10 - normal eye 
et ai. 11 - active lesion involving one-third or less of the cornea 
(1976) 12 - active lesion involving one-third to two-thirds of the cornea 
13 - active lesion involving two-thirds or more of the cornea 
14 - active lesion with cornea perforation 
21 - healed lesion on one-third or less of the cornea 
22 - healed lesion involving one-third to two-thirds of the 
cornea 
23 - healed lesion involving two-thirds or more of the cornea 
24 - healed blind eye including phthisical (shrunken) and 
buphthalmic (enlarged) eyes 
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"hooded structure" of the eyelid protecting the cornea in Bos indicus cattle and also 
may include immunological factors (Dodt, 1977). 
Increases in populations of face flies are associated with an increase in the 
incidence of IBK (Punch and Slatter, 1984). This may be due to the facts that M-
bovis can be viable on the exterior of flies for up to three days and that irritation to 
the conjunctival sac by the flies is likely to increase the susceptibility of the eye to 
the development of IBK (Steve and Lilly, 1965). Gerhardt et ai. (1982) reported 
that the incidence of IBK was decreased by controlling flies. In the absence of the 
face fly, it is considered that the house fly or the stable fly could fulfill a similar 
role (Hughes and Pugh, 1970). 
Experimentally, other infectious agents such as infectious bovine rhinotracheitis 
(IBR) virus have been shown to aid the pathogenicity of M. bovis. probably by 
damaging the conjunctiva (Hughes and Pugh, 1971). Mycoplasma also exhibited 
similar effects (Langford and Dorward, 1969; Rosenbusch and Knudtson, 1980). 
The age of the animal seems to play an important role in enhancing the 
disease. Calves are more often affected by IBK than older cattle. In most cases, 
this is considered to be due to prior exposure of the older cattle to M. bovis and 
their subsequent development of immunity (Hughes and Pugh, 1970). 
Wind, dust, tall grass, and grass seeds also have been implicated as mechanical 
irritants to the conjunctiva and cornea, and thus contribute to the pathogenesis of 
IBK (Hughes, 1981). 
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Treatment and Prevention Methods for Infectious 
Bovine Keratoconjunctivitis (IBK) 
Infectious bovine keratoconjunctivitis (IBK) is highly prevalent, particularly in 
the summer months. IBK has a high incidence in beef cows and calves, stock 
cattle, and replacement females. Transmission of the infection can occur by direct 
contact with ocular secretions, nasal secretion, or by face flies. The infection is 
extremely contagious, and once it has occurred in some animals within the herd, 
the whole herd may have to be treated. 
IBK can be treated or prevented by many methods. These methods can be 
classified into three main areas: immunization, topical applications (e.g., eyedrops, 
sprays, or ointments), and ocular application of drugs using prolonged drug release 
systems. In addition, surgical treatment is often used either to suture eyelids shut 
to speed up recovery of corneal lesions or to enucleate severely affected eyes to 
prevent loss of the animal due to septicemia (Punch and Slatter, 1984). 
Immunization 
Numerous attempts have been made to protect cattle against IBK through 
immunization with bacterins (Hughes and Pugh, 1971; Pugh et al., 1976). However, 
protection obtained by these vaccines was limited, and the need to give repeated 
vaccinations was considered impractical under field conditions. Webber and 
Selby (1981) found better immunity against heterologous strains of M. bovis. 
following the administration of formalin-inactivated vaccines, than against 
homologous strains. Their explanation for these results was that the homologous 
strain was more virulent than the heterologous strains of M. bovis investigated. In 
their study, they also compared vaccinating animals in three sites: 
subconjunctivally, periorbitally, and subcutaneously on the neck. Granulomatous 
reactions occurred in 18 of 20 eyes vaccinated subconjunctivally, in 10 out of 10 
eyes vaccinated periorbitally and in 2 of the 5 calves vaccinated subcutaneously in 
the neck. They suggested that the latter was the most effective vaccination site for 
the development of resistance to IBK. 
Since pili were believed to be essential for pathogenicity, Pugh and Hughes 
(1976) and Pugh et al. (1979) prepared pili fractions from virulent cultures of M. 
bovis. When used as a vaccine, pili stimulated immunity against homologous 
strains of M. bovis and some heterologous strains. Disiiipted cells used in the same 
investigation (Pugh and Hughes, 1976) produced no immunity. Incorporation of 
Freund's Incomplete adjuvant (Hughes et al., 1977) or Mvcobacterium 
paratuberculosis (Pugh et al., 1978) have been found to be unsuccessful in 
enhancing the immunogenicity of M. bovis bacterin. However, the incorporation of 
Diptheria-pertussis-tetanus toxoid (DPT) has been shown to enhance the protection 
provided by M. bovis vaccine (Pugh et al, 1984). Ribosomes from M. bovis have 
also been extracted and used as a vaccine, but no protection against IBK was found 
(Pugh et al., 1981). 
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Additional work by Pugh et al. (1980, 1982b) has been aimed at controlling 
IBK in young calves. Animals that are vaccinated with pili vaccines (Pugh et al., 
1982b) or formalin-killed vaccines (Pugh et al., 1980) tend to have higher levels of 
antibody in colostrum,^ and appear to be less susceptible to IBK. 
Since an effective vaccine is difïïcult to produce, vaccination as an approach in 
the control of IBK has not been practical. However, recently two commercial 
vaccines were marketed for preventing IBK One is Piliguard® Pinkeye of Schering 
Corporation, and the other is Norden Laboratories' BovEye. Both products are 
piliated, inactivated, adjuvanted whole cell bacterins (Troutt and Schurig, 1985). 
Field tests conducted by Schering in Florida and Wisconsin indicate that Piliguard® 
Pinkeye controls and significantly prevents IBK caused by M. bovis. However, 
Bateman et al. (1986) found that the bacterin (Piliguard®) did not affect the 
incidence of IBK, but did appear to reduce the severity of lesions, treatments 
required, and withdrawals from pasture required in one of their two field trials. 
They concluded that IBK can not be prevented by just utilizing the bacterin alone. 
However, they suggested that the bacterin, when used in conjunction with fly 
control and other good husbandry techniques such as early antibiotic therapy, may 
reduce the incidence of IBK Norden has also conducted extensive efficacy tests on 
its product (BovEye). Field trials conducted in six states on 1,840 animals given 
two injections each at three week intervals showed an incidence of 2.8% among 
vaccinated animals as compared to 10% in 2,200 unvaccinated control animal 
(Troutt and Schurig, 1985). These field trials indicate that BovEye also 
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significantly reduces the incidence of IBK. Recently, Gerber et al. (1988) studied 
the efficacy of a Moraxella bovis bacterin containing attachment and cornea-
degrading enzyme antigens for the control of IBK. The test was conducted in 32 
herds within 6 states. Overall, the rate of infection was 11.2%. Calves that were 
vaccinated with an M. bovis bacterin that contained a Relative Enzyme Activity 
(REA) of 0.63 appeared to be less susceptible to IBK. REA is defined as a lytic 
unit of test bacterin per lytic unit of reference bacterin. The incidence of IBK was 
reduced from 11.2% in the non-vaccinated controls to 4.3% in cattle vaccinated 
once, and to 3.1% in cattle vaccinated twice. 
Due to the difficulty experienced in producing an effective vaccine, it has been 
suggested that the use of good husbandry techniques, such as isolating infected 
stock and treating them with antibiotic, may offer a better alternative to control 
IBK than by using vaccination (Pugh et al., 1982a; Hughes et al., 1979). 
Topical applications 
Early cases of IBK are usually treated with topical applications of eyedrops, 
ointments, or sprays containing chemotherapeutic or antibiotic agents. Sprays have 
retention times similar to eyedrops (of the order of 1/2 hr), but sprays cause less 
irritation. Viscosity-enhancing agents such as methyl cellulose are added to an 
eyedrop preparation, or the drug is provided as an ointment in order to sustain 
intimate drug/eye contact. Topical ointments are usually preferred over sprays and 
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eyedrops. Biophth L.A. ophthalmic (benzyl penicillin), a topical ointment 
which has a good affinity for corneal and conjunctival tissue and provides a 
prolonged antibiotic release for the treatment of IBK, has been investigated by 
Binkhorst (1987). The slow-release formulation which contains procaine benzyl 
penicillin and dihydrostreptomycin was investigated in parallel with a cloxacillin eye 
ointment in 12 cows. After a single topical application, the therapeutic 
concentrations of penicillin were sustained for 48 to 92 hours, and of cloxacillin for 
32 to 48 hours. The persistence of antibiotic concentrations in lacrimal fluid after a 
single topical application of a slow-release ointment of procaine benzyl penicillin 
and dihydrostreptomycin suggests that long-acting ointments which allowed a 
prolonged antibiotic release would simplify the treatment of field cases of infectious 
bovine keratoconjunctivitis. However, since tears rapidly wash the drug from the 
eyes, therapeutic levels of drugs can not be maintained during the whole period of 
therapy which is from 5 to 7 days for IBK (Slatter et al., 1982c), and drugs must be 
applied repeatedly. Repeated treatments of corneal disease, such as IBK, with 
commercial drugs containing corticosteroid and antibiotic collyria can cause 
damage to corneal epithelial cells (Maudgal et al., 1981). Such damage may impair 
the healing capacity of the epithelium and its resistance to superinfections. 
Cattle with a severe corneal ulceration may be treated by applying 
subconjunctival injections of antibiotics (plus a corticosteroid to reduce 
inflammation). These subconjunctival injections are used to concentrate drugs 
locally, reducing their rate of loss from the eye, and thus promoting healing. 
However, the levels of drug fall off rapidly and are often low, or undetectable, after 
a few hours of injection (Barza et ai., 1984). Saunders and McPherson (1980) 
investigated the drug levels of cefazolin after subconjunctival injection in rabbits. 
They found that the levels of cefazolin in the aqueous humor (of the eye) increased 
from an average level of 8.2 Mg/ml to 30.9 fig/ml within 2 hours. The drug level 
then decreased quickly to an average level of about 1.7 Mg/nil within 6 hours after 
subconjunctival injection. Since the levels of drug cannot be maintained above the 
therapeutic level for a long period, of time, repeated injections are necessary to 
treat severe cases of infections. 
Recently, drug delivery methods have been developed to incorporate 
antibiotics into biodegradable lipid vesicles with an aqueous core (e.g., liposomes) 
as a means to retard their dissipation from the conjunctival depot. Barza et al. 
(1984) studied the effects of liposome-encapsulation for sustained release of 
antibiotic in the cornea of rabbit eyes afrer subconjunctival injection. In their 
study, they compared the effect of liposome-encapsulated gentamicin with 
gentamicin plus "empty" liposomes, and with gentamicin alone. They found that the 
levels of drug in the sclera and the cornea following subconjunctival injection were 
markedly higher with the liposome-encapsulated drug than with gentamicin alone 
or gentamicin plus empty liposomes. After 24 hours of injection, corneal levels 
were 5- to 20-fold higher with the liposome-encapsulated drug than with the other 
two formulations. Their results suggested that liposome-encapsulation may be a 
useful means of extending the effect of a subconjunctival injection of antibiotic so 
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as to produce sustained, high corneal levels. Their study also suggested that other 
liposomal formulations (e.g., ones containing cholesterol) might be of interest for 
even slower release and more prolonged levels that could be of clinical benefit. 
Systemic antibiotics have also been shown to be effective in reducing the 
severity of clinical diseases as well as eliminating the carrier state. Pugh and 
McDonald (1977) administrated long-acting oxytetracyline intramuscularly to calves 
infected with IBK. At a dosage of 7 mg/kg body weight, ten out of fifteen calves 
remained infected. However, at a higher dosage (11 mg/kg body weight) only five 
calves remained infected. George et al. (1988) studied the effectiveness of topically 
applied furazolidone (FZ) or parenterally administered oxytetracyline (OTC) for 
the treatment of IBK. They concluded that parenterally administered OTC was 
more effective than topically applied FZ for the treatment of IBK. The corneal 
ulcers of OTC-treated calves were smaller and healed more rapidly than did those 
of FZ-treated calves. Calves of the OTC treatment also had the fewest multiple 
corneal ulcer recurrences. In addition, parenterally administered OTC has a higher 
efficacy for elimination of ocular Moraxella bovis infection. 
Ocular application of inserts for the treatment of IBK 
It is well recognized that ocular drug delivery systems that provide a steady 
sustained release offer therapeutic advantages over conventional methods such as 
topical application of eyedrops, ointments, or sprays, and parenteral injection of a 
variety of antibiotics and sulfonamides. Several ocular inserts were suggested as 
the treatment system for providing pinkeye therapy for cattle. Hawley (1954) 
developed a terramycin eye pellet that provided a therapeutic concentration of 
terramycin in the tears for 31 hours. The pellet consisted of 5 mg of oxytetracyline 
hydrochloride in crystalline form, polymyxin B sulfate (10,000 units) and tetracaine 
hydrochloride (1 mg) as an anesthetic. The pellet was relatively small (7/32 inch in 
diameter) compared to the eye. It was tableted in order to adhere to the eyeball 
without producing irritation. Each pellet was implanted by placing it at the bottom 
of the lower eyelid and then was released to allow the lower eyelid to fold back to 
the normal position. Efficacy studies were conducted for a total of 1121 cattle that 
were treated for IBK using the eye pellets. Early infections were cured by using a 
single implantation of one pellet, whereas severe infections often required 
additional implantations. 
In recent years, significant advances have been made in the field of ocular 
drug deliveiy systems. For example, work by Hughes and Pugh (1980) and recent 
work by Ryoo (1989) disclose a typical drug dispensing ocular insert in the form of 
a ring which releases controlled amounts of drug to the eye. These devices have 
the added advantage of permitting slow release of drug over prolonged periods of 
time. The ring-shaped devices are fabricated of materials that are biologically 
inert (e.g., polyethylene, polyvinyl chloride, and nylon tubing), non-allergenic, and 
non-bioerodible in tear liquid. Ryoo (1989) used a ring-shaped polyvinyl chloride 
tubing dip-coated with layers of hydrogel-drug mixture. Tylosin tartrate was used 
as the antibiotic in the hydrogel. The hydrogel used is a copolymer of HEMA 
and MMA. The hydrogel-drug matrix on the surface of the polyvinyl chloride ring 
was shown to be capable of sustained drug release for a period of several days. To 
initiate the therapeutic program, the ring device is inserted by holding the eyelids 
open while one side of the ring is directed into the inferior fornix of the conjunctival 
sac. The rest of the ring is then directed under the lids and finally onto the outer 
surface of the nictitating membrane (third eyelid) where it remains visible in the 
medial canthus. Since the material from which the ocular insert is formed is not 
erodible by tear liquid, it retains its integrity during the course of therapy, acting as a 
reservoir to continuously release drug to the eye and surrounding tissues at a 
controlled rate. A single ocular insert can provide the complete ophthalmic dosage 
regimen for a particular time period, on the order of 24 hours or longer. More 
frequent repeated applications are thus avoided. On termination of the therapeutic 
program, the ocular insert is removed from the eye. 
While the ocular inserts described above have proved to be markedly superior to 
the prior art ointments and liquid sprays, a disadvantage is that the insert remains 
intact during the course of therapy and must be removed on termination of 
treatment. This represents additional time-consuming treatment costs. Prior work by 
Micheals (1975) demonstrated that ocular inserts (fabricated from sodium alginate 
crosslinked with polyvalent metal ions such as Al^^ Ca^^ and Zn^^) can be made 
that are biodegradable in the tear environment of the eye. This approach 
provides a way to overcome the disadvantage. Such inserts biodegrade into 
innocuous products concurrent with the dispensing of the drug and thus do not have 
to be removed at the end of the therapeutic program. The structure of these inserts 
is relatively small as compared to the eye and is generally in the shape of a thin 
elliptical, solid body. They are designed for insertion into the ventral fornix of the 
conjunctival sac. When inserted in the sac of a human eye and a monkey's eye, these 
devices released the drug at a controlled rate and completely bioeroded in the eye at 
the end of the therapeutic program without any side effects. However, the 
biodegradable ocular inserts are only adapted for insertion in the cul-de-sac of the 
conjunctiva between the sclera of the eye ball and the lower lid. Such insertion is 
suitable for treatment of the human eye but is unsuitable for the treatment of the 
eyes of farm animals which posess a nictitating membrane or third eyelid. A primary 
function of the third eyelid is to remove foreign objects from the eye; therefore, the 
ocular inserts described above would be rejected immediately after insertion, or at 
best, after an extremely short retention period (Hughes and Pugh, 1980). 
Theodorakis et al. (1983) and Brightman and Theodorakis (1984) prepared an 
ocular insert which was made from a composite of chloramphenicol sodium succinate 
(CASS) and polylactic acid (PLA). This device was designed to attach to the third 
eyelid of cattle and rabbits. The insert included a disc impregnated with CASS in 
controlled-release form and a spear of bioerodible PLA for attachment of 
insert to the third eyelid. Upon biodégradation of the spear at the end of the 
treatment period, the disc becomes free and is subsequently flipped from the eye, 
thereby terminating treatment. In in vivo testing, the insert was retained in the eye 
for at least four days. The release levels of CASS from the composite in an in vitro 
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test achieved therapeutic level of CASS during a period of seven days in the eyes of 
four rabbits. However, they did not test the release of CASS in bovine eye. 
Although this device solved the problem of retention of the insert in the eye, the 
fabrication technique is time-consuming. Also, the spear must penetrate the third 
eyelid in order to hold the device in the eye which can cause some problem during 
insertion and cause discomfort to the animals. 
Slatter et al. (1982b) investigated the release of gentamicin from an insoluble 
collagen film for the treatment of IBK, In their research, a good correlation between 
in vitro and in vivo drug release data in bovine eyes was found. Concentrations in 
the precorneal film during the first 24 hours after insertion were still at the minimum 
inhibitory concentration level for gentamycin for M. bovis control. They proposed 
that this type of insert was suitable as a sustained drug delivery system for the 
treatment of IBK. In further research. Punch et al. (1985) have compared the 
release of gentamycin fi'om a soluble and an insoluble collagen film impregnated 
with gentamycin. They found succinylated collagen films could release higher levels 
of gentamycin than the insoluble films and maintain the therapeutic levels (0.37 
/ig/ml in in vitro tests) necessary to treat Moraxella bovis. (but only for 24 hours). 
The inserts showed no irritation reaction when initially placed in the eye, and the 
inserts were well tolerated by the animals in contrast to a previous study by Punch 
and co-workers using hydrophilic contact lenses. 
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Punch et al. (1987) examined the release rate of procaine, penicillin, 
erythromycin and erythromycin estolate from soluble and insoluble collagen films in 
an in vitro test to develop a biodegradable ocular insert for the treatment of IBK. 
The combination of erythromycin estolate and soluble collagen produced the most 
useful sustained drug-delivery system. However, they failed to design an ocular insert 
suitable for use in the conjunctival sacs of cattle due to the lack of rigidity of their 
insert material. Ring inserts tore and swelled quickly after insertion, and this led to 
poor retention of the ocular inserts in the eye. 
The Bovine Eye 
In the development of an ocular drug delivery system for treatment of eye 
infections in cattle, a knowledge of the anatomy.of the bovine eye is essential in 
order to design an ocular insert which can be retained in the eye for a prolonged 
period of time (e.g., 24 hours or longer). 
The bovine globe is small compared to the orbit in which it is housed. The 
volume ratio between the orbit and the globe is 6:1. This is the largest ratio seen 
for all domestic animals (Severin et al., 1980). The sclera covers the major portion 
of the globe. It varies in thickness from 1 mm to 2 mm with the thinnest point at the 
equator and the thickest point at the cribiform plate. The color of the sclera 
varies among animals from almost white to a greenish gray. The cornea of the 
bovine eye has the shape of an egg, with the widest portion located nasally. Outside 
of the cornea is the thin protective membrane called the conjunctiva. The inner 
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surface of the upper and lower eyelids, both sides of the third eyelid (nictitating 
membrane), and the exposed surface of the globe up to the limbus are covered with 
this layer. The conjunctiva contains isolated nodules of lymphatic tissue and contains 
associated lacrimal glands. The nictitating membrane is located nasally and moves 
over the cornea in a dorsalateral direction. Its primary function is to remove foreign 
objects from the eye. Therefore, the anatomic structure of the 
third eyelid should be considered in designing an ocular insert in order to achieve 
satisfactory retention times in the bovine eye. 
The bovine eyelids are thick. The sebaceous glands (or tarsal glands) are 
located close to the inner surfaces of the lids. The ducts of the tarsal glands open 
onto the margins of the eyelids. Their secretions onto these margins help prevent 
tears from overflowing between the eyelids. The orbicularis oculi muscle serves to 
close the eyelids. The other eyelid muscle of importance is the levator palpebral 
superioris. It elevates the upper eyelid and thus enlarges the palpebral fissure. 
The bovine eye has several lacrimal glands that contribute to the secretions 
forming the tear film. The moisture within the conjunctival sac and the serous 
component of the tear fluid are produced by these glands. The nictitans gland also 
contributes a serous secretion and the Hardens gland adds a mucoid secretion to 
the tear film. Through a number of ducts, tears (mixed with the mucous products 
of the Hardens gland) reach the conjunctival sac at the upper fornix. The tear fluid 
maintains a well organized fluid film over the entire anterior surface of the eyeball. 
The nasolacrimal duct which drains the tears from the eye to the nostril passes from 
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the lacrimal sac through the lacrimal bone and under the nasal mucosae to its 
opening near the lateral wall of the nostril. 
The tears are a clear, salty, slightly alkaline, watery fluid. The tear fluid 
contains lysozyme, whose bactericidal activity reduces the bacteria count in the 
conjunctival sac. Water constitutes approximately 98-99% of the tear fluid. The 
chemical constituents of tears include the nondiffusible substances of large molecular 
size and the divisible substances which are composed of ionized and nonionized 
compounds. The ionic component of tears includes cations such as Na"^ and and 
anions such as CI" and phosphates. The concentration of sodium in the tear fluid is 
almost equal to physiological saline (Duke-Elder, 1968). Other nonionized 
substances in the tears include glucose, urea, and amino acids. 
For an ocular drug delivery system that is capable of bioeroding in the tear 
fluid, the tear flow rates can influence the bioerosion rate of the device and, 
eventually, the erosion time of the device within the environment of the eye. Slatter 
and Edwards (1982) measured unstimulated tear flow rates in the bovine by 
cannulating the nasolacrimal duct and removing the tears with a suction pump. They 
found that the mean tear flow rate that was obtained from 327 collection 
periods of 30 minutes each for 11 animals was 1.96 ± 1.84 ml/hr. Hoffmann and 
Spradbrow (1978) obtained tear flow rates from two cattle using the catheterization 
technique. Their values varied between 0.18 to 1.86 ml/hr. In cattle with ocular 
disease, excessive lacrimation can occur as a result of irritation to the eye or of 
ocular pain. 
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Controlled Release Drug Delivery Systems 
A controlled release drug delivery system is a combination of a biologically 
active agent and an excipient, commonly a polymeric material, designed to allow 
delivery of the agent to the target (e.g., an organ) at controlled rates over a 
specified period of time. A controlled release drug delivery system is capable of 
achieving the following benefits: (1) maintenance of optimum therapeutic 
concentration within the target organ with minimum fluctuation; (2) predictable 
and reproducible release rates for extended duration; (3) enhancement of activity 
duration for short half-life drugs; (4) elimination of side effects, frequent dosing, 
and waste of drug; and (5) optimal therapy and better patient compliance (Langer 
and Peppas, 1981). 
For controlled release, the delivery rate constants are important parts of the 
delivery scheme. A controlled release formulation of the drug is frequently 
administered to the total systemic biological envirormient by a conventional 
method. However, the formulation is a drug reservoir that delivers the agent to the 
biological system at a predetermined rate. 
According to Kim et al. (1980), factors that must be considered in designing of 
controlled release systems are: 
(a) the optimum level of drug necessary for the desired biological 
response. This level should be almost always lower than the level 
required for application by a conventional method. 
(b) the delivery kinetics and mechanisms for the drug that is to be 
released from the device chosen. 
I 
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(c) the influence of the biological environment on the mechanism and 
kinetics of the drug release. 
(d) the mechanisms and rates of all drug removal systems operable in 
the biological environment (e.g., drug metabolism, excretion, and 
deactivation). 
(e) inherent restrictions on the physicochemical properties of delivery 
materials dictated by the particular applications. 
The release rate of drug from a controlled release system can be regulated by 
the device itself. By employing proper materials and selecting an adequate design 
of the system, accurate, reproducible, and predictable predetermined rates of drugs 
can be achieved. 
Controlled release systems may be classified according to physical mechanisms 
of release of the incorporated solute. The types of polymeric controlled release 
devices can basically be categorized as follows: (1) diffusion-controlled systems and 
(2) chemically-controlled systems. The ocular device developed in this research 
is a combination of (1) and (2). 
Diffusion-controlled systems 
Diffusion-controlled systems are the most widely used systems. They have 
been formulated in two basic configurations: (1) reservoirs and (2) matrices. 
Reservoir systems In these systems, a core of drug is surrounded by a 
swollen or non-swollen polymer film, and diffusion of the drug through the polymer 
is the rate limiting step. From a pharmaceutical standpoint, the principal 
advantage of reservoir systems is the ease with which they can be designed to 
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achieve zero-order release rates. Transport through membranes has been 
presented in literature (Baker and Lonsdale, 1974; Good and Lee, 1984). In 
general, there are two types of membranes: (1) the non-porous homogeneous 
polymer film and (2) the microporous membrane. In the non-porous membrane, 
the kinetics of drug release follow a solution-diffusion mechanism. The drug 
transport occurs by first dissolving in the membrane at one interface, followed by 
diffusion down a chemical potential gradient across the membrane. Eventually, it is 
released from the second interface into the external medium. In the microporous 
membrane, the drug diffuses through pores in the polymer structure. Between 
these two types of membranes, non-porous, homogeneous, polymeric films are the 
most commonly used membranes for controlled drug delivery systems. 
The permeation of drugs through membranes is determined by the steady state 
Pick's first law of diffusion as follows: 
J = - D(dCJdx) (1) 
where D is the concentration-independent drug division coefficient in the 
membrane, J is the drug flux, and dC„/dx is the drug concentration gradient within 
the membrane. For a concentration-independent diffusion coefficient and constant 
membrane thickness, equation (1) can be rewritten as: 
J = D(ACJl) (2) 
where 1 is the membrane thickness, and AC„ is the transmembrane concentration 
difference. Under steady state conditions, a membrane device having a saturated 
drug reservoir can maintain a constant thermodynamic activity gradient across the 
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membrane for an extended period of time. As a result, a constant rate of drug 
release (a zero-order release of drug) is established. The rate of release from such 
a system is generally dependent on the device geometry and the nature, thickness, 
and area of the membrane, whereas the duration of the release is governed by the 
size of the drug reservoir. 
For non-porous membrane systems, it is convenient to rewrite equation (2) as 
follows: 
J = dM,/Adt = DKAC/1 (3) 
where M, is the amount of drug released after time t, dM,/dt is the steady state 
release at time t, A is the total area of the device, and K is the drug partition 
coefficient which is the equilibrium ratio of the saturation concentration of the drug 
in the membrane to that in the surrounding release medium (e.g., water or 
biological fluid), and AC is the difference in concentration on two sides of a 
membrane. 
During the zero-order (or steady state) phase of the overall release profile, the 
rates of drug release from devices having simple geometries such as infinite slabs, 
infinite (flinders and spheres, may be described by the following equations (4)-(6), 
respectively (Baker and Lonsdale, 1974): 
Slab: dM,/dt = ADKAC/1 (4) 
Cylinder: dM,/dt = 2n^hDKAC/hi(r,/r;) (5) 
Sphere: dM,/dt = 47rDKAC(ror;/ro-rj) (6) 
For a slab, A is the total surface area including both sides but ignoring edge 
effects. For a cylinder, h is the length and r,, is the overall radius of the core 
plus surrounding membrane, and r, is the radius of the drug core only. For a 
sphere, r^ and r; have the same definitions as for a cylinder. The drug partition 
coefficient, K, is purely a thermodynamic parameter and is largely a measure of 
solute preference for the biomaterial relative to the surrounding release media 
(Langer and Peppas, 1981). If the solute has a chemical structure similar to that of 
the biomaterial, the partition coefficient will be high, whereas if the structures are 
different, K will be low. The terms D and K are not always easily measured and 
frequently values of permeability P (where P = DK) are used. 
Before the establishment of a steady state, the membrane device will exhibit 
an initial release rate higher or lower than the steady state value, depending on the 
prior fabrication condition of the device. For a newly prepared device, a time lag 
will be required to establish the steady state concentration profile within the 
membrane. However, after the device is stored for some time, the membrane 
becomes saturated with drug and subsequently give rises to an initial release rate 
higher than the steady state value. This initial high release rate is often referred as 
the burst effect. The burst and lag effects are commonly encountered in reservoir 
type devices. The magnitude of these transient effects is related to the drug 
diffusion coefficient in the membrane and the membrane thickness (Baker and 
Lonsdale, 1974). 
In the case of microporous membranes, equation (3) can be rewritten as: 
J = dM,/Adt = DctAC/tI (7) 
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where a is the porosity of the microporous membrane, and r is the tortuosity of 
the diffusive path within the pore-structure membrane (Langer and Peppas, 1981). 
Equation (7), like equation (3), predicts that release rates will be time 
independent, that is, zero-order kinetics will be exhibited. However, equation (7) is 
different from equation (3) in the following aspects: (a) the area of the divisional 
path is limited by the porosity of the membrane, (b) the diffusion coefficient refers 
to the transfer of drug through the pores in the membrane rather than through the 
polymer, (c) the partition coefficient, K, is not needed, and (d) the length of the 
diffusion pathway is increased by the irregularly channeled pores so that a 
tortuosity factor might be needed to allow for this effect. 
Membrane-reservoir systems (non-porous and microporous) have been utilized 
in many forms for the controlled delivery of therapeutic agents. These systems, 
including membrane devices, microcapsules, and hollow fibers, have been applied 
to a number of areas ranging from birth control and transdermal delivery to cancer 
therapy. Various polymeric materials (e.g., silicone rubber, hydrogels, vinyl acetate, 
and polyurethanes) have been employed in the fabrication of such membrane 
devices (Kim et al., 1980). 
Matrix svstems In these systems, the drug is uniformly distributed 
throughout a solid polymer matrix. The solubility of the solute in the polymer is 
the controlling factor in the mathematical analysis of these systems. 
One of the major advantages of matrix devices relative to other types of 
controlled release drug delivery systems (e.g., reservoir devices) is the ease of 
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fabrication. However, because of the different way in which drug is distributed, 
a zero-order release rate can not be achieved. For most conventional devices with 
simple geometries, the drug release rate is proportional to where t is the 
release time (Langer and Peppas, 1981; Graham and Wood, 1984). Matrix devices 
may be classified into four general types: (1) dissolved systems, (2) dispersed-type 
systems, (3) reservoir-dispersed matrix systems, and (4) porous systems. 
Dissolved svstems In these systems, the drug is dissolved on a 
molecular level in the polymer matrix and drug diffusion occurs via a solution-
diffusion mechanism. Approximation equations that describe the early and later 
stages of release profiles are usually preferred for practical purposes because 
complete mathematical expressions of these profiles are rather cumbersome. The 
approximate relationships for drug release kinetics from slabs, cylinders, and 
spheres have been developed and are discussed in literature (Baker and Lonsdale, 
1974). 
Dissolved matrix systems have been employed in the controlled release of 
some pharmaceutical ointments and creams (Higuchi, 1962). However, the use of 
these systems has not receive much attention since the solubility of a particular 
drug in a given polymer is much lower than that required to provide an adequate 
amount of drug in a device of limited size. 
Dispersed-type systems In these systems, the drug is present as finely 
divided particles uniformly dispersed in the polymer matrix. In dispersed-type 
matrix devices, the drug is released by diffusion within the polymer matrix. The 
I 
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release kinetics of this type of systems are described by Cardinal (1984). With 
time, two zones may be defined. The inner zone, which is composed of polymer 
containing dispersed drug, and the outer zone, designated as the zone of depletion, 
which is composed of polymer plus dissolved drug. The concentration of drug 
within the inner zone is assumed to be constant and equal to the initial drug load. 
However, within the zone of depletion, a concentration gradient exists. The nature 
of this gradient is dependent upon the geometry of the device (e.g., slab, cylinder or 
sphere). 
The rate of drug release at any time t from dispersed-type devices with a slab 
geometry can be described by the following equation: 
dM,/dt = A/2[ DC,(2Q - cyi''^ (8) 
where Q is the drug solubility in the polymer, Q is the initial drug loading, and A 
is the area of exposure. 
An example of the drug release from a silicone elastomer slab containing 
dispersed drug was present by Baker and Lonsdale (1974). The amount of drug 
released was seen to increase with the square root of time and approximately with 
the square root of the loading, in accordance with equation (9). 
M. = A[DtQ(2Q - Q)]V2 (9) 
Equations that describe the release kinetics for cylindrical and spherical 
matrices containing dispersed drug can also be found in the publication of Baker 
and Lonsdale (1974). 
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Reservoir-dispersed matrix systems Reservoir-dispersed matrix systems 
are composed of a core made from a matrix-type device which is encased by a 
polymer membrane which is of lower permeability than the inner drug core. 
The inner drug core contains drug dispersed as finely divided particles. Explicit 
mathematical expressions for the release of drugs from reservoir-dispersed matrix 
devices have not been extensively developed. However, the analysis of the release 
of drugs from these systems with simple geometry (e.g., slab, cylinder, and sphere) 
has been presented in the literature (Cardinal, 1984). 
Reservoir-dispersed matrix devices are somewhat more difficult to prepare 
than either matrix devices or membrane devices alone. However, these systems can 
be adapted to release drug at a constant rate for a prolonged period of time. An 
example of reservoir-dispersed matrk systems is a trilaminate device developed by 
Olanoff et al. (1979). The core matrix was prepared from a copolymer of 63 
mole% 2-hydroxyethyl methaciylate (HEMA) and 37 mole% methyl methacrylate 
(MMA) which contained tetracycline. The coating (or membrane) material was 
prepared 6om the same hydrogel materials, but their relative compositions were 
varied to decrease drug permeability in the coating material. The authors reported 
that both the solubility and the diffusion coefficient of tetracycline decrease as the 
mole% of MMA increases. In their work, constant release rates with time were 
achieved in devices with the barrier layers. 
Porous systems Porous matrix devices are those with continuous 
macroscopic channels or pores that exist within the polymer matrix upon leaching 
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the drug. Release from porous systems involves diffusion of drug through solvent-
filled pores or channels. The pores may also be an inherent part of the structure of 
the matrix as in swollen hydrogels and matrix devices formed by evaporation of a 
solvent containing dissolved polymer and drug. 
The release kinetics from these systems are similar to those described earlier 
for non-porous matrices (dissolved and dispersed) but other terms are included to 
account for the degree of porosity (a) and the tortuosity (T) of the pores (Langer 
and Peppas, 1981). For example, for a matrix device with slab geometry containing 
dissolved drug only, the rate of release is given by: 
dM/dt = 2ACd[D„or/(T7rt)]i/2 (10) 
and for a similar device containing dispersed drug particles, the release kinetics are 
given by: 
dM,/dt = A/2p„aC;(2Q - (11) 
where Cj is the initial drug loading of the system, and and are the diffusion 
coefficient and solubility in the eluting liquid, respectively. 
The release of drug 6om slab-type porous matrix device has been investigated 
by Desai et al. (1966) and Singh et al. (1967). In general, the release kinetics tend 
to follow the pattern predicted by equation (11). However, several factors were 
found to influence the release kinetics including: (1) degree of wetting at the 
polymer-solution interface, (2) the partition of the solute into the polymer phase, 
and (3) interactions between drugs and/or media which form the dispersed phase. 
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Chemically-controlled systems 
Chemically-controlled systems include all polymeric formulations where solute 
diffusion is controlled by a chemical reaction such as the dissolution of the polymer 
matrix or cleavage of the drug from a polymer backbone. Chemically-controlled 
systems can be classified in two different classes: bioerodible systems and drug-
polymer conjugates. Only bioerodible systems will be discussed here since they are 
of interest in this research. 
Bioerodible systems In these systems, the drug is distributed throughout a 
polymer in the same way as in matrix systems. However, the polymer phase in 
bioerodible systems will decrease with time. Consequently, as the polymer is 
eroded, the drug is released to the gurrounding environment. The main advantage 
of bioerodible systems over non-erodible systems is that biodegradable polymers 
are eventually absorbed by the body, thus eliminating the need for surgical removal. 
According to Heller (1984), polymer erosion can be controlled by the following 
three types of mechanisms: (1) water-soluble polymers insolubilized by 
hydrolytically unstable crosslinks; (2) water-insoluble polymers solubilized by 
hydrolysis, ionization, or protonation of pendant side groups; and (3) water-
insoluble polymers solubilized by backbone cleavage to small water soluble 
molecules. These mechanisms represent extreme cases, and erosion by a 
combination of mechanisms is possible. Each type of polymer erosion has certain 
advantages and limitations, and the choice of a polymer system is dependent on the 
specific application. 
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Two types of devices can be fabricated to release drugs from bioerodible 
polymers. One type involves a drug core surrounded by a rate-controlling 
bioerodible membrane, and the other is a bioerodible matrix device (Heller, 1984), 
For a device that has a rate-controlling bioerodible membrane, the rate of 
drug release is constant and predictable provided the membrane erodes well after 
drug delivery has been completed. However, if the rate-controlling membrane 
erodes significantly during drug delivery, any changes in membrane thickness or 
physical properties would affect the drug release rate. Therefore, for this type of 
device, the rate of drug release can be controlled only by changing the nature of 
the bioerodible rate-controlling membrane. After the drug delivery has been 
completed, the expended device is removed via bioerosion. 
Drug release from bioerodible matrix devices can be controlled by either 
diffusion or erosion (Heller and Baker, 1980). In the absence of erosion, the drug 
release rate can be described by the following model: 
dM^/dt = A/2[2PCo/t]^/2 (12) 
where M, is drug released at time t, P is the permeability of the polymer to the 
drug, A is the surface of both sides of the device, and Q is the initial concentration 
of drug in the polymer. 
This model proposes that drug is initially removed firom the surface regions of 
the polymer and consequently a progressively thicker drug-depleted layer forms 
adjacent to the surface of the device. The drug release declines continuously in 
proportional to t"-^ where t is the time. If the diffusional release is minimal and 
erosion is relatively fast, the rate of drug release can be controlled by erosion. 
With respect to the mechanism of drug release, it is important to distinguish 
between two types of hydrolytic erosion of water-insoluble polymers. On one 
hand, homogeneous erosion occurs by having hydrolysis at a uniform rate 
throughout the matrix. This is referred to as bulk erosion which is capable of 
increasing the drug permeability through the polymer as time proceeds, thereby 
producing an accelerated release by means of a combination of diffusion and 
erosion. On the other hand, heterogeneous erosion confines the hydrolysis to the 
surface of the device and is often referred to as surface erosion. Clearly, surface 
erosion is much more desirable because it can lead to constant drug release (zero-
order kinetics) provided divisional release of drug is minimal and the overall 
surface area of the device remains constant (Heller and Baker, 1980). 
Hopfenberg (1976) derived mathematical expressions for the release of solute 
from erodible slabs, cylinders, and spheres. The rate of drug release for various 
geometries can be calculated from the following general expression: 
M,/M. = 1 - [1 - k,t/Qa]" (13) 
where M* is the drug released at time t, M« is the drug released at device 
exhaustion, k,, is the erosion constant, Q is the uniform initial drug concentration 
in the matrix, a is the radius of cylinder, sphere, or half thickness of slab and, 
n = 1 for a slab, 2 for a glinder, and 3 for a sphere. 
Equation (13) describes idealized release kinetics of drugs from host polymers. 
Constant delivery rates can only be achieved in slab-shaped devices. Delivery rates 
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from spheres and cylinders will decrease with time because their surface areas will 
diminish. 
Many bioerodible polymers have been investigated for controlled release 
purposes. Polymer examples of a type 1 erosion mechanisms include copolymers 
of aciylamide or N-vinyl pyrrolidone with N,N'-methylenebisacrylamide (Heller and 
Baker, 1980) and gelatin crosslinked with formaldehyde (Heller, 1984). The 
release of the highly water-insoluble hydrocortisone acetate from a gelatin matrix 
crosslinked with formaldehyde follows first-order kinetics by a simple diffusional 
process. The first-order drug release suggests that matrix erosion is not important 
in the kinetics of drug release. The erosion of a crosslinked gelatin is slow, and 
drug depletion occurs well before significant matrix erosion is noted. Such a device 
may be useful in applications where zero-order kinetics are not important and 
removal of the expended device is not desirable. 
Polymers of the type 2 mechanism are represented by copolymers of vinyl 
monomers and maleic anhydride, partially esterified copolymers of methyl vinyl 
ether and maleic anhydride, or partially esterified copolymers of ethylene and 
maleic anhydride. Heller and Trescony (1979) used partially esterified copolymers 
of maleic anhydride to prepare devices which release drug by dissolution of the 
polymer. The rate of surface erosion is controlled by the particular ester group and 
the pH of the environment. Since no backbone cleavage takes place in type 2 
polymers, the solubilization does not result in any significant changes in molecular 
weight. Therefore, polymers of type 2 erosion would probably not be suitable for 
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implantation because a high molecular weight polymer is not readily excreted from 
the body (Heller, 1984). However, these polymers can be used as inserts, as 
opposed to implants. The degradation products would be less liable to be absorbed 
due to their high molecular weight. 
For polymers of the type 3 mechanism , polylactic acid and lactic/glycolic acid 
copolymers are the most commonly used biodegradable polymers. Other polymers 
include polyorthoesters, poly( e -caprolactone) and polyamino acids. Bioerodible 
drug delivery systems based on polylactic acid and lactic/glycolic copolymers have 
been investigated in areas of application such as steroidal contraceptives (Wise et 
al., 1980), narcotic antagonists (Yolles et al., 1974), antimalarials (Wise et al., 
1979), and anticancer agents (Yolles et al., 1975). The forms in which these 
delivery systems have been studied include implantable cylinders, spheres, films, 
and powdered formulations. Other polyesters, such as poly(e-caprolactone) and 
copolymers of e-caprolactone/DL-lactic acid, have been used in the area for 
subdermal delivery of contraceptive steroids (Pitt et al., 1979). Polyamino acids 
and their derivatives have been studied in several different disciplines. The in vivo 
degradation rate of copolymers of L-leucine and L-aspartic acid has been found to 
be dependent upon the degree of hydrophilicity of the polymer (Marck et al., 
1977). Also, copolymers of glutamic acid and leucine have been found to be 
biodegradable and well tolerated in rats (Anderson et al., 1974). 
The ideal situation where surface erosion is the only process contributing to 
drug release has rarely been observed in practice. The only polymers that undergo 
45 
true surface erosion are the partial esters of methyl vinyl ether/maleic anhydride 
copolymers (Heller and Baker, 1980). Most biomaterials that have been utilized 
for controlled release are generally hydrophilic and therefore bulk erosion may 
occur in addition to surface erosion. Furthermore, divisional release of a drug 
may occur in addition to erosion causing the release profile to be diffîcult to 
predict. However, it is possible to select polymer permeabilities and erosion rates 
in order to permit the design of systems that release drug by a diffusion controlled 
mechanism, and then the polymer erodes after the drug is exhausted. 
Hydrogels in Controlled Drug Delivery 
Hydrogels are polymeric materials which exhibit the ability to. imbibe large 
quantities of water without dissolving. They comprise both natural polymers, such 
as crosslinked proteins, starches or cellulosic derivatives, and hydrophilic polymers 
and copolymers of hydro^gr allgrl methacrylates (e.g., hydro;yethyl methaciylate 
(HEMA) and methyl methacrylate (MMA)), N-vinyl pyrrolidone (NVP), 
acrylamide, acrylic and methacrylic acid, polyethylene glycols and crosslinked 
polyglutamic acid. The hydrophilic macromolecules of hydrogels can crosslink to 
form a three-dimensional network. The crosslinkage may be physical, ionic or 
covalent. A characteristic of such systems is the permeability of low molecular 
weight solutes, a criterion that has been used in designing sustained release devices 
(Graham and McNeill, 1984; Lee et al., 1980; Hosaka et al., 1983). 
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Hydrogels can be prepared by polymerization of appropriate monomers or by 
crosslinking of existing hydrophilic polymers. The majority of hydrogels are 
synthesized through the copolymerization of hydrophilic monomers and crosslinking 
agents. The final properties of the hydrogels can be varied within a broad range by 
varying the composition of the polymerization mixture which includes the type of 
monomers, the amount and nature of the crosslinking agents, and the concentration 
of the diluents (or solvents). To control the mechanical properties and the degree 
of swelling (or water content), hydrophobic monomers have been introduced into 
the polymerization mixtures to produce hydrogels with a wide range of water 
contents (Ratner, 1981). Controlled release devices that were fabricated from 
poorly swollen copolymers of HEMA and MMA have been reported to give an 
almost zero-order release of low molecular weight solutes for long periods of time 
(Cowsar et al., 1976). 
Drug containing hydrogel devices have been described in the form of 
membranes, rods, eye inserts, bandages and intrauterine devices. The fabrication 
techniques usually involve casting the hydrogel mixture into a suitable mold. 
Hydrogel devices with a rate controlling membrane have been prepared by dip-
coating (Cowsar et al., 1976), impregnation (Lee et al., 1980) or by trilaminate 
membrane coating (Olanoff et al., 1979). Most successful devices are based on 
polyHEMA and related polymers, although hydrophilic homopolymers of polyNVP, 
polyvinyl alcohol (PVA), and copolymers have been used with some success 
(Ratner, 1981). 
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The release of drug from hydrogels is a function of the type of drug 
(hydrophilic or hydrophobic drug), the polymer composition, the water content in 
the hydrogel, and the amount and type of the crosslinking agent (Schacht, 1984). 
Hydrogels are more likely permeable to hydrophilic solutes than hydrophobic 
compounds. Permeation of solutes through hydrogels can occur (1) by means of a 
pore mechanism where diffusion occurs through the bulk water retained within 
pores that exist in the polymer network or (2) by means of a partition mechanism 
involving dissolution of the solute within the polymer followed by diffusion along 
and between polymer segments (Schacht, 1984). In the pore mechanism case, the 
diffusivity is influenced by the radius of the solute. Diffusion coefficients will 
decrease with increasing size of the solute (Wisniewski and Kim, 1980). On the 
other hand, permeation by means of a partition mechanism is less size dependent. 
Since hydrogels are capable of swelling in water and retaining a significant 
fraction (e.g., > 20%) of water within their structures, the degree of swelling (or 
hydration) of hydrogels also affects the rate of release of drug incorporated within 
the hydrogel. At equilibrium, the water content (WC) retained in a hydrogel is 
expressed by: 
WC = 100 X (WSG - WDG)/(WSG) (14) 
where WSG is weight of swollen gel, and WDG is weight of dry gel. 
Although the presence of imbibed water within a polymeric system is not a 
guarantee of biocompatibility, it is believed that high WC is intrinsically related to 
high biocompatibility (Ratner, 1981). The equilibrium water content of a hydrogel 
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is determined by the hydrophilicity of the monomers used in the polymerization 
mixture, the amount and nature of the crosslinking agent, and such factors as the 
temperature, tonicity, and pH of the hydration medium (Pedley et al, 
1980) but the swelling of homogeneous polyHEMA gels is little affected by 
these factors. A copolymer of HEMA with a hydrophobic monomer, such as 
MMA, will have less than 40% water content. On the other hand, more 
hydrophilic monomer combinations can produce hydrogels with water contents in 
excess of 90%. The concentration of the solvent in the polymerization mixtures can 
also affect the morphology and appearance of the hydrogel. Yasuda et al. (1966) 
reported that homogeneous transparent polyHEMA gels can be obtained if the 
concentration of water in the polymerization mixtures is less than 41%, On the 
other hand, opaque, porous hydrogels were the products if the water concentration 
exceeds 54%. The porous hydrogels will contain large amounts of bulk water and 
hence have high permeability for solutes especially water soluble drugs. 
The network structure of hydrogels can also be influenced by the crosslinking 
density. The diffusion coefficient will decrease with increasing crosslinking density 
due to a reduced pore size and a decreased fraction of bulk water in the hydrogel 
(Zentner et al., 1979; Wood et al., 1982). Consequently, the dissolution-diffusion 
process will dominate the permeation mechanism. Wisniewski et al. (1976) 
investigated the permeation of water through fully swollen polyHEMA hydrogels 
containing varying concentrations of ethylene glycol dimethacrylate (EGDMA) and 
tetraethylene glycol dimethacrylate (TEGDMA) crosslinkers using tritiated water 
f 
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and a diffusion cell. They found that the diffusion coefficients decrease as the 
concentration of crosslinker increases. The coefficients decrease sharply at 
crosslinker concentration of 0-2.5 mole% and reach a limiting value at 
crosslinker concentration between 2.5-7.5 mole%. Their study indicated that a 
crosslinked polyHEMA membrane may provide both partition and pore 
mechanisms of solute transport based on crosslinker concentrations. Anderson et 
al. (1976) prepared polyHEMA hydrogel films containing hydrocortisone succinate. 
Analysis of in vitro release data showed a linear decrease of the logarithm of the 
apparent diffusion constant with increasing weight percent of crosslinker. Schacht 
(1984) has shown that the content of procainamide (a cardiac depressant) depends 
upon the nature of the crosslinker. The rate of release of procainamide 
hydrochloride from poly(HEMA) hydrogels decreased as increasing amounts of 
crosslinking agents were added to the polymerization mixture. 
In addition, the drug release rate fi-om hydrogels can be controlled by the 
device geometry, coating membrane thickness, drug loading, and membrane coating 
copolymer composition (Olanoff et al., 1979). Fabrication parameters such as drug 
particle size, drug loading and matrix coating can significantly affect release kinetics 
in sustained macromolecule release (Rhine et al., 1980). Due to the formation of 
larger channels or pores in the hydrogel matrix, the release rate increases as the 
drug particle size increases. Similarly, increased loading may provide simpler 
pathways and greater porosity for diffusion, both of which would facilitate the 
movement of water into the matrix and solute out of the polymer network. Good 
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and Mueller (1980) have developed polymer systems which can control the 
diffusion mechanism. The permeation of solutes depends heavily on structure and 
thermodynamic interactions within crosslinked polymer networks. These networks 
were synthesized by simultaneous copolymerization and crosslinking of polyHEMA 
in the presence of a hydrophobic macromer, polytetramethylene oxide. Therefore, 
by using different polymeric systems or altering polymer-drug incorporation 
techniques, a wide variety of release kinetics can be achieved. 
Materials for Ocular Applications 
The materials used for fabrication of ocular devices for a specific target such 
as the bovine eye should be sufficiently pliable to permit conformation to the eye 
structure, but should also possess some rigidity to maintain the basic shape of the 
device. In addition, they should be nontoxic and biocompatible to the tissues of the 
eye. Materials used for the development of an erodible ocular insert in this 
research are known as either nontoxic or biocompatible to the tissues of the eye. 
These materials include bioerodible crosslinked alginates, copolymers of HEMA 
and MMA, an antibiotic (tylosin tartrate), and Tween 80 (polyo^grethylene sorbitan 
(20) monooleate) which is incorporated as a plasticizer into crosslinked alginates to 
vary or improve their mechanical properties. 
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Bioerodible crosslinked alginates 
The main ingredient of the bioerodible crosslinked alginates is one of the 
soluble alginates (e.g., sodium alginate, a sodium salt of alginic acid). Alginic acid 
or polymannuronic acid (molecular weight of about 240,000) is a hydrophilic, 
colloidal polysaccharide obtained from seaweed in the form of mixed salts of 
calcium, magnesium, and other bases. It can also be regarded as a family of 
polymers containing varying proportions of D-mannuronic acid and L-guluronic acid 
linked through the 1- and 4-positions (Hirst et al,, 1964). Alginic acid is insoluble 
in water, but some of its salts are not. Since the polar carboxyl groups are free to 
react, alginic acid can be changed to an alginate very readily. Among the inorganic 
salts of alginic acid, only sodium, potassium, and ammonium alginate are soluble in 
water. The molecular weight of the alginate compounds varies widely, depending 
on the manufacturing treatment. The greater the molecular weight, the more 
viscous the alginate-water solution. 
The water soluble alginates can be converted into insoluble alginates by 
crosslinking them with polyvalent metal cations from metal salts such as CaClg or 
AICI3. For example, sodium alginate can react with calcium chloride (CaClg) to 
form calcium alginate as follows. 
Na^Alg + n/2 CaClj > Ca„/2Alg + n NaCl (15) 
where n is an integer. In this reaction, the calcium ion may replace the sodium 
ions in two adjacent molecules to produce a crosslinking between the two 
molecules (Skinner, 1973). As the reaction progresses, a crosslinked molecular 
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complex or polymer network forms. 
In the presence of excess sodium chloride (e.g., as in tear fluid) the reaction is 
reversible, that is, the polyvalent metal ions (e.g., Ca^^) of the crosslinked alginate 
are replaced by the monovalent noncrosslinking ions (Na^) in the tear fluids. 
However, the displacement process of polyvalent ions with monovalent ions from 
the tear fluids is much slower compared to the crosslinking process of the soluble 
alginates. This characteristic makes crosslinked alginates ideal materials for use in 
drug dispensing devices for the controlled continuous and prolonged administration 
of drugs. 
Crosslinked alginates, such as calcium alginate, are hydrophilic, water insoluble 
in their crosslinked state, compatible with the tissues of the eye and bioerodible in 
the environment of the eye (Michaels, 1975). Soluble sodium alginate, on the other 
hand, is widely used as an emulsifier and stabilizer in commercial ice cream and in 
pharmaceutical applications. It is not decomposed or absorbed appreciably when 
ingested, and it does not swell in acid medium (Gleason et al., 1969). Sodium 
alginate has been injected into the vitreous body of rabbits and of patients with 
retinal detachment without notable toxic effect (Grant, 1986). 
The rate of drug release from crosslinked alginates is influenced by the 
solubility of the particular drug itself in the tear fluid, and by the degree of 
crosslinking or the amount of polyvalent metal ions in the alginate material 
(Michaels, 1975). Due to the hydrophilicity of crosslinked alginates, hydrophilic 
drugs (or water-soluble drugs) diffuse through the controlling alginate materials 
faster than hydrophobic drugs. Increasing the amount of metal ions (or crosslinking 
time) increases the amount of crosslinking and lowers the drug release rate. When 
an ocular device is placed in the environment of the eye, the rate controlling 
crosslinked alginate material absorbs tear liquid and swells, achieving a 
microporous structure which is permeable to drugs. In this manner, the drug 
diffuses continuously through these micropores in a permeation controlled mode of 
release. 
Copolymers of HEMA and MMA 
PolyMMA and hydrogels of polyHEMA are the most commonly used materials 
in ophthalmology. PolyHEMA is extensively used for the production of soft contact 
lenses because of its well known biocompatibility and excellent molding properties 
(Refojo, 1975). On the other hand, most hard contact lenses are made from 
polyMMA. PolyMMA is a high optical quality, nonirritating material with excellent 
machining and molding characteristics. In its polymeric form, polyMMA is 
essentially inert and nontoxic, but the monomeric MMA is moderately toxic when 
absorbed into the body. The monomeric form has been reported as being lethal at 
doses of from 6 to 9 gm/kg in experimental animals (Gleason et al., 1969). 
However, the polymerized plastic with MMA content of 3.7% when placed in the 
anterior chamber of rabbit eyes gave no evidence of toxicity during a year of 
observation (Grant, 1986). Therefore, it is questionable whether there was enough 
residual MMA in the material or the ocular device to initiate a toxic response 
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which has been a concern for many ophthalmologists. Copolymers of HEMA and 
MMA have been employed in various drug delivery systems (Olanoff et al., 1979; 
Langer and Peppàs, 1981; Ryoo, 1989). 
Antibiotic 
Moraxella bovis is sensitive to most antibiotics. Penicillin and streptomycin 
have been used widely for the treatment of IBK. However, tylosin, erythromycin, 
and tetracycline were known to be more effective against Moraxella bovis infection 
(Perlman, 1970). Among these antibiotics, tylosin has an inhibitory concentration 
as low as 0.63 Mg/ml (Leytem, 1984). Tylosin (C45H77NO17 , molecular weight 
916.1) is a macrolide developed and marketed specifically for agricultural use 
particularly as supplement in animal feeding (Vazquez, 1975). Tylosin has been 
incorporated as a feed additive for swine, cattle, and chickens at concentrations 
ranging from 10 to 1000 gm/900 kg in attempts to control diseases produced by 
tylosin-sensitive organisms. In these animals, residues above the regulatory 
tolerance of 0.2 ppm were not detected in tissues of animals that were fed with 
tylosin at concentrations of 100, 200, or 500 gm/900 kg (Huber, 1982). Tylosin is 
excreted in urine and in bile. Peak plasma levels usually occur within 1-2 hours 
and the half-life of tylosin ranges from 1-3 hours (Fraser and Mays, 1986). The 
toxicity of tylosin is very low. The LD50 of tylosin for the intravenous (IV) route 
and for the oral route in mice and rats are 600 mg/kg and 5000 mg/kg, 
respectively. In dogs, oral administrationa at doses of 200 and 400 mg/kg/day for 2 
years produced no visceral damage (Huber, 1982). Tylosin is active in the 
inhibition of a number of Gram-positive bacteria and has a high level of activity 
against Mycoplasma, the organisms involved in chronic respiratory disease in 
poultry and in swine enteritis. Tylosin is a weak base that is very soluble 
in most common organic solvents and reacts readily with mineral acids and a 
number of organic acids to form water-soluble crystalline salts, e.g., tylosin tartrate. 
Aqueous solutions of tylosin are stable over the pH range 5.5 to 7.5 at room 
temperature for periods as long as three months. This antibiotic is essentially 
nontoxic and nonirritating to the eye and conjunctival sac (Ellis and Barnes, 1961). 
Tylosin tartrate (C49H83NO23 , molecular weight 1066.2) is also commercially 
available as an agricultural antibiotic (McGuire et al., 1961). Tylosin tartrate has 
been used for medication of water or of food for swine. The dose in water is 
generally of the order of 250 mg/liter and in food 200-400 gm/ton (Blood and 
Radostits, 1989). The solubility of tylosin tartrate in water is greater than 300 
mg/ml. Aqueous solutions of tylosin tartrate (pH 4-9) are stable at room 
temperature for at least one month (Ose and Barnes, 1960). 
Tween 80 (polvoxvethvlene sorbitan monooleate^ 
Tween 80 is used as an emulsifying and dispersing agent in pharmaceuticals. It 
has been added in small quantities to many foods, beverages, and cosmetics 
(Gleason et al., 1969). Also, Tween 80 is used as a plasticizer for food, plastics, 
and cosmetics (Flick, 1986). Standard tests using applications to rabbit eyes have 
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indicated Tween 80 to be nonirritating. It is well tolerated in aqueous solutions in 
concentration up to 20% when dropped on the human eye (Grant, 1986). When 
digested, Tween 80 is absorbed. No single oral dose is known to be lethal in 
laboratory animals (Gleason et al., 1969). 
Reproduction of IBK 
The fact that the incidence of IBK is highest during the warm months and then 
tapers off to a rapid decline when the cold weather arrives suggests there are 
predisposing or contributing factors associated with the disease (Gallagher, 1954; 
Hughes and Pugh, 1970). 
During summer months, dust, tall grasses, sunlight, wind, pollen, and flies are 
considered to be contributing factors to the incidence of IBK. Among these, 
sunlight (ultraviolet (UV) irradiation) appears to be the most important 
predisposing factor for IBK. Ultraviolet radiation possibly acts by enhancing the 
virulence of M- bovis (Hughes and Pugh, 1970). Also, it is believed that UV 
radiation damages the corneal epithelium and thus facilitates the penetration of 
virulent M- bovis (Troutt and Schurig, 1985). Experimentally, IBK can reproduced 
by direct exposure of the eye to UV light, followed by the instillation of M. bovis 
(Hughes et al., 1965). 
Hughes et al. (1965) reported that M. bovis infection alone produced only a 
mild disease. However, with daily doses in the middle ultraviolet light range (280 
to 320 nm), M. bovis infections cause severe clinical signs of keratoconjunctivitis. 
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The resulting disease was indistinguishable from field cases of IBK. The use of a 
UV irradiation method in combination with exposure to M. bovis makes possible 
the study of IBK under controlled conditions at any time of year. Further work 
was done by the same co-workers (Hughes et al., 1968) to determine the effects of 
different lengths of irradiation using a sunlamp each day. They found that 
irradiation of cattle eyes by using a sunlamp at a distance of 61 cm for 15 minutes, 
or less, each day did not cause gross corneal damage, but irradiation for 20 minutes 
or longer did. Ultimately, the optimal conditions were obtained by irradiating the 
eyes twice for 10 minutes, 24 hours apart, at a distance of 61 cm between the 
sunlamp and the eye. After the second irradiation, instillation of M« bovis resulted 
in infection and corneal opacity. However, some eyes failed to develop the disease 
under the "optimal conditions" of irradiation and infection. 
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MATERIALS AND METHODS 
In order to produce ocular inserts for in vitro and in vivo experiments, water-
soluble sodium alginates, with particles of a copolymer of hydrogels containing an 
antibiotic were used. The ocular devices were fabricated by encasing the hydrogel-
drug matrix within a sodium alginate membrane using a casting technique and a 
mold. The cast devices were then coated with a layer of soluble sodium alginate 
solution, and then were crosslinked in a polyvalent metal solution for a 
predetermined period of time. The retention charateristics of these inserts in the 
eyes were then evaluated using calves. Various formulations of sodium alginates 
were used to produce ocular inserts with a wide range of physical properties. The 
formulation that produced inserts with the best retention charateristics was used to 
fabricate ocular devices for use in the other experiments (e.g., the in vitro 
degradation studies of the ocular insert, the in vitro drug release studies of the 
ocular insert, and the infection study). 
Fabrication of Ocular Inserts 
Synthesis of hydrogel copolymer 
The copolymer of HEMA and MMA was synthesized by a batchwise process. 
To produce a copolymer of HEMA and MMA based on a 10:90 molar basis of 
HEMA: MMA, the following materials were added to a one-liter Erlenmeyer flask: 
570 ml of absolute ethanol, 380 ml of deionized water, 5.17 ml of HEMA (Lot # 
82459, Polyscience Inc., ophthalmic grade, Warrington, PA) and 41.4 ml of MMA 
(Lot # 850960, Fisher Scientific Co., Fair Lawn, NJ). The flask was sealed with a 
rubber stopper and the reaction mixture was purged of oxygen by bubbling it 
vigorously with nitrogen for 30 minutes. The polymerization was then initiated by 
the addition of 0.25 gm NagSgOg (Lot # 112F-0655, Sigma Chemical Co., St. Louis, 
MO) and 0.125 gm of K^SgOg (Lot # 852170, Fisher Scientific Co., Fair Lawn, NJ). 
The nitrogen pressure was then adjusted to a slow continuous bubbling (about 1 
bubble/sec) and the reaction was allowed to proceed at room temperature for a 
period of ten days to completion. On the tenth day, the copolymer of HEMA and 
MMA was precipitated in the form of a white, sticky polymer. The solution 
containing the copolymer was then added to a flask containing 3 liters of deionized 
water. The liquid was filtered through Whatman-1 quantitative filter paper in a 
Buchner funnel under vacuum. Each time the funnel was full of the copolymer 
precipitate, the copolymer was washed 5 times with deionized water (approximately 
25-30 ml each time) in order to remove the initiators and any unreacted monomers. 
The washed copolymer was then placed in a beaker covered with filter paper to 
prevent contamination, and the copolymer was dried in a vacuum oven at 50°C at a 
pressure level of 25 mm Hg for a period of 5 days. 
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Fabrication of the mold 
Various Teflon™ ring-shaped molds were used to fabricate the ocular inserts. 
The mold had a central movable part and a base. The central movable part was 
attached to the base by a screw. The base and the central movable part together 
formed a mold which had the shape of a circular ring. The mold space where the 
alginate solution could be injected had a width of 1.5 mm and a thickness of 1.8 
mm. While drying in the oven, the alginate ring shrank and tightened around the 
central movable part which could be removed from the base by unscrewing the base. 
The outside diameter of molds that were used varied from 37 to 52 mm, with an 
increment of 1 mm in order to cover the range of eye sizes between 30 mm to 
43 nmi side-to-side diameters. 
Preparation of hydrogel-drug particles 
The hydrogel-drug particles were prepared as follows. One gram of the 
hydrogel copolymer was dissolved in 20 ml of N,N'-dimethyl formamide (Lot # 
856540, Fisher Scientific Co., Fair Lawn, NJ) and the mixture was heated to 
approximately 55°C for 3-4 hours to provide complete dissociation of the polymer. 
The mixture was then allowed to cool to room temperature and to this mixture 0.5 
gm of tylosin tartrate (Lot # 124F-0198, Sigma Chemical Co., St. Louis, MO) was 
added, and the solution was stirred to dissolve the antibiotic. The ratio of hydrogel 
to drug was 2 to 1 for this type of hydrogel-drug matrix (100 mg to 50 mg per ring). 
The final hydrogel-drug mixture was a yellow viscous solution. This solution was 
61 
poured into a glass petri dish and the solvent (N,N'-dimethyl formamide) was 
allowed to evaporate at room temperature in a hood for 5 days. When dried, the 
hydrogel-drug became brittle and it was ground into small particles using a mortar 
and a pestle. The particles were then screened through a 100 mesh nylon sieve to 
retrieve hydrogel-drug particles with size of the order of 150 microns or less in 
diameter. 
Preparation of sodium alginate solution 
The solution of sodium alginate was prepared by mixing 7.5 gm of the 
formulated sodium alginates (Alginic acid type VI, Lot # 128F0050 and Alginic acid 
type IV, Lot # 72F-0078, Sigma Chemical Co., St. Louis, MO) with 200 ml of 
deionized water. An amount of Tween 80 (polyoxyethylene (20) sorbitan 
monooleate) (Lot # 752139, Fisher Scientific Co., Fair Lawn, NJ) was added to the 
solution as plasticizer. This amount of plasticizer was determined based on the 
formulation used. The amount of Tween 80 varied from 0.03 gm to 1.03 gm. A 
Fisher Stedi-speed® stirrer (Model 12, Fisher Scientific Co., Pittsburgh, PA) was 
used to obtain a uniform sodium alginate solution. An average of 4 to 6 hours was 
required for complete dissociation of sodium alginate in water. Each sodium 
alginate solution was prepared freshly and used within one week from the time of 
preparation. 
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Production of the finished ocular device 
The ocular insert was fabricated in a Teflon™ ring-shaped mold. About 2 ml of 
sodium alginate solution was injected into the mold and dried in an oven at 40°C 
for 4 to 6 hours. This formed a thin sodium alginate film about 4 mils thick. The 
configuration of the film followed the contour of the mold in a shape similar to a 
trough. Then 150 mg of hydrogel-drug particles were dispersed evenly over the dry 
alginate film. Another 2 ml of sodium alginate solution was then injected over the 
hydrogel-drug layer in small amounts at a time and allowed to dry in an oven at 
40°C for another 4 hours. The final ring device was then taken out of the mold, 
and all protruding edges were trimmed. Next, the ring device was dipped into a 
sodium alginate solution (same solution as was used to make the ring) and then was 
quickly immersed into a 30 weight percent calcium chloride solution (pH 6.7) to 
crosslink the sodium alginate. The crosslinking time (or immersion time) was varied 
for a range from 48 hours to 168 hours. The calcium ions (divalent ions) of the 
calcium chloride solution replaced the sodium ions (monovalent ions) in the water-
soluble sodium alginate to form a water-insoluble calcium alginate. After the 
specific crosslinking time, the ring device was removed fi-om the calcium chloride 
solution, rinsed with a 1:1 glycerol-water solution 3 times, and dried in an oven at 
40°C for at least 6 hours. To maintain the circular shape of the ocular insert, the 
ring device was placed on a Teflon™ mandrel of an appropriate size while the 
device dried in the oven. To vary the mechanical properties of the ocular insert. 
various mixtures of sodium alginates (alginic acid type VI (low molecular weight) 
and type IV (high molecular weight)), containing different concentrations of 
plasticizer (Tween 80), were used (Table 2). The plasticizer was used to impart 
flexibility, reduce brittleness, and increase the resistance of the alginate membrane 
to failure produced by mechanical stress (e.g., stress caused by muscles of the eye). 
In addition, the stiffiiess of the ocular insert was improved by further crosslinking 
the ring device in a 10 weight percent AlClg ôHgO solution (pH 3.1) for various 
amounts of time (e.g., 15 minutes, 30 minutes, etc.) after it was crosslinked in a 30 
weight percent calcium chloride solution. In this case, the ocular device was rinsed 
with a 1:9 glycerol-water solution 3 to 4 times and dried as before. However, in 
order to assure that the surface of the insert was free of residual AlClj'ôHjO, 
representative samples of ocular inserts were extracted with deionized water, and 
the extracted solution was tested for the presence of traces of AICI36H2O using a 
silver chloride test (Shriner et al., 1980). The silver chloride test was a technique 
used to detect the presence of CI" ions, and ultimately any traces of AICI36H2O. In 
the presence of chlorine ions in the extract solution, a white precipitate is formed 
upon the addition of a few drops of 0.1 M AgNOg. The test indicates a negative 
result if only a faint turbidity or opalescence or a clear solution is produced. This 
means that there are no CI' ions present or that the concentration of chlorine is too 
low to be detected. This test was sensitive to AICI36H2O at a concentration as low 
as 5 parts per million. To date, no detectable traces of AICI3 6H2O were found on 
any ocular inserts tested using the sensitive silver chloride test. 
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TABLE 2. Various formulations used to fabricate the ocular insert 
and preliminaiy retention test data 
Formulation and 
crosslinking time 
# of rings 
made 
# of rings 
tested 
# of animals 
tested 
# of eyes 
tested 
(1) 100% LMW 
sodium alginate, 
48 hrs in 30% 
calcium chloride® 
200 22 3 (indoors) 6" 
(2) 100% LMW 
sodium alginate, 
96 hrs in 30% 
calcium chloride® 
21 9 3 (indoors) 6" 
(3) 100% LMW 
sodium alginate, 
96 hrs in 30% 
calcium chloride*" 
36 9 3 (indoors) 6" 
(4) 100% LMW 
sodium alginate, 
168 hrs in 30% 
calcium chloride*" 
18 6 2 (indoors) 4" 
(5) 75% LMW/25% HMW« 36 
sodium alginates, 
96 hrs in 30% calcium 
chloride** 
6 3 (indoors) 3" 
(6) 100% HMW sodium 
alginate, 96 hrs in 
30% calcium chloride*" 
18 2 2 (indoors) 2 
®Low molecular weight. 
''More than one ring was inserted in the same eye within one week. 
Tlings were not dipped in a sodium alginate solution prior to crosslinking 
with calcium chloride. 
""Rings were dipped in a sodium alginate solution prior to crosslinking with 
calcium chloride. 
®High molecular weight. 
iTween 80 (polyoxyethylene (20) sorbitan monooleate). 
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TABLE 2. Continued. 
(7) 75% LMW/25% HMW 30 12 6 (2 indoors) 12 
sodium alginates, (4 outdoors) 
72 hrs in 30% calcium 
chloride'', 15 min 
in 10% aluminum chloride (AICI36H2O) 
(8) 75% LMW/25% HMW 30 
sodium alginates, 
72 hrs in 30% calcium 
chloride*', 30 min in 
10% aluminum chloride (AICI36H2O) 
(9) 75% LMW/25% HMW 21 
sodium alginates, 
2.7% plasticizer^, 
72 hrs in 30% calcium 
chloride*", 45 min in 
10% aluminum chloride (AICI36H2O) 
(10) 75% LMW/25% HMW 21 12 6 (2 indoors) 12 
sodium alginates, (4 outdoors) 
2.7% plasticizer, 
72 hrs in 30% calcium 
chloride*", 1 hr in 21 12 6 (outdoors) 12 
10% aluminum chloride (AICI36H2O) 
(11) 75% LMW/25% HMW 21 12 6 (outdoors) 12 
sodium alginates, 
5.4% plasticizer, 
72 hrs in 30% calcium 
chloride*", 1 hr in 10% 
aluminum chloride (AICI36H2O) 
(12) 75% LMW/25% HMW 21 12 6 (outdoors) 12 
sodium alginates, 
7.5% plasticizer, 
72 hrs in 30% calcium 
chloride*", 1 hr in 10% 
aluminum chloride (AICI3 6H2O) 
12 6 (2 indoors) 12 
(4 outdoors) 
12 6 (2 indoors) 12 
(4 outdoors) 
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TABLE 2. Continued. 
(13) 75% LMW/25% HMW 21 12 6 (outdoors) 12 
sodium alginates, 
10% plasticizer, 
72 hrs in 30% calcium 
chloride*', 1 hr in 10% 
aluminum chloride (AICI36H2O) 
(14) 75% LMW/25% HMW 21 12 6 (outdoors) 12 
sodium alginates, 12% 
plasticizer, 72 hrs in 
30% calcium chloride*®, 
1 hr in 10% aluminum 
chloride (AICI36H2O) 
(15) 75% LMW/25% HMW 21 12 6 (outdoors) 12 
sodium alginates, 6.5% 
plasticizer, 72 hrs in 
30% calcium chloride*', 
1 hr in 10% aluminum 
chloride (ÀICI3 6H2O) 
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In Vivo Retention Studies of the Ocular Insert 
As part of the retention studies, the ring device was evaluated for the ease of 
insertion, the amount of local reaction, and the period of retention. By using the 
sizing criteria obtained by Ryoo (1989), the ring size was taken as 1.2 X the eye size 
of the animals for most cases. The optimum ring size was determined as equal to 
1.18 to 1.23 X the eye size. 
Animal sources 
Six Holstein calves were used for the retention test of the ocular insert. The 
average weight of these animals was approximately 590-600 lbs. Table 3 is a listing 
of the animal data for the retention tests. Most animals were kept outdoors except 
those used in the early stage of this study in which any local reaction of the eye due 
to the presence of the ocular insert was monitored, if present. The eye size of each 
animal was measured as the distance from medial canthus to lateral canthus. A 
ruler was used to measure the eye size to the nearest 0.5 mm. 
Preconditioning of ocular inserts 
The ocular device was hard and brittle in its dry state, but became flexible and 
somewhat soft upon contact with water or other biological fluids such as saline. 
Therefore, it was necessaiy to condition the ocular insert prior to use to achieve 
the smoothness of the surface and a suitable degree of flexibility. This was 
accomplished by placing the ocular device in approximately 20 ml of sterile 
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TABLE 3. Animal data for the retention test 
Animal # Age® Eye Size (mm) Ring size (mm) 
1.2 X eye size 
Animal 
Source** 
8L 8 months 36 43-44 WLDF 
8R 36.5-37 44-45 
9L 11 months 39-40 47-48 WLDF 
9R 39-40 47-48 
lOL 11 months 40 48 WLDF 
lOR 40 48 
IIL 9 months 36-36.5 43-44 WLDF 
IIR 35-36 42-43 
23L 7 months 36.5-37 43-44 WLDF 
23R 36.5-37 43-44 • 
24L 6 months 35.5-36 42-43 WLDF 
24R 35-35.5 42-43 
® Age when put on test. 
'' Woodland Dairy Farm in Story City, Iowa. 
saline (0.9% sodium chloride) in a petri dish (100 mm x 15 mm). In most cases, the 
ring devices were conditioned in saline for 18-24 hrs before used. 
Insertion of ocular devices 
Insertion of ocular inserts was carried out indoors (in stancheons). The head of 
the calf was restrained by a halter. Disposable gloves (Tru-touch, Becton-Dickinson, 
Rutherford, NJ) were worn by all personnel carrying out the ring insertion. A fresh 
pair of gloves was used for each animal. Normally, the eye size of each animal was 
obtained a few days prior to ring insertion, and an appropriate ring size was 
selected for each eye. The ring was then conditioned in saline as described above. 
Before insertion of the device, each eye was observed to insure that it appeared to 
be normal. If the tissues were red and the eye showed some signs of irritation (e.g., 
significant tearing or swelling) no ring was inserted. The ring was inserted by 
holding the eyelids open while one side of the ring was directed into the superior 
fornix of the conjunctival sac. The rest of the ring was then directed under the lids 
and finally onto the outer surface of the nictitating membrane where it was seen on 
the medial canthus. After inserting the ring device in the eye, the animal was 
monitored for about 30 minutes to make sure that the ring was properly retained 
and that no excessive tearing was observed. Signs of tearing and eye irritation 
(redness, swelling of eye) were monitored twice a day. The presence of the ring was 
also monitored by observing a portion of the ring device which was commonly 
visible near the medial canthus of the eye for the retention time period following 
insertion. In the early stage of the retention test, 2 to 3 animals were kept indoors 
so that the local reaction of the eye due to the presence of the insert could be 
closely monitored. During this time (approximately 3 months), the eyes of the 
animals were examined daily (2 times a day) for signs of irritation, excessive tearing, 
swelling, and redness of the eye tissues caused by the ocular insert. The ring which 
was visible near the medial canthus of the eye was also monitored for the degree of 
swelling of the ring and degradation of the ring (e.g., some material may come out 
of the eye). It was of interest to see if these observations could be correlated with 
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the in vitro degradation study observations (described in the next section). Various 
formulations of sodium alginates (low molecular weight (LMW) and high molecular 
weight (HMW)) and crosslinking times have been employed to produce inserts with 
different mechanical properties and degradation characteristics for the retention 
studies (Table 2). Most animals were exposed to every formulation, and all animals 
received medicated rings. There was no attempt to retrieve rings from the eyes of 
the animals since none was present beyond the 7th day of each experiment. 
In Vitro Degradation Tests of the Ocular Insert 
Degradation of (he ocular insert 
The degradation of . the ocular inserts was determined by using a weight loss 
method. Formulations (10), (11), and (12) (Table 2) were used to fabricate the 
inserts for the test. These formulations were known to produce ocular devices with 
good retention characteristics in the eyes of calves in this development study. Since 
the weight loss method was used, the antibiotic (tylosin tartrate) was not included in 
the ring, and was replaced with hydrogel particles which did not dissolve in saline. 
The antibiotic was excluded because it was soluble in saline and thus would affect 
the weight loss results. In this experiment, each ring contained approximately 140 
mg of hydrogel particles (< 150 nm in diameter). The original weights of the inserts 
(formulations (10), (11), and (12)) were 0.2227, 0.1993, and 0.1930 gm, respectively. 
In these inserts, the weight of the crosslinked alginates ranged from 50 mg to 80 mg. 
Each insert was placed in a glass container containing 48 ml of 0.9% saline (for a 
tear flow rate of 2 ml/hr (Slatter and Edward, 1982)) and the glass container was 
put into a heated shaking water bath (Model 127, Fisher Scientific Co., Pittburgh, 
PA) at a water temperature of 37°C. The speed of the shaker bath was adjusted to 
about 25-30 cycles per minute. Every 24 hrs, the insert was taken out of the 
container, dried in an oven at 45°C for 4 hrs and then weighed. After weighing, the 
insert was put back in the glass container containing fresh saline and was then 
returned to the shaking water bath. The weight of each insert was recorded every 
24 hrs for the first 600 hrs when the erosion rate was relatively fast, and every 48 
hrs for the rest of the experiment when the erosion rate was relatively slow. 
However, the saline was replaced every 24 hrs. Also, the appearance of the 
degradation product was observed as the experiment proceeded. 
Degradation of crosslinked alginate films 
Two samples of crosslinked sodium alginate films were fabricated from 
formulations (10) and (12) (Table 2) containing 5.4% and 7.5% of plasticizer, 
respectively. Again, these formulations had produced ocular inserts with good 
retention characteristics and had good potential for use in the eyes of infected 
animals. The film samples were crosslinked in a 30% CaClg solution for 72 hrs, and 
then for 1 hr in a 10% AICI3 ôH^O solution. They were rinsed with 1:9 glycerol-
water solution and were dried in an oven at 40-45°C for at least 6 hrs. The 
thickness of these alginate films was similar to the thickness of the alginate 
72 
membrane in an ocular insert (0.1 mm). The weight of each film sample was 
adjusted so that its initial weight was almost identical to that of an alginate 
membrane found in an ocular device. For example, a ring weighing 0.22 gm had 
approximately 0.150 gm of hydrogel-drug particles and about 0.07 gm (70 mg) of 
crosslinked alginates. 
Each film sample was placed in a glass container containing about 48 ml of 
0.9% saline. The container was then put on a heated shaking water bath at 37°C. 
The speed of the shaking water bath was set at 25-30 cycles per minute. Every 24 
hrs, the sample was removed from the glass container, and the saline on the surface 
of the film was removed by pressing the sample lightly between two pieces of filter 
paper (Whatman # 40). The sample was dried in an oven at 45-50°C for about 2 
hrs and then was weighed using an analytical balance. After weighing, the sample 
was put back into a container with fresh saline and the container was returned to 
the shaking water bath. The weight of the sample was determined every 24 hrs for 
the first 500 hrs and then every 48 hrs for the rest of the experiment. The saline 
was replaced every 24 hrs. The experiment was carried out until the film sample 
was dissolved completely or to until only a negligible amount was left. 
Determination of the amount of plasticizer leaching out from crosslinked alginates 
It was hypothesized that a significant amount of plasticizer (Tween 80) was 
leached out of crosslinked ocular inserts upon contact with liquid in the eye. 
Therefore, a weight loss method experiment was carried out to determine the 
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amount of plasticizer that was leached out. 
Two formulations of sodium alginates (formulations (12) and (13), Table 2) 
containing 7.5% and 10% of plasticizer, respectively, were used. The sodium 
alginate solutions were casted on glass plates in order to achieve thin films (about 
0.2 mm thick). The cast films were immediately crosslinked with a 30% CaCl^ 
solution for 72 hrs. They were then crosslinked further with a 10% AICI3 ôHjO 
solution for another hour. Next, they were rinsed with 1:9 glycerol-water solution, 
and were dried in an oven at 45°C for 3 to 4 hrs. Thin films of sodium alginate 
were used in order to assure that complete crosslinking was achieved (i.e., all 
sodium sites were saturated with polyvalent metal ions, either or Al^^). 
The dried alginate films were weighed and their initial weights were recorded. 
Each film sample was place in a glass container and 50 ml of deionized water was 
then added. The extraction of plasticizer from crosslinked alginate films was carried 
out in a heated shaking water bath (37°C) at a fi-equency of 25-30 cycles per minute. 
Every 24 hrs, the sample was removed from the container, dried in an oven at 45°C 
for 3 hrs, and then weighed using an analytical balance. After weighing, the sample 
was put back in the container (into fresh deionized water) and the container was 
then returned to the shaking water bath. Extraction of plasticizer firom crosslinked 
alginate films was carried out until constant weights were obtained. Since 
crosslinked alginates do not dissolve in water (Michaels, 1975), the weight loss from 
the sample determined the amount of plasticizer that leached out from the alginate 
film. 
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In Vitro Drug Release Studies of the Ocular Insert 
Drug release process 
The release of tylosin tartrate from ocular inserts in vitro was carried out using 
a drug elution system. This system consisted of a syringe infusion pump, a precision 
heating water bath, and a sample fraction collector. 
Three ocular insert samples (formulation (12), Table 2) were used. These 
inserts possessed the best retention characteristics in the eye based on studies using 
the calves. Each ocular insert contained approximately 46 mg of tylosin tartrate, 
and the weight of each sample was also known. Table 4 lists the charateristics of 
devices that were tested. Each device was placed into a ring-shaped compartment 
which was connected to the syringe infusion pump (Model 22, Harvard Apparatus, 
South Natick, MA). The sample compartment was positioned above the fraction 
collector (Model LC 200, Buchler Instruments, Lenexa, KS) so that the droplets 
which were obtained from the sample compartment fell directly into the glass test 
tubes arranged below in the slots of the fraction collector. The infusion line 
between the sample compartment and the syringe pump was immersed in a heated 
water bath (Model 182, GCA Corporation, Chicago, IL). Mammalian Ringer's 
solution (8.60 gm NaCl, 0.30 gm KCl, 0.33 gm CaClg in 1.0 liter of deionized water) 
was used as elution solvent. The syringe pump was programmed to pump at a flow 
rate of 2 ml/hr. The temperature of the water bath was set at between 50-55°C so 
that when the elution solvent reached the sample compartment, the temperature of 
the elution medium was about 31-32°C. The fraction collector was programmed 
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TABLE 4. Characteristics of ocular devices for in vitro drug release testing 
Device 
# 
OD= 
(mm) 
ID" 
(mm) 
Thickness 
(mm) 
Weight 
(gm) 
SI 36 34 2.0 0.1980 
S2 35 33 2.0 0.1827 
S3 37 35 2.0 0.2210 
®0D: outside diameter of the ring. 
''ID: inside diameter of the ring. 
to move the slots once every hour, and in each test, 168 samples of the elution 
medium were collected in 7 ml test tubes during the ring drug release test periods 
of 168 hrs (7 days). The syringe pump was capable of providing a continuous flow 
for more than 24 hrs after which the syringe was refilled with Ringer's solution. 
The refilling period was relatively short (of the order of a few minutes) and it did 
not affect the drug release process. 
Quantitative analysis of tvlosin tartrate 
The amount of tylosin tartrate released from ocular devices as a function of 
time was analyzed using a thin layer chromatography (TLC) technique. 
After all the samples were collected, they were placed in an oven at 50°C to 
evaporate the solvent (Ringer's solution). The dried samples contained the drug 
(tylosin tartrate) and the salts (NaCl, KCl, and CaCl;) from Ringer's solution. To 
each drug sample, an amount of water (50 to 1000 jitl) was added, based on the 
anticipated concentration of drug and the associated TLC requirements. For 
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example, release rates were high during the first 12 to 24 hrs of the drug release 
process, but leveled off to much lower concentrations (e.g., 5-20 Mg/hr) after that. 
Also, samples were diluted so that they bracketed the range of standards. 
Whatman LKC18F (20 cm x 20 cm) (Whatman Chemical Separation Inc., 
Clifton NJ) reverse phase TLC plates were used for drug analysis. These plates 
were first developed in a glass chamber containing 100% methanol. The purpose of 
this development was to elute and wash all impurities to the top one centimeter of 
the plate. All fully developed TLC plates were dried for 2 to 3 days at room 
temperature and then stored for subsequent use. 
Four standards with known concentrations of tylosin tartrate (0.5, 1.0, 2.0, and 
4.0 Mg of tylosin tartrate/2.5 jul Ringer's solution ) were prepared. Six samples and 
the four standards were spotted on each TLC plate. A volume of 2.5 nl of each 
standard or redissolved sample was spotted onto the preadsorbent area of the TLC 
plate, about 3-4 mm below the developing line, by using a Drummond 0-10 n\ 
micropipette (Drummond Scientific Co., Broomall, PA). All spots were allowed to 
diy at room temperature before the plate was developed. 
Since the salts in the Ringer's solution tended to bind to the adsorbent media 
on the TLC plate which could affect the spot size and cause band broadening, it was 
important that all standards had the same amount of salts as the samples. For 
example, if the original volume of a collected sample (2 ml) was reduced to 0.2 ml, 
the concentration of salts in the redissolved sample increased ten fold. Therefore, 
the standards required ten times the concentration of the salts of the normal 
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Ringer's solution in order to assure that all spots had the same migration 
properties. 
The dried TLC plates were developed in a developing chamber. A developing 
solvent containing 85 volume percent methanol and 15 volume percent deionized 
water was used. The developing chamber was equilibrated in the presence of the 
solvent by lining the wall of the chamber with moist Whatman type 1 filter paper 
(Type 1-qualitative, Whatman Limited, London, England) on the side facing the 
plate. Each plate was developed until the solvent front reached approximately 8 cm 
above the spotting area. The temperature of the room was kept below 70°F 
(21.rC) to achieve tighter spots and to minimize band broadening. After the plate 
was developed, it was removed from the developing chamber and was allowed to 
dry at room temperature. Indirect visualization of the tylosin tartrate spots on the 
TLC plate was accomplished by using an ultraviolet (UV) light (Model UVGL-25, 
UVP, Inc., San Gabriel, CA). Normally, only spots with concentrations greater than 
2 ng were seen under the UV light. The spots on the plate were visualized directly 
by spraying the plate with 10 volume percent of reagent grade sulfuric acid in 
methanol onto the developed area at a rate of approximately 15 ml/min for about 
15-20 seconds using a sprayer. The plate was then heated in an oven at 105-110°C 
for 5 minutes, after which brown spots or light brown spots were visible on the 
plate. The plate was allowed to cool to room temperature, and the concentration of 
each spot on the plate was analyzed using a densitometer (Model 800 Fiber Optics 
Scanner, Kontes Scientific Instrument Group, Vineland, NJ). The densitometer 
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scanned the intensity of the spots in a direction perpendicular to the direction of 
development after the reading head was visually aligned with the tylosin spots. The 
densitometer was connected to a data acquisition system consisting of an IBM PC 
AT (IBM Corporation, Boca Raton, FL). Keithley 570 data acquisition hardware 
(Keithley Data Acquisition and Control, Cleveland, OH) was used. A basic 
program (ACQ.BAS) was used to acquire the data and it was stored on floppy disks. 
Another basic program (AREABAS) was used to analyze the data and calculate the 
concentration of drug in each sample. The parameters used for the densitometer 
were as follows: scan speed 10 cm/min, attenuation 1 or 2, normal output, B-A 
scanning mode (head B scans, head A is reference), and 450 nm filter. The 
computer was used to control the scanning process of the densitometer. In this 
study, all drug samples were analyzed in order to determine the cumulative release 
as a function of time. Since the ocular insert was erodible, it was desired to see if a 
bursting release pattern existed. 
Infection Study 
In order to test the efficacy of the ocular device for treating IBK, an ultraviolet 
(UV) radiation method was used in conjunction with M. bovis instillations to 
duplicate the disease in calves. Eight animals were used. They were divided into 
two groups. One group was used for the ring studies, and the other group was used 
for subconjunctival injections using an antibiotic (Azimycin®). Table 5 summaries 
the experimental procedures for each group of animals. 
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TABLE 5 Summary of experimental procedures for each animal group 
Group Animal Experimental treatment method Post treatment method 
No. 
I 
No. 
229L non-medicated ocular insert 
229R medicated ocular insert 
260L non-medicated ocular insert 
260R medicated ocular insert 
262L non-medicated ocular insert 
262R medicated ocular insert 
263L medicated ocular insert 
263R non-medicated ocular insert 
medicated ocular insert 
medicated ocular insert 
t l  I I  
medicated ocular insert 
medicated ocular insert 
subconjunctival injection 
of Azimycin®® 
n 232L subconj. injection, sterile saline*" medicated ocular insert 
232R " " Azimycin® f t  I I  
9172L subconj. injection, sterile saline medicated ocular insert 
9172R " " Azimycin® I t  t t  
261L Subconj. injection, sterile saline medicated ocular insert 
261R " " Azimycin® M I I  
228L Subconj. injection, sterile saline medicated ocular insert 
228R Azimycin® I I  I I  
®Inject 1 ml of penicillin-dihydrostreptomycin-dexamethasone (Azimycin®, 
Schering Corp., Union, NJ), 
•"Inject 1 ml of sterile saline. 
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Efficacy testing of ocular inserts 
Animal sources Eight Holstein calves were used. The age of these calves 
varied from 6 to 8 months, and their weight ranged from 250 to 450 lbs. The 
animals were not vaccinated and were raised on antibiotic-free calf feed. The 
animals were kept indoors in isolation units, excluding sunlight and flies. The 
quarters where the calves were housed were well ventilated. 
Bacterial cultures Strain 118F of M. bovis grown as second passage was 
used as a seed. To eliminated low levels of contamination (bacteria other than M-
bovis). ten fold dilutions of the seed in 10% MgCl2 were made. These dilutions 
ranged from 10'^ to 10"^. To each blood agar plate (Blood agar plates are made 
with tryptose blood agar base (Difco, Detroit, MI) with 5% defibrinated bovine 
blood), 0.1 ml of each dilution was added, and spread using a sterile bent Pasteur 
pipette. The plates were then incubated in an incubator for 24 hrs at 37°C, and 4% 
COg, and were then left at room temperature for another 24 hrs. The low level 
dilution (e.g., 10'\ 10'^) plates showed signs of some contamination and were 
discarded. The higher dilutions (10'^ 10"®) had only M. bovis and were used as a 
source of seed culture. 
From an uncontaminated plate, 20-30 smooth, corroding type colonies were 
picked using a sterile cotton swab. These colonies were dispersed in 2.5 ml of 
phosphate buffered saline (PBS). From this solution, 15 blood agar plates were 
inoculated using sterile cotton swabs. The plates were then incubated in an 
incubator at 37°C, and 4% CO; for 20 hrs after which the bacteria were harvested. 
The bacteria from each BAP were harvested by using a sterile plastic scraper. They 
were suspended in IS ml of 1:1 lactose glutamate-0.5% bovine serum albumin 
solution and kept on an ice bath. Immediately after resuspension, 1 ml portions of 
the suspension were aliquoted into 1 ml ciyotubes and were frozen in a dry ice bath 
(dry ice and ethanol). All cryotubes were stored in a freezer at -70°C. Since the 
bacterial seed had been grown twice on culture media, the final harvest was 
designated as passage 4 (passage 2 was the seed). 
Titration of frozen Mi bovis stock An aliquot (1 ml) of frozen M. bovis 
stock was thawed at room temperature and ten fold dilutions (10'^ to 10"®) were 
made using 10% MgCl; as diluent. A ten fold dilution was made by mixing 0.9 ml 
of 10% MgCl2 with 0.1 ml of the original bacteria solution. A second dilution was 
made by mixing 0.1 of the first dilution with 0.9 ml 10% MgClj diluent. In a similar 
manner, 3rd to 8th dilutions were made. One tenth milliliter of each dilution was 
added to a blood agar plate and spread evenly with a sterile bent Pasteur pipette. 
The plates were then incubated for 24 hrs at 37°C with 4% €0%. The lower dilution 
plates (10*^ to 10^) were used to determine if the frozen challenge was 
contaminated, and the higher dilution plates were used to obtain the titer expressed 
in colony-forming units/ml (CFU/ml), by counting the number of M. bovis colonies 
on a plate. The colony-forming units are defined as the number of separated 
colonies which grew on the blood agar plate. 
Pretreatment of animals In order to assure that the eyes of all animals were 
free of normal flora, each eye was treated with 1/2 tube (1.5-1.7 gm) of antibiotic 
ointment (Ophthocort®, Parke-Davis, Morris Plains, NJ). Each gram of antibiotic 
ointment contained 10 mg of chloramphenicol, 10,000 units of polymycin B, and 5 
mg of hydrocortisone acetate. Two to four days after the treatment with antibiotic 
ointment, samples from each calf were collected from the conjunctival area by using 
sterile cotton swabs. The sample (cotton swab) was stored in a sterile tube and 
capped. To each tube containing the swab sample, 1 ml of sterile phosphate 
buffered saline (PBS) was added, and the contents of the tube were mixed using a 
vortex mixer (Vortex-Genie, model K-550-G, Scientific Industries, Inc., Bohemia, 
NY). The swab was then discarded using a sterile forceps. Next, 0.1 ml of the 
sample solution was added to a BAP and spread with a sterile bent Pasteur pipette. 
All plates were incubated for 24 hrs at 37°C, with 4% CO2. The plates were 
checked after 24 hrs for the presence of any bacteria that remained in the eyes of 
the calves. 
First ultraviolet (UV) irradiation Two sunlamps ( Model RSK6, General 
Electric Co., Nela Park, Cleveland, OH) were used as sources of UV radiation. 
Each animal was confined in a portable cattle chute. The head of the calf was tied 
to the cattle chute in order to restrict its movement. The UV lamp was positioned 
at a distance of 61 cm from the plane of the cornea of the eye, and just below the 
height of the eye so that the eye was in the center of the beam. In this way, UV 
radiation could still get into the eye even if the eyelids of the animal were partially 
closed. Each eye was irradiated for 15 minutes. The sun lamp had a constant 
output of 251-276 m Watts/cm^ at a distance of 61 cm after it was switched on for 2 
minutes. Prior to irradiation, the output of each sunlamp was obtained using a 
calibrated UV meter (Model DM-300N (280-320 run), Spectronics Corporation, 
Westbury, NY). 
Second UV irradiation and inoculation with M. bovis inoculum One day 
after the first UV irradiation, a second UV irradiation was done using the same 
procedure as the first irradiation. After the second irradiation, a M- bovis inoculum 
was prepared from uncontaminated frozen stock of M* bovis (previously cultured, 
harvested, and stored in a freezer). The frozen stock samples of M. bovis (118F, 
passage 4) were thawed at room temperature and each milliliter of stock M- bovis 
(titer 2 x 10' CFU/ml) was diluted with 4 ml of a gram negative wash solution (0.5 
M sucrose, 5 mM phosphate buffer (pH 7), 50 mM MgClj, and 0.05% bovine serum 
albumin) to make a challenge solution containing approximately 4 x 10® CFU/ml. 
The challenge was kept on ice and was prepared just prior to inoculation. Each eye 
received 2 ml of the diluted challenge. The bacteria were instilled slowly into the 
eye using a 3 ml sterile syringe. A small portion (0.2-0.3 ml) was instilled at a 
time, and the eye was rubbed for about 5-10 seconds after each instillation. A 
portion of the diluted challenge was saved for titration to determine the exact titer. 
Titration of Mi bovis inoculum After inoculation of all eyes, 0.1 ml of the 
inoculum was titrated to determine the titer. As usual, ten fold dilutions (10"^ to 
10"®) were made using 10% MgCl; as diluent. One tenth milliliter of each dilutions 
was added to a plate and spread using a sterile bent Pasteur pipette. The titration 
plates were incubated for 24 hrs in 4% COg at 37°C. The number of M. bovis 
colonies on a plate was counted. The titer was calculated in colony-forming 
units/ml (CFU/ml). Subsequently, the number of M. bovis colonies per eye was 
obtained by multiplying the titer by the number of milliliters instilled per eye. 
Bacteriological evaluation before treatment After a M- bovis challenge 
exposure, conjunctival swab samples were obtained from the eyes of the calves twice 
during the first 5 days (2 days apart) of the experiment using sterile cotton swabs. 
After the head of the animal was restrained, the eyelids were parted and the cotton 
swab was put into the lower conjunctival sac near the medial canthus and gently 
rotated a few times to obtain a good sample. The swab was then pulled out quickly 
without touching any outside parts of the eye, and was then immersed in a 
centrifuge tube containing 3 ml of ice-cold gram negative wash solution. The tube 
was capped and kept on ice. A fresh pair of disposable gloves was used for each 
animal to prevent transmission of bacteria from one animal to another animal. All 
sample tubes containing a swab sample were agitated using a mixer. The swab was 
discarded by pulling it out of the tube with a sterile forceps after squeezing most of 
the fluid out of the swab into the tube. The tubes were then spun at 12,000 
revolutions per minute for 10 minutes at 4°C. The supernatant was gently 
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poured off and discarded leaving a M- bovis pellet on the inside of the tube. Three 
tenths of a milliliter of gram negative wash was added to the ttibe containing the M-
bovis pellet, and the contents of the tube were agitated gently using a mixer. From 
this suspension (0.3 ml of undiluted sample), 0.1 ml was added to a plate 
(representing 1/3 dilution of the original sample). Another of 0.1 ml of the 
undiluted sample was added to 2.9 ml of 10% MgCl^ to make a 1/30 dilution 
(representing 1/90 of the swab burden per eye). Another dilution was made by 
mixing 0.1 ml of 1/30 dilution with 0.9 ml of 10% MgCI^ diluent (representing 
1/900 of the swab burden per eye). One tenth milliliter from diluted samples was 
also added to individual plates, and the samples were spread using a sterile bent 
Pasteur pipette. These dilutions were made in order to reduce the number of M-
bovis colonies on a plate so that they could be counted individually and accurately. 
The plates were incubated at 37°C with 4% COg for 24 hrs, after which the number 
of M- bovis colonies were read. If a plate had many smooth, corroding type 
colonies (e.g., over 500 colonies), the total number of colonies was determined by 
counting colonies in a fractional portion of the plate and then multiplying this 
number by the appropriate factor to give the count for the whole plate. The plates 
were left at room temperature for an additional 24 hrs in order to verify the counts 
as well as to distinguish the cultured M- bovis colonies from other bacteria on the 
plates. The bacteria counts were expressed as a logarithm of colony-forming 
units/swab, i.e., logioCFU/swab. 
86 
Clinical observations All calves were observed once a day to record 
clinical signs of IBK using visual examination. In order to describe the disease 
more effectively, a clinical grading chart was developed based on the severity of the 
disease through various stages, modified from those described by Jackson (1954) 
and Pugh et al. (1982). Table 6 lists the clinical grading scales for IBK. 
TABLE 6. Clinical grading scales for IBK 
Scale Description 
Grade 0 Normal eye 
Grade 1 Conjunctivitis (red mucosa), mild tearing 
Grade 2 Grade 1 + severe conjunctivitis, engorgement of bulbar 
conjunctival vessels, severe tearing 
Grade 3 Grade 2 + diffuse corneal opacity affecting < 50% of 
cornea, mild corneal surface erosion 
Grade 4 Grade 2 + diffuse corneal opacity affecting > 50% of 
cornea, surface erosion, profuse wateiy tearing 
Grade 5 Grade 3 + heavy corneal opacity and shallow corneal 
erosion, profuse serous tearing 
Grade 6 Grade 5 + corneal ulceration 
Grade 7 Grade 5 + keratoconus 
Comparison of treatments of ocular inserts and subconjunctival injections 
Five days after M. bovis was instilled into the eye, both groups of animals were 
treated. The effectiveness of the ocular insert containing tylosin tartrate was 
evaluated in infected eyes in parallel with the subconjunctival injections of 
Azimycin® (a conventional method of treating severe IBK infections in cattle). For 
each animal, both eyes were used. One eye was used as a treated eye, and the 
other as a control eye. The eyes with severe signs of infection were used as treated 
eyes. For calves used in the ring studies, the treated eye received a medicated 
ocular insert, and the control eye received a non-medicated ring. All rings were 
selected based on the criterion of 1.2 X eye size of each animal. The rings were 
conditioned in saline for over 18 hours. For the subconjunctival treatment group, 
the treated eye was injected with 1 ml of Azimycin® into 3 or 4 places of the bulbar 
conjunctiva and the palpebral conjunctiva. Each milliliter of Azimycin® contained 
0.5 mg of dexamethasone, 10 mg of chlorpheniramine maleate, 250 mg of 
dihydrostreptomycin, and 200,000 units penicillin G procaine. In a similar manner, 
the control eye was injected with 1 ml of sterile saline. In order to treat the animals 
with subconjunctival injections, each animal was sedated with xylazine (Rompun®, 
concentration 20 mg/ml, Haver-Lockhard, Shawnee, KS). The doses were 0.2-0.25 
ml for large animals (350-450 lbs) and 0.1 ml for the small animals (150-300 lbs). 
Bacteriological evaluation after ring insertion and subconjunctival injection 
Due to the presence of the ocular ring device in the eyes of animals that were 
treated with medicated rings, the conjunctival swab sampling method was modified 
somewhat in order to avoid touching the surface of the medicated ring with a swab, 
or damaging the erodible ring whose mechanical properties decreased as a function 
of time. A sample was obtained by pushing a sterile cotton swab into the lower 
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conjunctival sac near the medial canthus. The cotton swab was held still while it 
was allowed to absorb tear fluid during a period of a few seconds ( 5 to 10 seconds). 
The swab was then pulled out quickly without touching any portion of the ring or 
outside parts of the eye, and was then stored in a centrifuge tube containing 3 ml of 
ice-cold gram negative wash. If a swab did not absorb a sufficient amount of tear 
fluid, the subsequent results of the bacteria count would not be representative. 
However, since the sampling method was applied for all animals, the relative errors 
would be small among animals as well as between the two treatment methods (ring 
device and subconjunctival injection). Conjunctival sampling and bacteriological 
evaluation were carried out for 3 consecutive days after the animals were treated 
(on day 5) and then every 2 days for the next 4 days for a total of 7 days. The 
clinical signs were also observed on a daily basis. 
Post treatment gf animals At the end of the experiment, about 7 days after 
the comparison of both treatment methods, all but one eye (# 263 right eye) were 
treated with medicated ocular inserts in order to cure all control eyes, and to obtain 
more data on the retention of the ring in the eyes of infected animals. The right 
eye of calf # 263 was treated with subconjunctival injections of 1 ml Azimycin® into 
3 or 4 locations within the bulbar conjunctiva and palpebral conjunctiva. The 
retention of the ring was monitored daily by observing the presence of the 
insert in the eye of each animal. Five days after the post treatment, tear samples 
were again collected to make sure that the eyes were free of M. bovis or that the 
number of bacteria was reduced to a negligible level (only a few colonies present). 
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Statistical analyses A two-tailed t-test was used to compare the average 
bacteriological results and the average clinical results between the two treatment 
methods (ocular devices and subconjunctival injections of Azimycin®). The 
significance levels (p values) were generated by using the Statistical Analysis System 
(SAS) software system. 
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RESULTS 
Fabrication of Ocular Inserts 
Various formulations of sodium alginates and various crosslinking times were 
employed to produce ocular inserts with a wide range of physical characteristics. In 
addition, a combination of polyvalent metal cations was used to achieve various 
degrees of flexibility and stiffness of the insert. 
The ring device that seemed to have best physical properties was fabricated 
from a formulation containing 75% low molecular weight (LMW) sodium alginate 
(alginic acid, type VI), and 25% high molecular weight (HMW) sodium alginate 
(alginic acid, type IV). The content of plasticizer (Tween 80) in the sodium alginate 
mixture was 7.5%. The ocular device was dipped in a solution of sodium alginate 
(same formulation) and crosslinked for 72 hrs in 30% CaClg solution, and then 
crosslinked one hour in a 10% AICI36H2O solution. 
The ocular device had a thickness (the diameter of the cross section) of 1.8-2.0 
mm. Each ocular insert contained 140 mg of hydrogel-drug particles of which 46 
mg was tylosin tartrate. The sizes of the hydrogel drug particles were equal to or 
smaller than 150 /xm. By limiting the size of the hydrogel-drug particles to 150 nm 
or less, a rough insert surface texture was minimized. Also, these fine particles 
could be washed away easily by the tear solution in the event that they were 
released into the eye. 
A variety of ring sizes, with outside diameters ranging from 37 mm to 52 mm, 
were available to accommodate a wide range of eye sizes from 31 mm to 43 mm 
in diameter for each increment of 1 mm in diameter. A typical ring device that was 
selected for use is shown in Figure 1. In the dry state, the ocular insert was brittle 
and hard, but became somewhat soft and flexible upon contact with an aqueous 
solution of saline or tear fluid (Figure 2). The surface textures of the ring device in 
the dry state and wet state are shown in Figures 3 and 4, respectively. 
Rings that were fabricated from the LMW sodium alginate, and only 
crosslinked in 30% CaClj solution, did not have the stiffness necessary to maintain 
the desired shape and dimensional stability when immersed in biological fluids 
(e.g., saline) for a long period of time (24 hrs or longer), especially those that were 
FIGURE 1. A typical ring device in the dry state (magnification = IX) 
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FIGURE 2. A ring device in the wet state (after conditioning in saline for a few 
hours) (magnification = IX) 
FIGURE 3. Surface texture of a ring device in the dry state 
(magnification = 32X) 
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FIGURE 4. Surface texture of a ring device after conditioning in saline for 
a few hours (magnification = 32X) 
not dipped in a sodium alginate solution prior to crosslinMng (formulations 1-4, 
Table 2). 
A combination of crosslinking in 30% CaClg solution and then in 10% 
AICI3 6H2O solution tended to produce ocular inserts that had a sufficient degree of 
flexibility and stififaess to comform to the configuration of the eye, and at the same 
time, maintain the basic shape of the ring. Formulations that contained a mixture 
of sodium alginates (75% LMW/25% HMW sodium alginate) and various 
concentrations of plasticizer (2.7% to 7.5%) were capable of producing ocular 
inserts that have potential for use in the bovine eye environment. The ring became 
stiffer and more brittle as the crosslinking time in 10% AICI36H2O increased from 
15 minutes to 1 hour. Beyond 1 hour of crosslinking, the ring tended to become so 
brittle that it was easily broken during handling and insertion. The amount of 
plasticizer in the sodium alginate solution seemed to influence the physical 
charateristics of the ocular device. The physical properties of the insert tended to 
improve as the amount of plasticizer was increased from 1.3% to 7.5%. However, 
at a level above 7.5%, the physical characteristics of the ring tended to change (the 
ring became brittle). This was evidenced by the fact that a high percentage of the 
rings was broken during the fabrication process. In addition, by adding more 
plasticizer to the sodium alginate solution, there was less material (sodium alginate) 
left for crosslinking since the plasticizer was not capable of crosslinking with 
polyvalent metal ions. It was observed that at a high concentration (e.g., > 8%), 
the plasticizer acted as a disintegrating agent instead of as a binding or dispersing 
agent. Sodium alginate solutions containing more than 12% of plasticizer had a 
cloudy appearance and were not useful. 
By using a mixture of sodium alginates (LMW and HMW), a stronger ring was 
obtained. However, if the concentration of HMW sodium alginate was greater than 
25%, separation between two components (LMW and HMW) was observed and 
fabrication became much more difficult due to a very high viscosity of the sodium 
alginate solution. A non-uniform ring was easily broken when it was taken out of 
the mold. 
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In Vivo Retention Studies of the Ocular Insert 
In the retention study, 6 animals were used (Table 3). The rings were tested in 
the eyes of these animals on a weekly basis. All animals received medicated rings. 
All formulations (Table 2) were used and most animals were exposed to every 
formulation. The formulations were developed as the retention test progressed in 
order to modify and obtain a ring device with better retention characteristics in the 
eyes. The ring size was taken as 1.2 X eye size of the eye. The effect of sizing 
(ring size) was also tested in eyes by using rings that had outside diameters larger or 
smaller than the optimal criterion (1.2 X eye size). All animals were monitored 
twice daily for signs of irritation, excessive tearing, swelling of the eye, and redness 
of the eye tissues caused by the ocular insert. None of these signs were seen 
throughout the test period. The ocular inserts that were used during the early stage 
of the retention test (formulations (1) to (8), Table 2) had poor mechanical 
properties and did not stay in the eyes of the calves for more than a few hours. The 
majority of these rings fell out within minutes. 
Rings that were fabricated from LMW sodium alginate, and only crosslinked 
with 30% CaClg solution, tended to become soft in the eye of the animal in a short 
time. As a result, the ring collaped and was pushed out by either a rubbing or a 
blinking action initiated by the animal. In addition, it was difficult to insert a soft 
ring into the eye since the ring was deformed and broken apart during or just after 
the insertion. Increasing the crosslinking time of the ocular device in a 30% CaCl; 
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solution from 48 hrs to 96 and to 168 hrs did not improve the retention 
characteristics of the ring (Figure 5). This suggested that when saturation occurred, 
further crosslinking of the material had no affect on the properties of the already 
crosslinked alginate. The maximum crosslinking time in 30% CaClg solution was set 
at 72 hrs for all devices in order to assure a complete crosslinking. 
The thickness (or the diameter of the cross section) of the ring was also an 
important variable. If the ring was too thick (> 2 mm), the insert tended to come 
out too quickly (poor retention of the ocular device in the eye). For this reason, the 
thickness of all inserts used in this experiment was limited to 2 mm or less. 
By using a mixture of sodium alginates (75% LMW and 25% HMW), a 
significant improvement in the retention of the ocular insert in the eyes of the 
calves was achieved. This effect is shown in Figure 6 and is compared with 
formulations containing 100% LMW sodium alginate and similar crosslinking times 
in 30% CaCl; solution. 
Stiffness and flexibility seemed to be the most important properties that an 
ocular insert must possess in order to guarantee a long term retention in the bovine 
eye. The ring must be flexible enough to conform to the shape of the eye, but must 
also be sufficiently stiff to maintain its basic circular shape. The change in flexibility 
of the ring was achieved by crosslinking the ring with calcium chloride. 
Furthermore, as the displacement process of the polyvalent metal ions by the 
monovalent (sodium) ions in the tear fluids proceeded, the ring became soft and 
more flexible as a function of time since it was erodible. The stiffiiess of the ocular 
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device was achieved by further crosslinking of the ring in a 10% AlCl^ôHgO 
solution for various amounts of time. In addition, the swelling of the insert in saline 
was significantly slowed down since it would require more monovalent ions (sodium) 
to replace a trivalent ion (Al^^) than a divalent ion (Ca^^) in terms of the kinetics 
of the reaction. The longer the crosslinking time in 10% AICI36H2O solution, the 
stiffer the ring. However, crosslinking times longer than 1 hour were avoided since 
the crosslinked ocular insert became so brittle that it was easily broken during the 
manufacturing process. 
As the crosslinking time in 10% AICI36H2O solution increased, the retention of 
the ring in eyes tended to improve. This is illustrated in Figures 7 and 8. Figure 7 
shows that the retention time of the ring in calves eyes was doubled by just 
increasing the crosslinking time from 15 minutes to 30 minutes while keeping other 
variables constant (e.g., the composition of the sodium alginate solution, and the 
plasticizer content). Figure 8 shows a similar trend for crosslinking times of 45 
minutes and 1 hour. These results clearly indicated that stiffness was an important 
property of the ring for achieving long term retention. 
To reduce the brittleness of the insert, and also to improve the life time of the 
ring in eyes, various amounts of plasticizer (Tween 80), ranging from 2.7% to 12%, 
were added to the sodium alginate solution. Good retention characteristics were 
achieved when formulations of sodium alginates containing more than 2.7% of 
plasticizer were used. The ring devices were crosslinked further in 10% AICI36H2O 
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for 45 minutes to 1 hour. Most ring devices (> 90%) stayed in the eyes of the 
calves for at least one day, and about 50% stayed in the eye for at least 3 days. The 
overall period ranged from 1 day to more than 6 days. Figure 9 shows the effect of 
the content of plasticizer on the retention characteristics of the ring in calves eyes. 
The retention of the ring seemed to improve as the amount of plasticizer increased 
from 2.7% to 7.5%. However, the ring exhibited poorer retention characteristics as 
the content of plasticizer was increased beyond 7.5%. This was possibly due to the 
fact that at higher percentages of plasticizer, there was less material for crosslinking. 
As a result, the ring was weaker (due to a non-uniform ring) and this led to poor 
retention in eyes. The retention time of the ring for the formulation 75% 
LMW/25% HMW sodium alginates, crosslinked for 72 hrs in 30% CaClg, and 1 
hour in 10% AICI36H2O, along with a listing of the various amounts of plasticizer is 
given in Tables 7-12. Table 13 lists the average retention times of the ocular insert 
for the same formulation above with various plasticizer concentrations. The size (or 
the outside diameter) of the ring device was also an important factor affecting the 
retention time of the insert. The effect of ring size is shown in figure 10. If a ring 
was too large or too small, the ring tended to be forced out earlier. However, 
larger rings seemed to have poor retention in calves eyes during the first 24 hrs 
after insertion (Figure 10). It is important that all rings stay in the eye for at least a 
day in order to guarantee an effective treatment of IBK since according to work by 
Ryoo (1989), the organisms (M. bovis) were suppressed within one day after the 
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TABLE 7. Retention time of ocular inserts (formulation 10®) 
Animal # 
and eye 
Eye size'' 
(mm) 
Ring size® 
(mm) 0 
Retention time (day) 
1 2 3 4 5 6 7 
8L 36.0 43-44 I + + F 
8R 36.5-37 44-45 I + F 
9L 39-40 47-48 I + F 
9R 39-40 47-48 I + F 
lOL 40 48 I + F 
lOR 40 48 I + F 
IIL 36-36.5 43-44 I + + + F 
IIR 35-36 42-43 I + + + + + F 
23L 36.5-37 43-44 I + + F 
23R 36.5-37 43-44 I + + + + F 
24L 35.5-36 42-43 I + + + + F 
24R 35-35.5 42-43 I + + + + + F 
®75% LMW/25% HMW sodium alginates, 2.7% plasticizer, crosslinked for 72 
hrs in 30% CaClj solution, 1 hr in 10% AlClg ôHgO solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
Tling size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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TABLE 8. Retention time of ocular inserts (formulation 11®) 
Animal # 
and eye 
Eye size'' 
(mm) 
Ring size® 
(mm) 0 
Retention time (day) 
1 2 3 4 5 6 7 
8L 36.0 43-44 I F 
8R 36.5-37 44-45 I + F 
9L 39-40 47-48 I + + F 
9R 39-40 . 47-48 I + F 
lOL 40 48 I F 
lOR 40 48 I + F 
IIL 36-36.5 43-44 I + + + F 
IIR 35-36 42-43 I + + + + + F 
23L 36.5-37 43-44 I + F 
23R 36.5-37 43-44 I + + F 
24L 35.5-36 42-43 I + + + + + F 
24R 35-35.5 42-43 I + + + + + F 
'75% LMW/25% HMW sodium alginates, 5.4% plasticizer, crosslinked for 72 
hrs in 30% CaClg solution, 1 hr in 10% AlO^ ôH^O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
®Ring size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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TABLE 9. Retention time of ocular inserts (formulation 12®) 
Animal # Eye size'' Ring size® Retention time (day) 
and eye (mm) (mm) 0 1 2 3 4 5 6 7 
8L 36.0 43-44 I + + F 
8R 36.5-37 44-45 I + F 
9L 39-40 47-48 I + + + + F 
9R 39-40 47-48 I + F 
lOL 40 48 I + F 
lOR 40 48 I + F 
IIL 36-36.5 43-44 I + + + F 
IIR 35-36 42-43 I + + + F 
23L 36.5-37 43-44 I + + + + F 
23R 36.5-37 43-44 I + + + + F 
24L 35.5-36 42-43 I + + + + + F 
24R 35-35.5 42-43 I + + + + + + F 
"75% LMW/25% HMW sodium alginates, 7.5% plasticizer, crosslinked for 72 
hrs in 30% CaClj solution, 1 hr in 10% AIQ36H2O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
^Ring size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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TABLE 10. Retention time of ocular inserts (formulation 13®) 
Animal # Eye size** Ring size® Retention time (day) 
and eye (mm) (nmi) 01234567 
8L 36.0 43-44 I + F 
8R 36.5-37 44-45 I + F 
9L 39-40 • 47-48 I + + F 
9R 39-40 47-48 I + F 
lOL 40 48 I F 
lOR 40 48 I + F 
IIL 36-36.5 43-44 I + F 
IIR 35-36 42-43 I + + F 
23L 36.5-37 43-44 I + F 
23R 36.5-37 43-44 I + F 
24L 35.5-36 42-43 I + + + F • 
24R 35-35.5 42-43 I + + F 
"75% LMW/25% HMW sodium alginates, 10% plasticizer, crosslinked for 72 hrs 
in 30% CaCl; solution, 1 hr in 10% AICI36H2O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
®Ring size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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TABLE 11. Retention time of ocular inserts (formulation 14®) 
Animal # 
and eye 
Eye size'' 
(mm) 
Ring size® 
(mm) 0 
Retention time (day) 
1 2 3 4 5 6 7 
8L 36.0 43-44 1 + F 
8R 36.5-37 44-45 I + F 
9L 39-40 47-48 I + F 
9R 39-40 47-48 I F 
lOL 40 48 I F 
lOR 40 48 I F 
IIL 36-36.5 43-44 I + F 
IIR 35-36 42-43 I + F 
23L 36.5-37 43-44 I F 
23R 36.5-37 43-44 I + F 
24L 35.5-36 42-43 I + F 
24R 35-35.5 42-43 I + + F 
®75% LMW/25% HMW sodium alginates, 12% plasticizer, crosslinked for 72 
hrs in 30% CaClg solution, 1 hr in 10% AlCljôHjO solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
Tling size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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TABLE 12. Retention time of ocular inserts (formulation 15®) 
Animal # 
and eye 
Eye size*' 
(mm) 
Ring size® 
(mm) 
Retention time (day) 
0 1 2 3 4 5 6 7 
8L 36.0 43-44 I + + + + F 
8R 36.5-37 44-45 I + + + F 
9L 39-40 47-48 I + + F 
9R 39-40 47-48 I + F 
lOL 40 48 I + F 
lOR 40 48 I + F 
IIL 36-36.5 43-44 I + + F 
IIR 35-36 42-43 I + F 
23L 36.5-37 43-44 I + F 
23R 36.5-37 43-44 I + + F 
24L 35.5-36 42-43 I + + + + + F 
24R 35-35.5 42-43 I + + + + + + F 
®75% LMW/25% HMW sodium alginates, 6.5% plasticizer, crossUnked for 72 
hrs in 30% CaCl2 solution, 1 hr in 10% AICI36H2O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
"Ring size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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ring was inserted. The average retention time of ocular inserts based on the 
criterion of size alone is given in Table 14. Tables 15-17 list the retention time of 
the ring device for each sizing criterion examined. 
TABLE 13. Average retention time of ocular inserts and effect of plasticizer 
content in the formulation® 
Plasticizer content (%) Retention time (day) Standard deviation 
2.7 3.5 ± 1.42 
5.4 2.91 ± 1.50 
6.5 3.42 ± 1.73 
7.5 3.92 ± 1.73 
10 2.33 ± 0.78 
12 1.75 ± 0.45 
"Formulation: 75% LMW/25% HMW sodium alginates, crosslinked for 72 
hrs in 30% CaCl2 solution, 1 hour in 10% AICI36H2O solution. 
TABLE 14. Average retention time of ocular inserts, effect of sizing" 
Ring size criterion Retention time (day) Standard deviation 
1.2 X eye size + 1.5 mm 3.67 ± 2.23 
1.2 X eye size 4.50 ± 1.31 
1.2 X eye size - 1.5 mm 3.42 ± 1.56 
'Formulation: 75% LMW/25% HMW sodium alginates, 7.5% plasticizer, 
crosslinked for 72 hrs in 30% CaClg solution, 1 hour in 10% AICI36H2O solution. 
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TABLE 15. Retention time of ocular inserts (formulation 12*) 
(1.2 X eye size + 1.5 mm) 
Animal # 
and eye 
Eye size"' 
(mm) 
Ring size*^ 
(mm) 0 
Retention time (day) 
1 2 3 4 5 6 7 
8L 36.0 44-45 I + F 
8R 36.5-37 45-46 I F 
9L 39-40 48-49 I + + + + + F 
9R 39-40 48-49 I + F 
lOL 40 50 I F 
lOR 40 49.5 I F 
IIL 36-36.5 44-45 I + + + F 
IIR 35-36 43-44 I + + + + + F 
23L 36.5-37 44-45 I + + + F 
23R 36.5-37 44-45 I + + + + F 
24L 35.5-36 43-44 I + + + + F 
24R 35-35.5 43-44 I + + + + + + F 
'75% LMW/25% HMW sodium alginates, 7.5% plasticizer, crosslinked for 72 
hrs in 30% CaCl2 solution, 1 hr in 10% AlClg ôHgO solution. 
^Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
Tling size is outside diameter. 
I = insertion. 
F = ring fell out or not present. 
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TABLE 16. Retention time of ocular inserts (formulation 12*) 
(1.2 X eye size -1.5 mm) 
Animal # 
and eye 
Eye size'* 
(mm) 
Ring size® 
(mm) 
Retention time (day) 
0 1 2 3 4 5 6 7 
8L 36.0 42-43 I + F 
8R 36.5-37 43-44 I + + + F 
9L 39-40 46-47 I + + + + + F 
9R 39-40 46-47 I + F 
lOL 40 47 I + F 
lOR 40 46.5 I + F 
IIL 36-36.5 42-43 I + + + + + F 
IIR 35-36 41-42 I + F 
23L 36.5-37 42-43 I + + F 
23R 36.5-37 42-43 I + + F 
24L 35.5-36 41-42 I + + + + F 
24R 35-35.5 41-42 I + + + F 
"75% LMW/25% HMW sodium alginates, 1.5% plasticizer, crosslinked for 72 
hrs in 30% CaClg solution, 1 hr in 10% AlCl^ ôHgO solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
®Ring size is outside diameter. 
I = insertion. 
F = ring fell out or not present. 
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TABLE 17. Retention time of ocular inserts (formulation 12°) 
(1.2 X eye size) 
Animal # 
and eye 
Eye size*) 
(mm) 
Ring size® 
(mm) 
Retention time (day) 
0 1 2 3 4 5 6 7 
8L 36.0 43-44 I + + + F 
8R 36.5-37 44-45 I + + + F 
9L 39-40 47-48 I + + + F 
9R 39-40 47-48 I + + + F 
lOL 40 48 I + + + F 
ICR 40 48 I + F 
IIL 36-36.5 43-44 I + + + + + F 
IIR 35-36 42-43 I + + + + F 
23L 36.5-37 43-44 I + + + + + F 
23R 36.5-37 43-44 I + F 
24L 35.5-36 42-43 I + + + + + + F 
24R 35-35.5 42-43 I + + + + + F 
®75% LMW/25% HMW sodium alginates, 7.5% plasticizer, crosslinked for 72 
hrs in 30% CaClj solution, 1 hr in 10% AICI36H2O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
®Ring size is outside diameter. 
I = insertion. 
F = ring fell out or not present. 
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In Vitro Degradation Tests of the Ocular Insert 
Degradation of the ocular insert 
The in vitro degradation (or the erosion) of bioerodible ocular devices was 
determined by using a weight loss method. Appendix A contains the data for the 
degradation of ocular devices. Figure 11 shows the degradation characteristics of 
ocular inserts fabricated from the same formulation of sodium alginates (75% 
LMW/25% HMW) with various amounts of plasticizer. The rings were crosslinked 
for 72 hrs in 30% CaCl2 solution, and then 1 hour in 10% AICI3 6H2O solution. The 
weights of all ocular inserts decreased relatively fast for the first 200-300 hrs of the 
experiment, especially during the first 48 hrs in saline. Then they slowly decreased 
along with the rupture of the crosslinked alginate membrane and the release of 
hydrogel particles. The results from Figure 11 suggested that there were three 
different erosion rates governing the degradation process of the erodible ocular 
device. For the first 200 hrs, the rate of degradation could be attributed to the 
leaching of plasticizer from the ring and the erosion of calcium alginate at the 
surface of the ring. Since the ring was not significantly eroded after 96 hrs in saline 
and under constantly shaking, the weight lost during the first 48 hrs may possibly be 
due to the leaching of plasticizer from the crosslinked alginate matrix. From 48 hrs 
to 200 hrs, the erosion of calcium alginate seemed to contribute to all weight losses 
observed. This was evidenced by the fact that rings which were only crosslinked 
with 30% CaCl; solution became soft and swelled fast in the eye of the animals 
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during the retention test. Between 228 to 300 hrs, a sharp decrease was due to the 
lost of some hydrogel particles when the alginate membrane was ruptured at some 
places on the ring. The time at which the membrane was ruptured might be of 
interest, since in the case that the hydrogel particles containing antibiotic were 
released into the environment in which the ring was used, an increase in the rate of 
drug released might be expected. Between 300 hrs to about 1300 hrs, there was a 
combination of losses of calcium alginate, hydrogel particles, and aluminum 
alginate. From the time of 1600 hrs to the end of the experiment, the erosion rate 
might be attributed to the degradation of aluminum alginate alone since there were 
no hydrogel particles left during this time. In addition, the erosion of aluminum 
alginate was shown to be much slower than calcium alginate in saline (Mahmoud, 
1988). The ring completely eroded after 2000 hrs in saline and under constantly 
shaking on a water bath at 37°C. Figures 12 and 13 show the surface of the ring 
after 4 days and 7 days in saline, respectively. At day 7, significant surface erosion 
was observed. Figure 14 shows the degradation product of the ring after 1200 hrs 
(50 days) in saline. It was observed that there was no diâerence in degradation 
characteristics for rings containing various amounts of plasticizer. The results 
suggested that the plasticizer was not a crosslinked component of the ring. The 
degradation of the ring in vitro seemed to be slow even though the ring was 
fragmented into small pieces after 450 hrs in saline solution. In the eyes of the 
animals, the erosion process seemed to be faster. Figure 15 shows the surface 
erosion of a ring after 5 days in the eye of a normal animal. There was significantly 
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FIGURE 12. Surface of an ocular insert after 4 days in saline 
(magnification = 32X) 
FIGURE 13. Surface of an ocular insert after 7 days in saline 
(magnification = 32X) 
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FIGURE 14. Degradation product of the ocular insert in vitro (after 1200 hrs 
in saline) (magnification = IX) 
FIGURE 15. Surface erosion of an ocular insert (5 days in the eye of normal 
animals) (magnification = 32X) 
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more erosion of the insert in vivo (Figure 15) than in vitro (Figure 13). 
Accelerated erosion was observed with rings used in the eyes of infected calves. 
Figures 16 and 17 show the erosion of rings retrieved from the eyes of infected 
(EBK) animals after one day in the eyes. The ring in Figure 16 (calf number 262L) 
was retrieved from a moderately affected eye. Figure 17 (calf number 9172R) 
shows the surface of a ring retrieved from a severely affected eye. In both cases, 
erosion was intense at the surface of the ring within 24 hrs after insertion. The 
factors that contributed to erosion in vivo were not known. Perhaps, besides the 
sodium cations, other cations such as K^, and bacteria in the tear fluid and in the 
eye, participated in the degradation of the ring as a whole. 
FIGURE 16. Surface erosion of an ocular insert after 1 day in a moderately 
affected eye (magniftcation = 32X) 
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FIGURE 17. Surface erosion of an ocular insert after 1 day in a severe affected 
eye (magnification = 32X) 
Degradation of crosslinked alginate films 
Two samples of crosslinked sodium alginate films containing 5.4% and 7.5% 
plasticizer, respectively were used. The films were fabricated from the formulation 
containing 75% LMW and 25% HMW sodium alginates, and were crosslinked for 
72 hrs in 30% CaClj solution and then 1 hour in 10% AICl^ ôH^O solution. The 
erosion process of crosslinked alginate films is shown in Figure 18. Again, there 
seemed to be three erosion rates governing the degradation of the crosslinked 
alginate films. The erosion was slow during the first 150 hrs, and then increased 
sharply between 150 hrs and 450 hrs. Beyond 450 hrs, the erosion was again slow. 
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FIGURE 18. In vitro degradation of crosslinked alginate films (formulation 
75% LMW/25% HMW sodium alginate, crosslinked for 72 hrs in 
30% CaClj solution, 1 hr in 10% AlCl^ ôHgO solution) containing 
5.4% and 7.5% plasticizer, respectively 
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It was expected that the crosslinked calcium alginate was the main erodible 
component for the first 150 hrs of the erosion process, followed by a combination of 
erosion of crosslinked calcium and aluminum alginates, and finally only the erosion 
of aluminum alginate. This pattern seemed to be consistent with the pattern 
observed in the degradation of crosslinked ocular inserts in vitro. However, the 
crosslinked alginate films eroded much faster than the ocular inserts which had 
similar amount of crosslinked alginates. It took 1200 hrs to dissolve the crosslinked 
alginate films as compared to more than 2000 hrs for the ocular inserts. This could 
be attributed to the fact that greater surface areas of the film samples were exposed 
to degradation. The films were eroded from both sides as compared to only the 
outer surface of the ocular insert. Appendix B contains erosion data for the films. 
Determination of the amount of plasticizer leaching out from crosslinked alginate 
films 
Two crosslinked alginate films containing 7.5% and 10% of plasticizer (Tween 
80), respectively were extracted with deionized water to determine the amount or 
percentage of plasticizer leached out upon contact with aqueous enviroimients. 
The amount of plasticizer leached out during the first 24 hrs in water was 
1.51% for the 7.5% sample, and 4.87% for the 10% sample. The total percentage 
of plasticizer lost from the samples within 48 hrs was 3.16% for the 7.5% sample 
and 6.31% for the 10% sample. After 48 hrs, the weights of the crosslinked alginate 
films were constant (Figure 19). Since crosslinked alginates do not dissolve in water 
(Michaels, 1975), the weight loss of the extracted sample accounted for the 
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FIGURE 19. Leaching of plasticizer from crosslinked alginate films 
(75% LMW/25% HMW sodium alginates, crosslinked for 
72 hrs in 30% CaCl2 solution, 1 hr in 10% AICI36H2O solution) 
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amount of plasticizer leaching out from the crosslinked alginate matrix. 
The results of this experiment suggested that there was a limit to the amount of 
plasticizer which could be incorporated into the sodium alginate matrix. Beyond 
this limit, the excess amount of plasticizer leached out upon contact with aqueous 
solutions. For this reason, increasing the content of plasticizer in the sodium 
alginate solution beyond 7.5% resulted in ring devices with poor retention 
characteristics since there was less material available for crosslinking and holding 
the ring together. 
In Vitro Drug Release Studies of the Ocular Insert 
After the release experiment was done, the elution solvent in the samples was 
evaporated, and the samples were redissolved with water and spotted on the TLC 
plates. The TLC plates were developed and the concentration of tylosin tartrate 
released from the ocular device as a function of time was evaluated. The TLC 
analysis data for all devices includes the collection time, the amount of drug in the 
spot, the release rate, and the cumulative drug release. Appendices C, D, and E 
contain the data of drug release from devices SI, S2, and S3. 
Figures 20 to 22 show the drug release profiles for ocular inserts SI, S2, and S3. 
All ocular devices had similar release patterns. The initial release rate was high for 
all devices during the first 24-30 hrs and then decreased to a nearly constant level 
throughout the rest of the release experiment. A bursting pattern was observed for 
all devices. This pattern should be expected from a device with an erodible , 
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membrane. However, the release profiles from Figures 20 to 22 indicated that the 
drug was released by a diffusional process and was influenced little by the erosion 
process. All devices released drug (tylosin tartrate) above the required release rate 
of 1.3 /xg/hr (Ryoo, 1986) necessary to treat IBK for at least 168 hrs (7 days) (Table 
18 and Figures 23-25), The release rate in Figures 23-25 was plotted on semilog 
scales to clearly demonstrate the level of drug release for 168 hrs. The fraction of 
drug released from the devices ranged from 14% to 39% of the original drug 
loading of 46 mg tylosin tartrate, assuming that no drug, or minimal amount of drug, 
was lost during the crosslinking process. 
TABLE 18. Summary of drug release characteristics of ocular devices 
Device Initial Release Release Cumulative Fraction 
No. rate, (fig/hr) rate, (Mg/hr) (Mg) of release 
0-2 days after 5 days (%) 
SI 17.6 - 348 4.3 - 13.8 6620.3 14.39 
S2 22-648 4.2 - 27.4 8952.6 19.46 
S3 43.1 - 1292 7.6 - 34.4 18037.3 39.21 
Since the fractional drug release was relatively low compared to the original 
drug load (46,000 pg), a perfect sink condition existed beyond the seven day period 
of drug release. In other words, the ring device continues to release drug at steady 
rate (above the required release rate of 1.3 Mg/hr) for a prolonged period of time 
because the amount of drug remaining in the ring was still very high compared to 
that of the external medium (e.g., 20,000-40,000 ng compared to only 1.3 ng). 
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The fractional drug release from the ocular devices in this research was 
relatively low compared to those of monolithic ocular devices developed by Ryoo 
(1986). For the same drug loading of about 50 mg of tylosin tartrate, the fractional 
drug release from hydrogel coated devices ranged from 28.7 to 36.8% (Group IV) 
and from 30.9 to 42.3% (Group I). The results from Table 18 suggested that the in 
vitro drug release from bioerodible devices was controlled by the erodible 
membrane. However, if the membrane eroded, the drug release rate was governed 
by the amount of drug released from the hydrogel-drug particles. 
Infection Study 
Efficacy testing of ocular insert 
Pretreatment of animals The eyes of all animals were treated with 
antibiotic ointment (Ophthocort®, Parke-Davis, Morris Plains, NJ). Two to four 
days after treatment, tear samples from the eyes of all animal were obtained to 
check whether or not there were any normal flora remaining in the eyes of the 
calves. Table 19 shows the results of the bacteriological examination performed 
after pretreatment of all animals. Out of 16 eyes, 12 eyes had no bacteria and 4 
eyes had only one or two colonies per swab sample. 
Titration gf Mi bovis inoculum The concentration of M. bovis challenge 
inoculum instilled in the eye of each calf for this experiment varied from 3.4 x 10^ 
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TABLE 19. Bacteriological examination results after pretreatment with 
antibiotic ointment 
Animal No. and eye Bacteriological examination results 
229L clean 
229R clean 
260L few bacteria 
260R clean 
262L clean 
262R few bacteria 
263L clean 
263R clean 
232L clean 
232R few bacteria 
9172L clean 
9172R few bacteria 
261L clean 
261R clean 
228L clean 
228R clean 
L = left eye; R = right eye. 
CFU/ml (colony forming units/ml) to 7 x 10® CFXJ/ml. Since each eye received 2 
ml of M. bovis challenge, the total concentration of M. bovis given to each eye 
ranged from 6.8 x 10® to 1.4 x 10' CFU/eye. 
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Comparison of treatment methods 
Quantitative results of M. bovis colonization in lh£ eyes The data of M. 
bovis colony forming units/swab (expressed as logjoCFU/swab) for each eye 
throughout a 17 day period are shown in Table 20. All calves had at least some 
degree of infection. The bacteriological results as a function of time (expressed as 
logioCFXJ/swab) for each calf are shown in Figures 26-33. Each figure illustrates 
the changes of the number of bacteria in the eye during the infection and treatment 
periods, and the post treatment period. The first 5-day period shows the general 
trend in the build-up of M. bovis in the eye after inoculation. The second 5-day 
period shows the pattern of the changes of the number of bacteria as a function of 
time after the eyes were treated with the ring devices or subconjunctival injections. 
For the treated eyes, they either received medicated ocular inserts or 
subconjunctival injections of Azimycin®. The control eyes either received non-
medicated ocular devices or subconjunctival injections of sterile saline. At day 12, 
the infected control eyes (7 out of 8 eyes) were treated with medicated ocular 
inserts or a subconjunctival injection of Azimycin® (for the right eye of calf 263 
only) in order to cure the M- bovis infection. Since it was of interest to obtain the 
retention data for ring devices in the infected eyes, 15 out of 16 eyes received 
medicated ring devices on day 12 (post treatment period). 
During the incubation period (first 5 days), the bacteria increased in number 
rapidly in both eyes (l(f - 10® CFU/swab were detected). During the second 5-day 
period, while the number of M. bovis colonies obtained from the conjunctival 
TABLE 20. Number of colony forming units of M- bovis in the eyes throughout the infection test period 
(logioCFU/swab) 
Days after inoculation with M. bovis 
Group Animal After inoculum" After treatment** 
No. No./eye 0 3 5 1 2 3 5 7 12(14)' 
I (ocular 229R 0 3.68 3.25 0 0 0 0.78 0.78 0 
device) 229L 0 2.54 2.88 4.21 3.22 3.23 2.56 3.44 0 
260R 0 3.17 3,57 0 0 0 0 0 0 
260L 0 2.59 5.66 3.72 4.25 3.10 3.03 3.62 0 
262R 0 4.27 5.62 0 0 0 1.59 0 0 
262L 0 1.38 3.07 0.48 0 0 3,36 1.86 0 
263L 0 3.47 5.18 0 0.78 4.43 3.75 4.98 0 
263R 0 3.67 3.80 4.91 4.41 4.12 4.33 4.62 2.73 
H (subconj. 232R 0 2.72 1.66 0 0 3.03 3.95 2,06 0 
injection) 232L 0 2.26 1.77 2.18 3.44 3.42 2.65 2.86 0 
9172R 0 2.86 3.58 4.97 3.95 3.68 3,01 2.83 0 
9172L 0 1.73 3.35 4.35 2.69 3.50 2.43 4.45 1.66 
261R 0 2.36 1.89 0 0 3.69 3,26 3.79 0 
261L 0 2.02 2,0 0.95 1,98 0.78 0 1.99 0 
228R 0 3.29 3.29 0 0 0 0.95 0 0 
228L 0 0.95 1,66 4.11 3.59 2.95 2.04 2.56 0 
®First row for each calf eye number represents the data for treated eye, while second row represents the data 
for control eye. R = right eye, L = left eye. 
''Day after treatment means the period after insertion of rings or subconjunctival injections. 
"Data for calf 263R only, subconjunctival injection for post treatment. The right eye was sampled on day 14 
(after treatment). 
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sample of the control eye remained similar to that seen during the first 5-day 
period, the bacterial growth trend for each treated eye was dependent on the type 
of treatment used. For eyes that received the medicated ocular devices, the number 
of M. bovis colonies dropped dramatically to nil within one day after the medicated 
rings were inserted. For the rest of the treatment period, most of these eyes had no 
M. bovis colonies or the number of colonies was low even though the majority of 
medicated rings fell out within 2 days after insertion. For eyes that were treated 
with subconjunctival injections of Azimycin®, 3 out of 4 eyes had no M. bovis 
colonies within one day after treatment. However, the number of M. bovis colonies 
obtained from swab samples in these eyes was again high (10^ -KX* CFU/swab) 2 
days after subconjunctival treatment. On day 12, 15 out of 16 eyes were treated 
with medicated rings. After day 12, all eyes, including the post-treated control eyes, 
showed the presence of no, or only negligible, numbers of bacterial colonies. The 
number of colony forming units associated with the conjunctival swab samples 
provides a useful index to monitor the changes taking place in the eyes in terms of 
the number of M. bovis colonies present for the entire experimental period (from 
the time of inoculation to the time when samples were obtained 5 days after all 
control eyes were treated), and to determine the effectiveness of each treatment 
method (ocular devices and subconjunctival injections). In this experiment, all 
treated eyes were only treated once, that is, each treated eye only received one 
medicated ring or was injected with 1 ml of Azimycin®. If the medicated ring fell 
out, the eye was left alone and no additional ring was inserted. 
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The bacterial growth trend with time for calves that were treated with 
medicated ring devices is shown in Figures 26-29. The bacterial growth trend with 
time for calf 263 is presented in Figure 26. The number of M- bovis colonies in the 
treated eye began to increase after the ring fell out on day 7 (2 days after insertion). 
In the presence of the medicated ring there were no or few bacterial colonies 
present as compared to the control eye (with non-medicated ring) which had a large 
number of bacteria present throughout the test period. Since no additional 
medicated ring device was again inserted, the number of M- bovis colonies 
continued to build up again until day 12 when the eye was treated with a medicated 
ring. The reason for this increase may possibly due to transmission of M. bovis 
from the infected contralateral control eye. After day 12, there were no bacteria 
present when a sample was obtained on day 20. By comparison, the control eye was 
treated with a subconjunctival injection of 1 ml of Azimycin® on day 12. The 
number of M- bovis colonies in this eye remained high (> 10'* CFU/swab) 2 days 
after treatment with subconjunctival injection. On day 20, the number of M- bovis 
colonies in the eye was still above 10^ CFU/swab. This result indicated that the 
subconjunctival injection of antibiotic may not have the ability to cure the disease 
rapidly by reducing the number of M. bovis colonies to a negligible level within a 
short time. 
139 
# 263 
L 
o 
g 
c 
F 
U 
/ 
s 
w 
a 
b 
6 8 10 12 14 16 18 20 22 24 0 2 4 
Days after Inoculation 
— T r e a t e d  e y e  ( L )  C o n t r o l  e y e  ( R )  
FIGURE 26. The bacterial growth trend with time for calf 263 
The bacterial growth trends for calf 229 and calf 260 are shown in Figures 27 
and 28, respectively. In the presence of the medicated ring, no bacteria were found. 
For calf 229, the medicated ring fell out one day after insertion. However, the 
number of M- bovis colonies obtained from swab samples remained low after the 
ring fell out until the end of the experiment, while the control eye still had high 
levels of bacteria. Both the control eye and the treated eye were uninfected after 
they were treated with medicated rings on day 12, and sampled 5 days after that. In 
Figure 28, the medicated ring in the treated eye of calf 260 did not fall out until 4 
days after insertion. As a result, this eye remained uninfected throughout the 
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treatment and post-treatment periods. The number of M* bovis colonies in the 
control eye of calf 260 was high throughout the test period and was completely 
suppressed after day 12 when a medicated ring was used to cure the infected eye. 
The bacterial growth trend with time for calf 262 is shown in Figure 29. The 
medicated ring fell out less than one day after insertion. However, there were no 
M. bovis colonies, or only low levels of bacteria, present in the eye throughout the 
test period even though the initial level of bacteria in the first 5-day period was high 
(10® - 10*^ CFU/swab). Two data points for the control eye (day 7 and 8) indicated 
that no bacteria were present. The bacteria then increased back to a relatively 
high level prior to insertion of the medicated ring for post-treatment. These data 
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points may be explained by the fact that the control eye of this calf did not show 
any clinical signs of infection. Also, errors may be contributed from the sampling 
method. If a swab did not absorb sufficient tear fluids, the subsequent colony 
forming unit results may not be representative. It seemed that when the ring fell 
out, if there was no other infection source nearby, the increase of bacteria would be 
low and would eventually diminish (Figure 29). 
The bacterial growth trends for calves that were treated with a subconjunctival 
injection of Azimycin® are shown in Figures 30-33. The bacterial growth trend with 
time for calf 232 is shown in Figure 30. The number of M. bovis colonies in the 
treated eye dropped to a nondetectable level after one day of treatment, while the 
control eye had a relatively high level of M- bovis colonies. However, the bacteria 
# 232 
L 
o g 
c 
F 
U 
/ 
s 
w 
a 
b 
6 8 10 12 14 16 18 20 22 24 0 4 2 
Days after inoculation 
— ^  T reated eye (R) —Control eye (L) 
FIGURE 30. The bacterial growth trend with time for calf 232 
143 
in the treated eye again built up to a high level after 2 days of treatment and stayed 
the same for the rest of the experimental period until both eyes were treated with 
medicated rings (day 12). A similar trend was seen for calf 261 (Figure 31). The 
control eye of calf 261 did not have any bacteria on day 10 and then the bacteria 
level was again increased on day 12 prior to insertion of the medicated ring. 
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FIGURE 31. The bacterial growth trend with time for calf 261 
The bacterial growth trend with time for calf 228 is shown in Figure 32. A 
similar pattern was observed as was seen in Figure 30 and Figure 31. However, the 
number of M- bovis colonies built up in the treated eye after subconjunctival 
injection of Azimycin® was low, while the bacteria level in the control eye remained 
high throughout the test period. 
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FIGURE 32. The bacterial growth trend with time for calf 228 
The bacterial growth trend with time for calf 9172 is shown in Figure 33. The 
number of M- bovis colonies in the treated eye increased after the eye was treated 
with subconjunctival injection of Azimycin®. The bacteria level in the treated eye 
was higher than that of the control eye for the whole 10-day period. The number of 
M. bovis colonies in the treated eye slowly decreased to the end of the experiment, 
but remained at a relatively high level. 
The results of post-treatment (Figures 27-33) indicated the usefulness of 
treating both eyes simultaneously. When both eyes of each animal were treated 
with medicated ocular inserts on day 12, the bacteria were no longer detectable, or 
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FIGURE 33. The bacterial growth trend with time for calf 9172 
only few colonies were present, 5 days after the rings were inserted even though the 
majority of ring devices fell out within 1-2 days. 
Clinical examination All eyes were observed almost on a daily basis and 
their conditions during the progress of the disease were evaluated visually. The 
clinical results for each animal group (ocular device or subconjunctival injection) as 
a function of time are listed in Table 21. The clinical scores used to assess the 
condition of the eye were given previously in Table 6. 
TABLE 21. Clinical observation of calves eyes throughout the infection period 
Days after inoculation with M. bovis 
Animal No./eye Treatment 0 1 2 3 4 5 6 7 8 9 10 12 IT 
229L NM 0 1 2 2 1 1 2 2 2 2 1 2 0 
260L NM 0 1 1 5 4 5 4 4 4 4 4 4 3 
262L NM 0 1 1 1 0 0 2 1 1 1 2 1 0 
263R NM 0 2 3 4 4 4 5 5 5 5 5 5 3" 
229R M 0 1 3 4 4 4 3 1 1 1 1 1 0 
260R M 0 1 1 4 5 4 2 1 1 1 1 1 0 
262R M 0 1 3 5 4 4 4 3 1 1 3 3 3 
263L M 0 2 3 4 4 4 5 3 3 3 3 3 3 
232L SCS 0 2 2 4 4 4 4 4 3 3 1 3 1 
9172L SCS 0 1 3 4 4 4 4 4 5 5 5 4 4 
261L SCS 0 1 1 2 1 1 2 0 2 1 1 1 0 
228L SCS 0 1 1 1 1 1 2 0 1 1 2 1 1 
232R SI 0 1 2 4 4 3 2 3 2 1 1 1 1 
9172R SI 0 1 4 5 5 4 5 5 5 5 4 4 4 
261R SI 0 2 3 5 5 5 6 6 6 5 5 5 4 
228R SI 0 2 3 3 3 3 3 1 2 2 2 1 1 
®Five days after post treatment with medicated ocular inserts. 
was treated with subconjunctival injection (Azimycin®). 
NM = non-medicated ocular insert; M = medicated ocular insert; SCS = subconjunctival control (injection 
with saline); SI = subconjunctival injection (Azimycin®). 
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After inoculation with M. bovis. and within 24 hrs, all eyes showed some signs 
of conjunctivitis and tearing. Most eyes gradually worsened with time as the disease 
progressed from mild to severe infection. Twelve out of 16 eyes had moderately 
severe to severe signs of infection. Four other eyes had some signs of mild 
infection. 
At the end of the treatment period ( second 5 days), all treated eyes had either 
very mild signs of IBK or were healing. For eyes that were treated with medicated 
ocular inserts, two eyes were normal, and two eyes had some degree of corneal 
opacity ( < 50% of cornea) even though other clinical signs such as tearing, and 
conjunctivitis were not seen. For eyes that were treated with subconjunctival 
injections of Azimycin®, two eyes still had some sign of mild infection (grade 1), and 
two eyes had some degree of corneal opacity (> 50% of cornea). However, some 
signs of conjunctivitis and severe tearing were still observed in severely infected eyes 
of within the subconjunctival injection animal group. 
Statistical comparison gf treatment methods In order to determine if 
there were any significant differences between the treatment method using the 
ocular devices containing tylosin tartrate and the treatment method using 
subconjunctival injections of Azimycin®, the average bacteriological results for each 
eye during the first 5-day period and the second 5-day period of the experiment 
were used. In a similar manner, the average of the clinical observations for each 
eye for the two periods were also used. The average bacteriological results for the 
treated and control eyes of the ocular-device-treated group are given in Table 22. 
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The average bacteriological results for the treated and control eyes of the 
subconjunctival injection-group are given in Table 23. The average clinical 
observations (treated and control eyes) for each group are listed in Tables 24 and 
25, respectively. 
The group average bacteriological results for the treated eyes and control eyes 
during the first 5 days and the second 5 days for eyes that received medicated ocular 
devices are listed in Table 26. The group average bacteriological results for eyes 
that were treated with subconjunctival injections of Azimycin® are given in Table 
27. In a similar manner, the group average clinical results (treated eyes and control 
eyes) for each treatment method are given in Table 28 and 29, respectively. 
The group average results of bacteriological evaluation for the first 5 days and 
second 5 days for both treated eyes and control eyes of the two treatment methods 
(ocular devices and subconjunctival injections) are summarized in Table 30. 
In bacteriological results evaluation (Table 30), the differences between the 
treatment using medicated devices and subconjunctival injections of Azimycin® for 
the second 5-day period were not significant (p < 0.20, by a two-tailed t-test). 
However, the differences between the reduction in bacterial burden of the eyes 
which were treated with medicated rings, and the reduction in bacterial burden of 
the eyes which were treated with subconjunctival injections of Azimycin® from the 
first 5-day period to the second 5-day period were significant (Table 31). The eyes 
that were treated with medicated ocular devices showed marked reduction of 
bacterial burden, when compared to those that were treated with subconjunctival 
TABLE 22. Summary of bacteriological results for 10 day period for calves under treatment with ocular inserts 
(data expressed as logmCFU/swah) 
Days after inoculation with M. bovis 
Animal No./eye After inoculation Average After treatment" Average 
0 3 5 1st 5 days 1 2 3 5 2nd 5 days 
Treated®* 229R 0 3.68 3.25 3.47 0 0 0 0.78 0.19 
260R 0 3.17 3.57 3.37 0 0 0 0 0 
262R 0 4.27 5.62 4.95 0 0 0 1.59 0.40 
263L 0 3.47 5.18 4.33 0 0.78 4.43 3.75 2.24 
Control 229L 0 2.54 2.88 2.71 4.21 3.22 3.23 2.56 3.31 
260L 0 2.59 5.66 4.13 3.72 4.25 3.1 3.03 3.53 
262L 0 1.38 3.07 2.23 0.48 0 0 3.36 0.96 
263R 0 3.67 3.8 3.74 4.9 4.4 4.12 4.33 4.44 
"Days after treatment means the period after insertion of ring devices. 
^Treated eyes received medicated rings. 
'Control eyes received non-medicated rings. 
TABLE 23. Summary of bacteriological results for 10 day period for calves under treatment with subconjunctival 
injections (data expressed as log^qCFU/swab) 
Days after inoculation with M. bovis 
Animal No./eye After inoculation Average After treatment® Average 
0 3 5 1st 5 days 1 2 3 5 2nd 5 days 
Treated** 232R 0 2.72 1.66 2.19 0 0 3.03 3.95 1.75 
9172R 0 2.86 3.58 3.23 4.97 3.95 3.68 3.01 3.90 
261R 0 2.36 1.89 2.13 0 0 3.69 3.26 1.74 
228R 0 3.29 3.29 3.29 0 0 0 0.95 0.24 
Control® 232L 0 2.26 1.77 2.02 2.18 3.44 3.42 2.65 2.92 
9172L 0 1.73 3.35 2.54 4.35 2.69 3.5 2.43 3.24 
261L 0 2.02 2.0 2.01 0.95 1.98 0.78 0 0.93 
228L 0 0.95 1.66 1.31 4.11 3.59 2.95 2.04 3.17 
®Days after treatment means the period after subconjunctival injections. 
"Treated eyes were injected with Azimycin®. 
•^Control eyes were injected with sterile saline. 
TABLE 24. Summary of clinical observations for 10 day period for calves under treatment with ocular inserts® 
Days after inoculation with M. bovis 
Animal/No. 
Eye 1 
After inoculation 
2 3 4 5 
Average 
1st 5 days 
After treatment'' 
1 2 3 4 5 
Average 
2nd S days 
Treated 
229R 1 3 4 4 4 3.20 3 1 1 1 1 1.40 
260R 1 1 4 5 4 3.0 2 1 1 1 1 1.20 
262R 1 3 5 4 4 3.40 4 3 1 1 3 2.40 
263L 2 3 5 4 4 3.40 5 3 3 3 3 3.40 
Control 
229L 1 2 2 1 1 1.40 2 2 2 2 1 1.80 
260L 1 1 5 4 5 3.20 4 4 4 4 4 4.0 
262L 1 1 1 0 0 0.60 2 1 1 1 2 1.40 
263R 2 3 4 4 4 3.40 5 5 5 5 5 5.0 
"Clinical scales described in Table 6. 
''Days after treatment means the period after insertion of rings (medicated or non-medicated) 
TABLE 25. Summary of clinical observations for 10 day period for calves under treatment with subconjunctival 
injections® 
Days after inoculation with M- bovis 
Animal/No. 
Eye 1 
After inoculation 
2 3 4 5 
Average 
1st 5 days 
After treatment'' 
1 2 3 4 5 
Average 
2nd 5 days 
Treated 
228R 2 3 3 3 3 2.80 3 1 2 2 2 2.0 
232R 1 2 4 4 3 2.80 2 3 2 1 1 1.80 
261R 2 3 5 5 5 4.0 6 6 5 5 5 5.20 
9172R 1 4 5 5 4 3.80 5 5 5 5 4 4.80 
Control 
228L 1 1 1 1 1 1.0 2 0 1 1 2 1.20 
232L 2 2 4 4 4 3.20 4 4 3 3 1 3.0 
261L 1 1 2 1 1 1.20 2 0 2 1 1 1.20 
9172L 1 3 4 4 4 3.20 4 4 5 5 5 4.6 
"Clinical scales described in Table 6. 
''Days after treatment means the period after subconjunctival injections (Azimycin® or sterile saline). 
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TABLE 26 Averages of bacteriological results. Treatment with ocular devices 
(data expressed as logigCFU/swab) 
Treated 1st 2nd Control 1st 2nd 
eye 5 days'* 5 days" eye 5 days 5 days 
229R 3.47 0.19 229L 2.71 3.31 
260R 3.37 0 260L 4.13 3.53 
262R 4.95 0.40 262L 2.23 0.96 
263L 4.33 2.24 263R 3.74 4.44 
Group 4.03 0.71 Group 3.20 3.06 
average average 
S.D.= ± 0.75 ± 1.03 S.D." ± 0.88 ± 1.48 
^Standard deviation. 
''Increase of bacteria. 
''Average of 5 days after medicated ring inserted. 
TABLE 27. Averages of bacteriological results. Treatment with subconjunctival 
injections (data expressed as logjoCFU/swab) 
Treated 
eye 
1st 
5 days'' 
2nd 
5 days" 
Control 
eye 
1st 
5 days 
2nd 
5 days 
232R 2.19 1.75 232L 2.02 2.92 
9172R 3.22 3.90 9172L 2.54 3.29 
26IR 2.13 1.74 261L 2.01 0.93 
228R 3.29 0.24 228L 1.31 3.17 
Group 
average 
S.D.= 
2.71 
± 0.63 
1.91 
± 1.51 
Group 
average 
S.D.= 
1.97 
± 0.51 
2.57 
± 1.1 
"Standard deviation. 
''Increase of bacteria. 
"Average of 5 days after subconjunctival injection of Azimycin®. 
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TABLE 28. Averages of clinical observations for calves under treatment with 
ocular devices 
Treated 1st 2nd Control 1st 2nd 
eye 5 days'' 5 days® eye 5 days 5 days 
229R 3.20 1.40 229L 1.40 1.80 
260R 3.0 1.20 260L 3.20 4.0 
262R 3.40 2.40 262L 0.60 1.40 
263L 3.40 3.40 263R 3.40 5.0 
Group 3.25 2.10 Group 2.15 3.05 
average average 
S.D.® ± 0.19 ± 1.01 S-D." ± 1.40 ± 1.74 
^Standard deviation. 
''Increase of bacteria. 
^Average of 5 days after medicated ring inserted. 
TABLE 29. Averages of clinical observations for calves under treatment with 
subconjunctival injections 
Treated 1st 2nd Control 1st 2nd 
eye 5 days'* 5 days® eye 5 days 5 days 
232R 2.80 1.80 232L 3.20 3.0 
9172R 3.80 4.80 9172L 3.20 4.60 
261R 4.00 5.20 261L 1.20 1.20 
228R 2.80 2.0 228L 1.0 1.20 
Group 3.35 3.45 Group 2.15 2.50 
average average 
S.D." ± 0.67 ± 1.80 S.ID/ ± 1.20 ± 1.6 
^Standard deviation. 
''Increase of bacteria. 
•^Average of 5 days after subconjunctival injection of Azimycin®. 
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TABLE 30. Comparison of averages of bacteriological results by treatment 
methods 
Treated eyes Control eyes 
Average** Average® Average Average 
± S.D.' ± S.D. ± S.D. ± S.D. 
1st 5 days 2nd 5 days 1st 5 days 2nd 5 days 
Ocular devices 4.03 0.71 3.20 3.06 
± 0.75 ± 1.03 ± 0.88 ± 1.48 
Subconjunctival 2.71 1.91 1.97 2.57 
injections ± 0.63 ±1.51 ± 0.51 ±1.1 
^Standard deviation. 
''Increase of bacteria. 
'^Average of 5 days after medicated ring inserted, or injection used. 
TABLE 31. Reduction in bacterial burden by treatment methods 
Treated eyes 
Average Average 
1st 2nd 
5 days® 5 days'' 
Reduction from 
1st 5 days to 
2nd 5 days'' 
Ocular devices 4.03 0.71 3.33 ± 1.0 
Subconjunctival 
injections 2.71 1.91 0.8 ± 1,59 
"Increase of bacteria. 
''Average of 5 days after medicated ring inserted, or injection used. 
^Reduction in number of bacteria (logioCFXJ/swab). 
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injections of Azimycin® (p < 0.03). 
There were no differences between the first 5 days and the second 5 days for 
eyes that were treated with subconjunctival injections of Azimycin® (p < 0.4). 
However, the differences between the two periods for eyes that received medicated 
ocular devices were significant (p < 0.01) (Table 30). 
For control rings, there were no differences between the first 5-day period and 
the second 5-day period (p < 0.8) (Table 30). Similarly, for subconjunctival 
injection controls, the differences between the two periods were not significant (p < 
0.4) (Table 30). 
In terms of clinical observation results (Table 32), the differences between the 
two treatment methods for the second 5-day period were not significant (p < 0.25). 
Similarly, the differences in clinical improvement from the first 5 days to the second 
5 days between two treatment methods (Table 33) were not significant (p < 0.14). 
TABLE 32. Comparison of treatment methods. Clinical observations 
Treated eyes Control eyes 
Average 
± S.D." 
1st 5 days 
Average 
± S.D. 
2nd 5 days 
Average 
± S.D. 
1st 5 days 
Average 
± S.D. 
2nd 5 days 
Ocular devices 3.25 2.1 2.15 3.05 
± 0.19 ± 1.01 ± 1.4 ± 1.74 
Subconjunctival 3.35 3.45 2.15 2.50 
injections ± 0.67 ± 1.8 ± 1.2 ± 1.6 
^Standard deviation. 
TABLE 33. Clinical improvements by treatment methods 
Treated eyes Control eyes 
Average Average Imp" Average Average Imp Differences 
1st 5 2nd 5 (1) 1st 5 2nd 5 (2) (1) - (2) 
days days days days 
Ocular 3.25 2.1 1.15 2.15 3.05 -0.9 2.05 ± 0.44= 
device 
Subconjunctival 3.35 3.45 -0.1 2.15 2.50 -0.35 025 ± 0.71 
injection 
^Improvement of eyes from 1st 5 days to 2nd 5 days. 
''Differences between the improvement of treated eyes and the improvement of the control eyes within a 
treatment group. 
Standard deviation. 
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However, the differences in clinical improvement of treated eyes compared to 
control eyes (Table 33; differences column) were highly significant between two 
methods (p < 0.008). There were no differences between control eyes which 
received non-medicated rings for the first 5-day period and the second 5-day period 
(p < 0.5) (Table 32). Also, the differences for the subconjunctival injection controls 
between the two periods were not significant (p < 0.8) (Table 32). Similarly, there 
were no differences between control eyes which received non-medicated rings and 
control eyes which were injected with saline for the first 5 days (p < 1.0), as well as 
for the second 5 days (p < 0.8) (Table 32). In other words, there were no 
differences between the control eyes of both groups for the whole testing period. 
Post treatment for infected eyes 
At the end of the experiment (on day 12), in order to suppress M. bovis 
infection completely, medicated ocular devices were inserted into both eyes of each 
animal. All eyes were sampled 5 days after treatment except calf 263 whose eyes 
were sampled 8 days after treatment. The results of post-treatment using medicated 
ring devices are summarized in Table 34. It seemed that when both eyes were 
treated with medicated rings, the number of M. bovis colonies in the eyes were 
suppressed within a short time even though more than 70% of ring devices were no 
longer present in the eyes after 1-2 days. One eye (263R), which was treated with a 
subconjunctival injection of Azimycin®, still showed the presence of a substantial 
number of M. bovis after 8 days of treatment. 
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TABLE 34. Summary of post-treatment for all infected eyes 
Animal No./eye Treatment M. bpvis colonies (logioCFU/swab) 
before after 
229L M" 0.78 0 
229R M 3.44 0 
260L M 3.62 0 
260R M 0 0 
262L M 1.56 0 
262R M 0 0 
263L M 4.98 0= 
263R SI" 4.62 2.73= 
232L M 2.86 0 
232R M 2.06 0 
9172L M 4.45 1.66 
9172R M 2.83 0 
261L M 1.99 0 
261R M 3.29 0 
228L M 0 0 
228R M 2.56 0 
^Medicated ocular insert. 
"'Subconjunctival injection of Azimycin®. 
®Eyes were sampled 8 days after treatment. 
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Retention ef ocular inserts in infected eyes 
The results of the retention of ocular devices in infected eyes are given in 
Table 35. In infected eyes the medicated ocular devices tended to come out of the 
eyes earlier, especially in those eyes with a severe infection. One day after the ring 
devices were inserted, only 6 out of 14 rings were still present in 5 calves. The 
average retention time for the ring device in the infected eyes was 2.1 ± 1.63 days. 
For the same formulation of sodium alginate, and similar crosslinking times in 30% 
CaClj solution and 10% AlClj'ôHjO solution, the average retention time for the ring 
device in the normal eyes was 3.92 ± 1.73 days. The differences between the 
retention time of the insert in normal eyes and that in the infected eyes were 
significant (p < 0.02). The retention time of the ocular insert in infected eyes was 
significantly shorter than that observed in normal eyes. Factors that influenced the 
retention time of the ocular device in infected eyes might be the tear flow rate 
(significantly higher in cattle with ocular disease) and possibly the bacteria present 
in the eyes. The retention characteristics of ocular inserts in infected eyes are 
shown in Figure 34. 
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TABLE 35. Retention time of ocular inserts in infected eyes (formulation 12®) 
Animal # 
and eye 
Eye size** 
(mm) 
Ring size® 
(mm) 0 
Retention time (day) 
1 2 3 4 5 6 7 
229L 35 42 I + + + + F 
229R 35 42 I + + F 
232L 35 42 I F 
232R 35 42 I F 
9172L 34.5 41 I F 
9172R 34.5 41 I F 
26IL 34 41 I F 
261R 34.5 41-42 I F 
260L 34.5 41-42 I + + + + + F 
260R 34.5 41-42 I + + F 
262L 34 41 I F 
262R 34 41 I + F 
228L 35 42 I F 
228R 35 42 I + F 
263L 34 41 I + + F 
263R 34-34.5 41-42 I + + + F 
®75% LMW/25% HMW sodium alginates, 1.5% plasticizer, crosslinked for 72 
hrs in 30% CaClj solution, 1 hr in 10% AlCl^^éH^O solution. 
''Eye size was determined by measuring the distance from the medial canthus to 
the lateral canthus. 
Tling size is outside diameter (1.2 X eye size). 
I = insertion. 
F = ring fell out or not present. 
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Infected eyes Normal eyes 
FIGURE 34. Retention characteristics of ocular inserts in normal eyes and 
infected eyes 
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DISCUSSION 
Fabrication of Ocular Inserts 
The physical characteristics of the ocular inserts were influenced by the 
composition of the sodium alginate mixture, the content of the plasticizer in the 
sodium alginate solution, and the combination of crosslinking times in 30% CaClj 
solution and 10% AICI36H2O solution. In addition, the nature of the sodium 
alginate material prior to crosslinking also influenced the physical properties of the 
ring device. If an ocular device was crosslinked after dipping it in a solution of 
sodium alginate, a stronger ring device was obtained since the material was 
completely crosslinked . On the other hand, if the device was crosslinked in the dry 
state, the ring device was weak and tended to swell quickly in water or saline. 
The fabrication process of the ocular insert was somewhat time consuming. It 
took approximately 86-90 hours ( 8 hrs to cast the ring device, and approximately 78 
hrs for crosslinking, rinsing, and drying) to finish the ocular device. Normally, a set 
of ocular ring devices (15-20 rings) was fabricated at a time. The finished ring 
devices were stored in a desiccator under Drierite® (CaSO^) for future use. Due to 
a lack of specialized equipment, the rings fabricated fi-om available Teflon™ molds 
were not very uniform. In addition, high viscosity sodium alginate solution could 
not be used with the currently available molds. However, the current bench scale 
manufacturing technique seemed adequate to allow the production of ocular inserts 
which could be used to demonstrate the concept of an erodible ring device for 
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treatment of IBK in cattle. 
The bioerodible ocular insert retained its ring-shaped configuration whether it 
was in the diy or wet state. It was observed that the dimension of the ring device 
did not change veiy much upon contact with saline for a long period of time (e.g., > 
20 hrs). Also, the ability of the ring device to absorb water seemed to make the 
surface of the ring smoother (which could minimize eye irritation). In comparison, 
the collagen ring-shaped devices developed by Punch and co-workers (1987) 
collapsed when they absorbed tears. In the dry state, their rings were shrunken and 
distorted. 
In this research, the formulation containing 75% LMW/25% HMW sodium 
alginate with a plasticizer content of 7.5% (Table 2) was preferred for fabrication of 
the ocular inserts to be used in the bovine eye due to the ease of fabrication and 
the superior physical properties of the ring which were achieved compared to other 
formulations studied. A desirable combination of flexibility and stif&iess of the ring 
device was obtained when the insert was crosslinked for 72 hrs in 30% CaCl; 
solution, and then for 1 hour in 10% AICI36H2O solution. 
In Vivo Retention Studies of the Ocular Insert 
The retention tests of the ocular device were designed to test the physical and 
biological properties of the insert in the environment of the bovine eye. In order to 
treat infectious diseases such as IBK in cattle effectively, it is important to develop 
an ocular device that can be retained by the eye for at least a day since according to 
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Ryoo (1989), after the ring devices were inserted into the eyes of infected animals, 
the number of M. bovis colonies in the eye was reduced to a negligible level within 
1 to 2 days. 
Fifteen formulations of sodium alginate were employed to fabricate ocular 
devices for the retention tests. However, only a few formulations were found to be 
suitable for use to produce ocular devices with satisfactory mechanical properties for 
achieving a retention time of the order of one day or more. Ocular devices that 
were fabricated from a mixture of sodium alginates (75% LMW/25% HMW) 
containing a plasticizer content ranging from 2.7% to 7.5%, and that were 
crosslinked for 72 hrs in 30% CaClg solution followed by a one hour crosslinking in 
10% AICI36H2O solution, tended to have good retention characteristics in the eyes 
of the calves. These ocular devices had sufficient flexibility and stiffness to permit 
conformation to the shape of the bovine eye. In addition, a stiffer ring was 
relatively easier to insert into the eye of the animals in a short time (2 minutes). By 
comparison. Punch and co-workers (1987) used four different collagen solutions 
(collagen content varying from 1.5% to 3%) to fabricate ocular inserts for insertion 
into the conjunctival sac of cattle. Formaldehyde was added to each solution to 
crosslink the collagen. The content of formaldehyde in the collagen solutions varied 
from 1.42% to 4.8%. The collagen solutions were then poured into ring-shaped 
molds and frozen at -4°C for 48 hrs after which the collagen ocular devices were 
thawed to room temperature and dried. None of these solutions produced collagen 
inserts that could be inserted into the conjunctival sac of cattle since they collapsed 
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in the wet condition. 
The best average retention time achieved in the retention test in the eyes of 
normal animals was 3.92 ± 1.73 days. This retention time is comparable to that of 
the ocular insert developed by Theodorakis and co-workers (1983). However, the 
ocular device developed by these investigators required a biodegradable spear for 
attachment to the third eyelid of cattle. For this type of insert, the insertion 
technique was usually time consuming and cumbersome. In comparison with 
soluble ring-shaped ocular devices studied by other investigators (Slatter et al., 
1982b; Punch et al., 1987), the ocular device used in this research exhibited longer 
retention times, and was easier to insert. The collagen inserts of these investigators 
were fragile and lacked rigidity. They either could not be inserted into the 
conjunctival sac or had poor retention characteristics. The majority of these inserts 
fell out within a few hours after insertion (Slatter et al., 1982b). Unlike the 
bioerodible gelatin ocular inserts which produced marked epiphora and some 
blepherospasm when inserted into the conjunctival sac of cattle (Punch et al., 
1985b), the ocular inserts used in this study were well tolerated by the calves. The 
eyes of the animals of the current study were monitored on a daily basis for signs of 
irritation such as tearing, swelling, and redness of eye tissues that might be caused 
by the presence of the ocular insert. None of these signs were seen during the 
testing period. Most of the time, tearing seemed to increase after the ring device 
was inserted into the eye of the animal but it usually subsided within a few minutes 
after ring insertion. Also, the insertion technique used to insert the ocular device 
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into the conjunctival sac of cattle was relatively simple as compared to that of other 
investigators (Hughes and Pugh, 1980; Punch et al., 1987). Attempts to insert the 
ocular device using the lateral insertion technique described by Hughes and Pugh 
(1980) were not successful. However, by putting the ring under the upper eyelid 
first and then placing the bottom of the ring beneath the lower eyelid, the alginate 
rings of the current study were easily inserted. 
The optimal size criterion indicated by Ryoo (1989) for selecting a ring size 
worked well in the retention study. Longer retention times were achieved for ring 
devices with an outside diameter equal to 1.2 X eye size of the eye than for those 
that had an outside diameter smaller or larger than 1.2 X eye size of the eye 
(Figure 10). 
In Vitro Degradation Tests of the Ocular Insert 
It required approximately 2000 hrs (>80 days) for the ocular ring insert to 
completely dissolve into a solution (e.g., saline) that contained monovalent sodium 
cations in a concentration similar to that of the tear fluids. This degradation time is 
slow compared to the degradation times of other collagen ocular inserts (Punch et 
al., 1985a) and gelatin inserts (Punch et al., 1985b). The succinylated collagen 
inserts (crosslinked in 37% formaldehyde for 2 hrs) disintegrated in about 18 days. 
The 6 mm thick gelatin films (crosslinked in 5% formaldehyde for 1 hr) dissolved in 
about 19 days. However, the ocular insert developed in the current study usually 
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fragmented into small pieces after 450 hrs (or 19 days) in saline. This amount of 
time is comparable to that of the collagen inserts which were crosslinked 
in 37% formaldehyde for 2 hrs. However, each collagen insert only weighed 20 mg 
as compared to 50-80 mg for the crosslinked alginates. In addition, the degradation 
process of collagen and gelatin was governed by the hydrolysis of the crosslinks 
(Punch et al., 1985a; 1985b) instead of polyvalent metal displacement as in the case 
of crosslinked alginates (Michaels, 1975). For the type of ocular devices used in this 
study, the erosion of the ocular insert was controlled by the displacement process of 
polyvalent metal ions (Al^^ and Ca^^) in the crosslinked alginate matrix by the 
noncrosslinking monovalent sodium ions from the saline solution. 
The degradation of the ocular device in vitro was slow as compared to that 
observed frôm the rings retrieved from the eyes of normal animals (Figure 15). 
This pattern was also observed by Punch and co-workers (1985b) for the gelatin 
inserts. In in vitro tests, the gelatin inserts dissolved in about 19 days. In the eyes 
of normal cattle, all gelatin inserts dissolved within 10 minutes. 
The fragmentation of the ocular devices in infected eyes (Figures 16 and 17) 
seemed to occur faster compared to that in vitro (Figures 12 and 13). This 
phenomenon has not been described in literature. In the infected eyes, the tear 
flow rate was significantly higher. The higher the tear flow rate, the more 
monovalent sodium cations available to displace the polyvalent metal ions from the 
crosslinked alginate. In cattle with an ocular disease such as IBK, the tear flow rate 
may be 6 to 15 times the normal tear flow rate (Nayar and Saunders, 1975). In 
169 
addition, other cations, such as from tear fluids or bacteria, may participate in 
the degradation process. 
In Vitro Drug Release Studies of the Ocular Insert 
The drug release profiles from all erodible devices followed a similar pattern. 
The initial release rate was high for all devices during the first 24-30 hrs, then it 
decreased exponentially and approached a somewhat constant level for the rest of 
the 7-day period. After 5 days, the drug release rate ranged from 4.2 jtxg/hr to 34.4 
Mg/hr. Since an elution rate of 2 ml/hr of Ringer's solution was used for the drug 
release process, the concentration of tylosin tartrate released still ranged from 2.1 
Mg/ml to 17.2 Mg/ml. This in vitro concentration was above the minimum inhibitory 
concentration (MIC) of 0.63 Mg/ml required to treat IBK (Leytem, 1984). Also, M-
bovis can be inhibited by tylosin at a level of 0.4 Mg/ml (Ellis and Barnes, 1961). 
Other studies indicate mean MICs of 2.5 to 6.69 Mg/ml (George et al., 1984). The 
in vitro sustained release of all devices was achieved for at least 7 days as compared 
to only 1 day for collagen inserts (Punch et al., 1987) and for gelatin inserts (Punch 
et al., 1985b). 
The fractional release of tylosin tartrate from bioerodible ocular inserts ranged 
from 14.4% to 39.2%, and this fraction tended to be a function of the surface 
area of the device. The release for a membrane device is proportional to the area 
(Langer and Peppas, 1981). Drug device S3 (Table 4) had the largest outside 
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diameter of three devices used in the experiment and as a result, had the highest 
fractional drug release (Table 18) of the three. 
The fractional drug release from ocular devices used in this research was 
relatively low compared to those hydrogel coated devices develop by Ryoo (1986). 
For the same drug loading of about 50 mg of tylosin tartrate, the fractional drug 
release from nonerodible hydrogel coated drug release devices ranged from 28% to 
43% as compared to 14.4 to 39% for the erodible ocular devices. This seemed to 
suggest that the drug release process from erodible ring devices was governed by the 
bioerodible rate controlling barrier when it was intact, that is, the drug was first 
released from the hydrogel-drug particles and then it diffused through the controlled 
crosslinked alginate barrier before reaching the external medium (e.g., the eye). 
However, if the membrane eroded, the drug release rate would be higher, 
approaching those of the hydrogel coated devices since, at that point, the rate of 
drug release is the release of drug from hydrogel-drug particles. 
Infection Study 
In the infection study, the efficacy of the ocular insert containing tylosin tartrate 
(antibiotic) was evaluated in parallel with the subconjunctival injection of Azimycin® 
(which is one of the conventional methods for treating field cases of bovine 
pinkeye). The treatment method using medicated ocular devices was more effective 
than the treatment method using subconjunctival injection of Azimycin®. The 
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clinical signs of eyes that received medicated ocular inserts tended to improve more 
rapidly than those that were treated with subconjunctival injections of Azimycin*. 
A factor that appeared to have a major role in the superior activity of the 
medicated ocular device was the ability of the device to release tylosin continuously 
suppressing the bacteria in the eyes within a short time and maintaining a 
satisfactory drug level. For eyes that received medicated ocular inserts, 3 out of 4 
eyes had no M- bovis colonies or only low levels of bacteria present after 3 days of 
treatment. For eyes that were treated with subconjunctival injections of Azimycin®, 
3 out of 4 eyes still had relatively high levels of bacteria (10^ - 10* CFU/swab) 
within 3 days after the eyes were treated. In addition, the clinical signs of these 
eyes remained the same or worsened. It is clear that the subconjunctival injection 
method failed to maintain an adequate level of drug. 
The pharmacokinetics of Azimycin* in the bovine eye after subconjunctival 
injection have not been reported in literature. Studies performed on other drugs 
such as cefazolin in rabbit eyes have shown that bactericidal levels in the aqueous 
humor could be maintained for more than 8 hours (Saunders and McPherson, 1980). 
However, the rabbit model may not be applicable for the bovine eye. 
In the infection study, the clinical scoring scale represents the severity of the 
disease through various stages. The scale is a modification of two scales (Jackson 
(1954) and by Pugh and co-workers (1982)). It is used to assess the clinical 
condition from the initial stage through progressive phases including the healing 
phase. Pugh and co-workers (1982) graded the clinical aspect of lesions with 
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respect to healing, and Jackson (1954) described symptoms or forms of various 
stages of IBK. 
The ocular devices used in this infection study had characteristics similar to 
the hydrogel coated devices developed by Ryoo (1989). Both have the ability to 
suppress M- bovis infections in a short time (of the order of one to two days). 
However, the bioerodible ocular inserts were retained in the eyes for a relatively 
shorter period of time compared to the nonerodible hydrogel ocular devices that 
were retained for 7 days or more. The rates of tylosin release and the release 
profiles were similar to those of the hydrogel coated inserts. 
For situations where one of the two eyes of a calf were treated with medicated 
ocular inserts, the bacteria levels in these eyes were reduced to a nondetectable 
level within one day after treatment. However, if the ring devices fell out within 2 
days after insertion, the bacteria in the eyes tended to increase somewhat (a low 
level). This increase was probably due to the transmission of M. bovis from the 
infected contralateral control eye. Therefore, if both eyes were treated with the 
medicated ring devices simultaneously, all infection sources could be eliminated in a 
short period and no recurrence could occur. This hypothesis was supported by the 
evidence obtained during the post-treatment period. At the end of the infection 
study (on day 12), medicated ring devices were inserted into both eyes of 7 calves, 
and the eyes were sampled 5 days after treatment. Subsequent bacteriological 
evaluation showed few bacteria present in one eye and no bacteria present in the 
other 13 eyes even though most ring devices fell out within 1-2 days after insertion. 
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Since the medicated ocular device has the ability to suppress the bacteria in a short 
time, the relatively long period of treatment (5-7 days) which is normally used with 
conventional methods for treating IBK may not be necessary for such a ring device 
that can release the drug continuously. 
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CONCLUSIONS 
An erodible ring-shaped ocular insert containing tylosin tartrate has been 
developed for use to treat bovine IBK. The ocular device is comprised of an outer 
crosslinked alginate membrane (Al-Ca-alginate) and a hydrogel-drug inner core of 
hydrogel-drug particles. The ocular device is capable of bioeroding in the 
environment of the eye without causing any adverse effect. The ocular insert is 
designed to contain an adequate amount of tylosin tartrate (approximately 50 mg) to 
treat a pinkeye infection in cattle. 
In the retention test of the ring devices in eyes of normal calves, the erodible 
ocular insert had an average retention time of 3.92 ± 1.73 days. The overall 
retention time of the ocular device ranged from 1 day to more than 6 days. 
Normally, about 50 to 70% of ring devices remained in the eyes of the animals for 
more than 3 days. In infected eyes, the erodible ocular device had an average 
retention time of 2.1 ± 1.63 days. Although a retention period in excess of 5 to 7 
days has not been achieved, the bioerodible ocular device used in this research has 
shown potential for treating eye infections in cattle, and it does not have to be 
removed from the eye at the end of the treatment period (thus eliminating some 
additional treatment costs). In addition, the ring device seems to be compatible 
with the eye tissues. During the retention tests, the eyes of the animals were 
repeatedly exposed to the ocular devices. However, no signs of irritation due to the 
presence of the insert were seen. 
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From the in vitro degradation results, the ocular device dissolved in saline 
solution in about 80 days which was much longer than a desired period of S to 7 
days. However, observations in vivo suggested that the ocular insert tended to 
erode much faster in the environment of the bovine eye. Ocular devices that were 
designed to erode within 5 to 7 days (in vitro) did not stay in the eyes of the 
animals for more than a few minutes due to poor mechanical properties (e.g., not 
sufficiently stiff to retain the basic shape of the ring). 
The drug release rate from the bioerodible ocular insert in vitro was initially 
high during the first 24-30 hrs of the release process and then decreased 
exponentially to a nearly constant level. After 5 days, the drug release rate still 
ranged from 4.3-34 Mg/hr which was above the minimum release rate of 1.3 Mg/hr 
required to a treat pinkeye infection in cattle. 
In the infection study, the efficacy of the bioerodible ocular insert has been 
evaluated and compared with the subconjunctival injections of Azimycin® in treating 
bovine pinkeye. Two groups of animals (4 animals each) were used. One group 
was designated for the ocular inserts studies, and the other group was used for 
subconjunctival injections. The disease (IBK) was reproduced in the eyes of these 
animals by using an ultraviolet radiation method followed by instilling a M- bovis 
inoculum. All eyes were infected, and the degree of infection of each eye varied 
from a mild (grade 1) to a severe (grade 5) infection. The effectiveness of each 
treatment method was compared in terms of the changes of the number of M. bovis 
colonies in the eyes of the animals and the clinical improvement of the eyes after 
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medicated ring devices were inserted into the eyes or after subconjunctival injections 
of Azimycin®. 
For the bacteriological results, eyes that received medicated rings had 
significantly suppressed bacterial burden when comparing the first 5-day period 
(before treatment) to the second 5-day period (after treatment), and this was much 
better than that for the eyes that were treated with a subconjunctival injection of 
Azimycin®. The medicated ocular device has the ability to suppress and reduce the 
number of bacteria in the eye to an undetectable or negligible level within a short 
time (within 1 to 2 days) after the rings are inserted. The bacteria levels in most of 
these eyes remained undetectable or low for the rest of the test period even though 
most medicated rings fell out of the eyes within 2 days after insertion. By 
comparison, for eyes that were treated with a subconjunctival injection of 
Azimycin®, after an initial decline (3 out of 4 eyes had negligible or undetectable 
levels of bacteria), the bacteria in most of these eyes again built up to a relatively 
high level (l(f - KX* CFU/swab) and remained at that level until the end of the 
experiment. This indicated that the subconjunctival injection technique was not 
effective in maintaining an adequate level of drug to treat severe cases of pinkeye. 
The eyes that received medicated ocular inserts tended to improve clinically 
within a few days. The eyes that were treated with subconjunctival injections of 
Azimycin® remained the same or worsened. 
In conclusion, the treatment method of pinkeye using the bioerodible 
medicated ocular device was more effective than the subconjunctival injection 
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method due to the fact that the medicated ring device suppressed the bacteria (M. 
bovis^ quickly and did not allow the bacteria to build up again. This may help to 
speed up healing by altering the progress of the disease. In addition, the ocular 
device is easy to insert into the eye of the animal and causes less discomfort to the 
animal compared with the subconjunctival injection method which is time 
consuming, painful, and awkward to use. 
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1682 
1730 
1778 
1826 
1874 
1922 
1970 
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Weight (gm) Comments 
Plasticizer content 
2.7% 5.4% 7.5% 
0.0396 0.0290 0.0410 
0.0367 0.0252 0.0369 
0.0341 0.0221 0.0318 
0.0318 0.0201 0.0292 
0.0297 0.0191 0.0273 
0.0287 0.0179 0.0253 
0.0246 0.0173 0.0243 
0.0206 0.0162 0.0231 
0.0179 0.0150 0.0210 
0.0150 0.0134 0.0188 
0.0126 0.0115 0.0165 
0.0107 0.0091 0.0132 
0.0080 0.0061 0.0106 
0.0053 0.0043 0.0078 
0.0023 0.0031 0.0060 
0 0 0 
small pieces 
tiny particles 
mostly 
dissolved 
APPENDIX B: 
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DEGRADATION OF CROSSLINKED ALGINATE FILMS 
Time (hr) Weight (gm) 
Plasticizer content 
5.4% 1.5% 
0 0.0794 0.0725 
24 0.0759 0.0682 
48 0.0748 0.0680 
72 0.0741 0.0655 
96 0.0732 0.0648 
120 0.0732 0.0642 
144 0.0730 0.0636 
168 0.0682 0.0574 
192 0.0649 0.0554 
216 0.0600 0.0509 
240 0.0589 0.0499 
264 0.0544 0.0459 
288 0.0500 0.0452 
312 0.0445 0.0410 
336 0.0428 0.0400 
360 0.0401 0.0379 
384 0.0369 0.0360 
408 0.0340 0.0332 
456 0.0300 0.0294 
504 0.0290 0.0289 
552 0.0267 0.0269 
600 0.0232 0.0238 
648 0.0219 0.0221 
696 0.0204 0.0202 
744 0.0178 0.0172 
792 0.0162 0.0158 
840 0.0140 0.0143 
888 0.0118 0.0120 
936 0.0100 0.0093 
984 0.0090 0.0081 
1032 0.0070 0.0061 
1080 0.0057 0.0050 
1128 0.0032 0.0028 
1176 0.0018 0.0016 
1224 0.0008 0.0005 
1248 0.0003 0.0005 
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APPENDIX C: DRUG RELEASE CHARACTERISTICS, DEVICE SI 
Release Volume of Tyl. Tartrate Total" Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (Mg) (Mg) (Mg/hr) (Mg) 
1 200 0.23 18.4 18.4 18.4 
2 400 0.51 81.6 81.6 100 
3 400 0.62 100.6 100.6 200.6 
4 400 0.43 69.6 69.6 270.2 
5 400 0.51 82.4 82.4 352.6 
6 400 0.74 118 118 470.6 
7 . 400 2.11 338.6 338.6 809.2 
8 400 1.95 313 313 1122.2 
9 400 2.17 347.7 347.7 1469.9 
10 400 1.62 260.2 260.2 1730.1 
11 400 1.14 183.6 183.6 1913.7 
12 400 1.69 270.4 270.4 2184.1 
13 300 2.49 299.1 299.1 2483.2 
14 300 0.62 74.1 74.6 2557.8 
15 300 0.55 66.1 66.1 2623.9 
16 300 0.50 60 60 2683.9 
17 300 0.46 54.8 54.8 2738.7 
18 300 0.81 96.7 96.7 2835.4 
19 300 0.73 88 88 2923.4 
20 300 0.53 62.4 62.4 2985.8 
21 300 0.68 82.4 82.4 3068.2 
22 300 0.63 75.5 75.5 3143.7 
23 300 0.53 62.4 62.4 3206.1 
24 300 0.53 63.6 63.6 3269.7 
25 100 0.58 23.1 23.1 3292.8 
26 100 0.65 26.2 26.2 3319 
27 100 0.52 20.8 20.8 3339.8 
28 100 1.75 70 70 3409.8 
29 100 1.57 62.8 62.8 3472.6 
30 100 2.34 93.7 93.7 3566.3 
31 100 2.25 90 90 3656.3 
32 100 1.75 70 70 3726.3 
33 100 2.63 105 105 3831.3 
34 100 1.69 67.6 67.6 3898.9 
35 100 2.92 116.8 116.8 4015.7 
36 100 2.80 112 112 4127.7 
Til 
(h] 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
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Volume of Tyl. Tartrate Total Release Cumulative 
dilution in spot drug Rate Release 
W) (Mg) (Mg) (Mg/hr) M 
100 1.90 76.0 76.0 4203.7 
100 1.44 57.6 57.6 4261.3 
100 0.92 37.4 37.4 4318.7 
100 1.58 63.2 63.2 4383.9 
100 3.14 125.8 125.8 4509.7 
100 3.22 129 129 4638.5 
100 0.77 30.8 30.8 4669.3 
100 0.90 36 36 4705.3 
100 0.64 25.8 25.8 4731.1 
100 0.44 17.60 17.60 4748.7 
100 1.40 56.20 56.20 4804.9 
100 1.73 69.20 69.20 4874.1 
100 1.22 48.80 48.80 4922.9 
100 1.45 58.20 58.20 4981.1 
100 2.00 80.0 80.0 5061.1 
100 1.16 46 46 5107.1 
100 2.03 81.6 81.6 5188.7 
100 3.28 131 131 5319.9 
100 0.98 40 40 5359.5 
100 0.99 39.8 39.8 5399.3 
100 0.90 30.6 30.6 5435.3 
100 1.01 40.4 40.4 5475.7 
100 1.93 77.2 77.2 5552.9 
100 1.12 44.8 44.8 5599.7 
50 0.41 8.20 8.20 5607.9 
50 0.35 7.0 7.0 5614.9 
50 0.30 6.0 6.0 5620.9 
50 0.52 10.4 10.4 5631.3 
50 0.60 12.0 12.0 5643.3 
50 0.55 11.0 11.0 5654.3 
50 0.33 6.6 6.6 5687.6 
50 0.67 13.5 13.5 5674.4 
50 0.33 6.6 6.6 5681.0 
50 0.33 6.60 6.60 5687.6 
50 0.29 5.8 5.8 5693.4 
50 0.82 16.4 16.4 5709.8 
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Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) M (Mg) (fig/hr) (Mg) 
73 50 1.51 30.2 30.2 5740.0 
74 50 0.78 15.7 15.7 5755.7 
75 50 0.88 17.6 17.6 5773.3 
76 50 0.59 11.8 11.8 5785.1 
77 50 0.89 17.8 17.8 5802.9 
78 50 0.39 7.8 7.8 5810.7 
79 50 0.35 6.9 6.9 5817.6 
80 50 0.30 6.0 6.0 5823.6 
81 50 0.39 7.7 7.7 5831.3 
82 50 0.35 7.0 7.0 5838.3 
83 50 0.68 13.6 13.6 5851.9 
84 50 0.35 7.0 7.0 5858.9 
85 50 0.39 7.8 7.8 5866.7 
86 50 0.67 13.30 13.30 5880.0 
87 50 0.55 11.0 11.0 5891.0 
88 50 0.86 17.2 17.2 5908.2 
89 50 0.51 10.2 10.2 5918.4 
90 50 0.69 13.8 13.8 5932.2 
91 50 0.54 10.7 10.7 5942.9 
92 50 0.45 8.97 8.97 5951.9 
93 50 0.62 12.5 12.5 5964.4 
94 50 1.06 21.3 21.3 5985.7 
95 50 0.75 14.9 14.9 6000.6 
96 50 1.24 24.8 24.8 6025.4 
97 50 0.52 10.4 10.4 6035.8 
98 50 0.45 9.1 9.1 6044.9 
99 50 0.69 13.7 13.7 6058.6 
100 50 0.59 11.7 11.7 6070.3 
101 50 0.64 12.7 12.7 6083.3 
102 50 0.54 10.7 10.7 6093.7 
103 50 0.53 10.7 10.7 6104.4 
104 50 0.34 6.90 6.90 6111.3 
105 50 0.44 8.7 8.7 6120.0 
106 50 0.41 8.10 8.10 6128.1 
107 50 0.71 14.2 14.2 6142.3 
108 50 0.42 8.34 8.34 6150.6 
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Release Volume of lyi. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (Mg) (Mg) (Mg/hr) (Mg) 
109 50 0.50 9.98 9.98 6160.6 
110 50 0.64 12.9 12.9 6173.5 
111 50 0.65 13.0 13.0 6186.6 
112 50 0.58 11.5 11.5 6198.1 
113 50 0.23 4.60 4.60 6202.7 
114 50 0.34 6.9 6.9 6209.6 
115 50 0.70 14 14 6223.6 
116 50 0.58 11.5 11.5 6235.1 
117 50 0.53 10.6 10.6 6245.7 
118 50 0.51 10.1 10.1 6255.8 
119 50 0.51 10.2 10.2 6266.0 
120 50 0.55 11 11 6276.9 
121 50 0.36 7.3 7.3 6284.2 
122 50 0.24 4.86 4.86 6289.0 
123 50 0.50 10.0 10.0 6299.0 
124 50 0.38 7.54 7.54 6306.5 
125 50 0.31 6.22 6.22 6312.7 
126 50 0.39 7.86 7.86 6320.6 
127 50 0.34 6.78 6.78 6327.4 
128 50 0.30 5.96 5.96 6333.4 
129 50 0.57 11.1 11.1 6344.5 
130 50 0.30 5.97 5.97 6350.5 
131 50 0.42 8.38 8.38 6358.9 
132 50 0.31 6.20 6.20 6365.1 
133 50 0.29 5.86 5.86 6371.0 
134 50 0.29 5.80 5.8 6376.8 
135 50 0.25 4.92 4.92 6381.7 
136 50 0.48 9.70 9.70 6391.4 
137 50 0.40 8.02 8.02 6399.4 
138 50 0.25 4.90 4.90 6404.3 
139 50 0.45 8.98 8.98 6413.3 
140 50 0.33 6.70 6.70 6420.0 
141 50 0.59 11.7 11.7 6431.7 
142 50 0.56 11.2 11.2 6442.9 
143 50 0.51 10.1 10.1 6453.0 
144 50 0.44 8.80 8.80 6461.8 
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Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) W) (Mg) (Mg) (Mg/hr) (Mg) 
145 50 0.27 5.42 5.42 6467.2 
146 50 0.34 6.82 6.82 6474.0 
147 50 0.35 6.92 6.92 6480.9 
148 50 0.29 5.90 5.90 6486.8 
149 50 0.31 6.10 6.10 6492.9 
150 50 0.40 8.0 8.0 6500.9 
151 50 0.31 6.2 6.2 6507.1 
152 50 0.23 4.60 4,60 6511.7 
153 50 0.69 13.8 13.8 6525.2 
154 50 0.22 4.3 4.3 6529.8 
155 50 0.45 9.0 9.0 6538.8 
156 50 0.51 10.1 10.1 6548.9 
157 50 0.38 7.6 7.6 6556.5 
158 50 0.44 8.80 8.80 6565.3 
159 50 0.26 5.20 5.20 6570.5 
160 50 0.32 6.32 6.32 6576.8 
161 50 0.28 5.52 5.52 6582.3 
162 50 0.24 4.74 4.74 6587.0 
163 50 0.24 4.76 4.76 6591.8 
164 50 0.37 7.30 7.30 6599.1 
165 50 0.24 4.76 4.76 6603.9 
166 50 0.28 5.64 5.64 6609.5 
167 50 0.29 5.76 5.76 6615.2 
168 50 0.26 5.14 5.14 6620.3 
"Total drug with respect to one 1 hr sample. 
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APPENDIX D: DRUG RELEASE CHARACTERISTICS, DEVICE S2 
Release Volume of Tyl. Tartrate Total® Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (Mg) (Mg) (Mg/hr) (Mg) 
1 200 2.09 167.2 167.2 167.2 
2 400 1.66 256.6 256.6 432.8 
3 400 2.32 371.2 371.2 804 
4 400 3.59 574.4 574.4 1378.4 
5 400 4.05 648 648 2026.4 
6 400 2.86 457.6 457.6 2484 
7 400 2.20 352 352 2836 
8 400 2.14 343 343 3179 
9 400 1.68 269 269 3448 
10 400 1.06 169.6 169.6 3617.6 
11 300 1.14 136.8 136.8 3754.4 
12 300 1.26 151.2 152.2 3905.6 
13 300 1.63 196.2 196.2 4101.8 
14 300 2.25 270.4 270.4 4372.2 
15 300 1.27 152.4 152.4 4524.6 
16 300 1.83 220.4 220.4 4745 
17 300 0.92 110.9 110.9 4855.4 
18 300 1.51 181.3 181.3 5036.7 
19 300 2.14 256.8 256.8 5293.5 
20 300 2.04 245 245 5538.5 
21 300 1.44 172.6 172.6 5711.1 
22 300 1.14 138 138 5849.1 
23 300 1.22 147.3 147.3 5996.4 
24 300 1.35 162.4 162.4 6158.8 
25 100 2.41 97 97 6255.8 
26 100 2.22 89 89 6344.8 
27 100 2.07 82.9 82.9 6427.7 
28 100 1.83 73.3 73.3 6501 
29 100 2.51 100.4 100.4 6601.4 
30 100 1.93 77.2 77.2 6678.6 
31 100 0.97 38.8 38.8 6717.4 
32 100 0.93 37.3 37.3 6754.7 
33 100 0.80 32.2 32.2 6791.9 
34 100 1.06 42.4 42.4 6834.3 
35 100 0.76 30.2 30.2 6864.5 
36 100 0.75 29.9 29.9 6894.4 
Til 
(hi 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
199 
Volume of Tyl. Tartrate Total Release Cumulative 
dilution in spot drug Rate Release 
(Ml) (Mg) (Mg) (Mg/hr) (Mg) 
100 1.21 48.4 48.4 6942.8 
100 0.98 39.2 39.2 6982 
100 1.00 40 40.0 7022 
100 1.45 58.0 58.0 7080 
100 0.84 33.6 33.6 7113.6 
100 0.85 33.8 33.8 7147.4 
100 0.64 25.4 25.4 7172.8 
100 0.76 30.4 30.4 7203.2 
100 0.76 30.3 30.3 7233.5 
100 0.75 30.1 30.1 7263.6 
100 0.68 27.0 27.0 7290.6 
100 0.55 22.0 22.0 7312.6 
100 0.86 34.4 34.4 7347 
100 0.78 31.1 31.1 7378.1 
100 0.71 28.3 28.3 7406.4 
100 0.42 16.7 16.7 7423.1 
100 0.29 11.8 11.8 7434.9 
100 0.22 8.6 8.6 7443.5 
100 0.38 15.1 15.1 7458.6 
100 0.37 14.6 14.6 7473.2 
100 0.50 20.0 20.0 7493.2 
100 0.44 17.4 17.4 7510.6 
100 0.49 19.4 19.4 7530 
100 0.61 24.6 24.6 7554.6 
100 0.73 29.4 29.4 7584 
100 0.61 24.3 24.3 7608.3 
100 0.69 27.4 27.4 7635.7 
100 0.77 30.8 30.8 7666.5 
100 0.89 35.6 35.6 7702.1 
100 0.84 33.6 33.6 7735.7 
50 1.31 26.2 26.2 7761.9 
50 1.47 29.2 29.2 7791.6 
50 1.61 32 32 7823.6 
50 0.68 13.5 13.5 7837.1 
50 2.00 40 40 7877.1 
50 1.81 36.2 36.2 7913.3 
Tin 
(hr: 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
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Volume of Tyl. Tartrate Total Release Cumulative 
dilution in spot drug Rate Release 
W (Mg) (Mg) (Mg/hr) (Mg) 
50 0.65 13.0 13.0 7926.3 
50 0.58 11.5 11.5 7937.8 
50 0.56 11.3 11.3 7949.1 
50 0.71 14.3 14.3 7963.4 
50 0.98 19.5 19.5 7982.9 
50 0.82 16.4 16.4 7999.3 
50 0.52 10.4 10.4 8009.7 
50 0.56 11.1 11.1 8020.8 
50 0.68 13.6 13.6 8034.4 
50 0.72 14.4 14.4 8048.8 
50 0.68 13.6 13.6 8062.4 
50 0.60 12.1 12.1 8074.5 
50 0.66 13.2 13.2 8087.7 
50 0.67 13.3 13.3 8101.0 
50 0.60 12.0 12.0 8113.0 
50 0.95 18.9 18.9 8131.9 
50 0.76 15.1 15.1 8147 
50 0.59 11.7 11.7 8158.7 
50 0.54 10.7 10.7 8169.4 
50 0.45 8.96 8.96 8178.4 
50 0.62 12.5 12.5 8190.9 
50 1.07 21.2 21.2 8212.1 
50 0.75 14.9 14.9 8227 
50 1.24 24.8 24.8 8251.8 
50 0.52 10.4 10.4 8262.2 
50 0.45 9.1 9.1 8271.3 
50 0.68 13.6 13.6 8284.9 
50 0.58 11.7 11.7 8296.6 
50 0.63 12.6 12.6 8309.2 
50 0.54 10.7 10.7 8319.9 
50 0.53 10.7 10.7 8330.6 
50 0.34 6.90 6.90 8337.5 
50 0.44 8.7 8.7 8346.2 
50 0.41 8.10 8.10 8354.3 
50 0.71 14.2 14.2 8368.5 
50 0.43 8.60 8.60 8377.1 
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Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) W) (Mg) (Mg) (Atg/hr) (Mg) 
109 50 0.50 10.0 10.0 8388.1 
110 50 0.64 12.9 12.9 8400.0 
111 50 0.65 13.0 13.0 8413.0 
112 50 0.58 11.5 11.5 8424.5 
113 50 0.23 4.50 4.50 8429.0 
114 50 0.34 6.8 6.8 8435.8 
115 50 0.70 14 14 8449.8 
116 50 0.58 11.5 11.5 8461.3 
117 50 0.53 10.6 10.6 8471.9 
118 50 0.51 10.1 10.1 8482.1 
119 50 0.51 10.2 10.2 8492.3 
120 50 0.55 11 11 8503.3 
121 50 1.00 20.0 20.0 8523.3 
122 50 0.67 13.3 13.3 8536.6 
123 50 1.37 27.4 27.4 8564 
124 50 1.03 20.6 20.6 8584.6 
125 50 0.86 17.1 17.1 8601.7 
126 50 1.07 21.4 21.4 8623.1 
127 50 0.34 6.80 6.80 8629.9 
128 50 0.30 6.00 6.00 8635.9 
129 50 0.57 11.1 11.1 8647.0 
130 50 0.30 6.00 6.00 8653 
131 50 0.42 8.40 8.40 8661.4 
132 50 0.31 6.20 6.20 8667.6 
133 50 0.29 5.90 5.90 8673.5 
134 50 0.29 5.80 5.8 8679.3 
135 50 0.25 4.90 4.90 8684.2 
136 50 0.48 9.70 9.70 8693.9 
137 50 0.40 8.00 8.00 8701.9 
138 50 0.25 4.90 4.90 8706.8 
139 50 0.45 9.00 9.00 8715.8 
140 50 0.33 6.70 6.70 8722.5 
141 50 0.59 11.7 11.7 8734.2 
142 50 0.56 11.8 11.8 8746 
143 50 0.51 10.1 10.1 8756.1 
144 50 0.44 8.78 8.78 8764.9 
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Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) W) (Mg) (/^g) (Mg/hr) (Mg) 
145 50 0.27 5.40 5.40 8770.3 
146 50 0.34 6.82 6.82 8777.1 
147 50 0.35 6.98 6.98 8784.0 
148 50 0.29 5.90 5.90 8789.9 
149 50 0.31 6,10 6.10 8796.0 
150 50 0,40 8.0 8.0 8804.0 
151 50 0.31 6,2 6,2 8810.2 
152 50 0,23 4,60 4,60 8814.8 
153 50 0.69 13,8 13.8 8828,6 
154 50 0,22 4.3 4.3 8832,9 
155 50 0,45 9,0 9.0 8841,9 
156 50 0,51 10,1 10.1 8852.0 
157 50 0.61 12.1 12.1 8864.1 
158 50 0,55 11,6 11.6 8875.7 
159 50 0.51 10,2 10.2 8885.9 
160 50 0,57 11.4 11.4 8897.3 
161 50 0.48 9.60 9.60 8906.9 
162 50 0.52 10,5 10.5 8917.4 
163 50 0.21 4.20 4.20 8921.6 
164 50 0.37 7.40 7.40 8929.0 
165 50 0.25 4.90 4.90 8933.9 
166 50 0.23 4.50 4.50 8938.4 
167 50 0.45 9.00 9.00 8947.4 
168 50 0.21 4.20 4.20 8951.6 
"Total drug with respect to one 1 hr sample. 
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APPENDIX E: DRUG RELEASE CHARACTERISTICS, DEVICE S3 
Release Volume of Tyl. Tartrate Total' Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (Mg) (Mg) (Mg/hr) (Mg) 
1 800 0.82 261.8 261.8 261.8 
2 1000 0.88 353.2 353.2 615.0 
3 1000 0.77 306.4 306.4 921.4 
4 1000 1.25 498.4 498.4 1419.8 
5 1000 1.34 534.2 534.2 1954.0 
6 1000 2.20 880.0 880.0 2834.0 
7 1000 1.75 700 700 3533.9 
8 1000 3.18 1272 1272 4805.9 
9 1000 2.15 860 860 5665.7 
10 1000 2.44 972 972 6641.7 
11 1000 2.38 952.2 952,2 7593.9 
12 300 5.57 669 669 8262,9 
13 300 2.73 328.4 328.4 8591,3 
14 300 . 5.23 629 629 9220.3 
15 200 3.63 291.1 291.1 9511.4 
16 300 4.58 550 550 10061.4 
17 200 4.51 361.5 361.5 10422.9 
18 300 5.34 641 641 11063.9 
19 200 3.88 310.9 310.9 11374.1 
20 300 4.79 575 575 11949.8 
21 200 2.32 186 186 12135.8 
22 300 4.25 511 511 12646.8 
23 200 2.17 173.6 173.6 12820.4 
24 300 1.84 221 221 13041.4 
25 100 2.77 111.1 111.1 13152.5 
26 100 4.19 168 168 13320.5 
27 100 3.42 136.9 136.9 13457.4 
28 100 4.72 189 189 13646.4 
29 100 2,51 100.5 100,5 13746.9 
30 100 3,99 168 168 13914.9 
31 100 3.45 138.3 138,3 14053.2 
32 100 3.41 137 137 14190.2 
33 100 1.51 60.6 60.6 14250.8 
34 100 3.76 151 151 14401.8 
35 100 1.43 57.5 57.5 14459.3 
36 100 1.65 66.2 66.2 14519.5 
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Release Volume of 1^1. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (Mg) (/ig) (Mg/hr) (Mg) 
37 100 1.61 64.4 64.4 14519.5 
38 100 1.75 70.1 70.1 14654 
39 100 1.73 69.3 69.3 14723.3 
40 100 1.46 58.7 58.7 14782.3 
41 100 1.70 68 68 14850.3 
42 100 1.15 46.1 46.1 14896.3 
43 100 1.46 58.7 58.7 14954.9 
44 100 1.07 43.1 43.1 14997.9 
45 100 1.45 58 58 15055.9 
46 100 1.45 58 58 15113.9 
47 100 2.29 91.8 91.8 15205.7 
48 100 1.15 46.1 46.1 15248 
49 100 1.84 73.7 73.7 15321.7 
50 100 1.05 42.3 42.3 15364 
51 100 . 1.45 58.0 58.0 15422 
52 100 1.11 44.5 44.5 15466.5 
53 100 0.66 26.3 26.3 15492.8 
54 100 0.87 34.7 34.7 15527.5 
55 100 0.84 33.5 33.5 15561 
56 100 0.59 23.4 23.4 15584.4 
57 100 1.06 42.4 42.4 15626.8 
58 100 0.82 32.6 32.6 15659.4 
59 100 0.73 29.1 29.1 15688.5 
60 50 1.92 38.4 38.4 15726.4 
61 100 0.42 16.7 16.7 15743.6 
62 50 0.79 15.8 15.8 15759.5 
63 50 1.00 20.0 20.0 15779.5 
64 50 1.92 38.4 38.4 15817.9 
65 50 1.40 28.0 28.0 15846 
66 50 1.90 38.0 38.0 15884 
67 50 1.59 31.8 31.8 15915.8 
68 50 2.41 48.2 48.2 15964 
69 50 1.59 31.8 31.8 15995.8 
70 50 2.79 55.8 55.8 16051.6 
71 50 1.38 115 27.5 16079.1 
72 50 1.46 29.2 29.2 16108.3 
205 
Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) (Ml) (fig) (Mg) (Mg/hr) (Mg) 
73 50 1.18 23.8 23.8 16132.1 
74 50 2.38 47.7 47.7 16179.8 
75 50 2.02 40.4 40.4 16220.2 
76 50 1.49 29.9 29.9 16250.1 
77 50 2.25 45.0 45.0 16295.1 
78 50 1.66 33.2 33.2 16328.3 
79 50 0.52 10.4 10.4 8009.7 
80 50 1.37 27.4 27.4 16393.4 
81 50 1.48 29.6 29.6 16423 
82 50 1.58 31.7 31.7 16454.7 
83 50 0.90 18 18 16472.7 
84 50 1.63 32.6 32.6 16505.3 
85 50 2.22 44.6 44.6 16549.9 
86 50 0.53 10.6 10.6 16560.5 
87 50 0.76 15.2 15.2 16575.7 
88 50 0.87 17.4 17.4 16593.1 
89 50 0.89 17.7 17.7 16610.8 
90 50 1.64 32.9 32.9 16643.7 
91 50 0.93 18.5 18.5 16662.2 
92 50 1.78 35.7 35.7 16697.9 
93 50 0.79 15.9 15.9 16713.7 
94 50 0.84 16.7 16.7 16730.4 
95 50 1.04 20.8 20.8 16751.2 
96 50 1.01 20.1 20.1 16771.3 
97 50 1.08 21.6 21.6 16792.9 
98 50 1.09 21.7 21.7 16814.6 
99 50 0.78 15.6 15.6 16830.2 
100 50 0.52 10.5 10.5 16840.7 
101 50 1.23 24.7 24.7 16865.4 
102 50 1.38 27.6 27.6 16893 
103 50 1.59 32 32 16925 
104 50 1.66 33.2 33.2 16958.2 
105 50 1.03 20.7 20.7 16978.9 
106 50 1.76 35.2 35.2 17014.1 
107 50 1.33 26.6 26.6 17040.7 
108 50 1.48 29.6 29.6 17070.3 
206 
Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) W) (Mg) (/ig) (Mg/hr) (Mg) 
109 50 1.07 21.4 21.4 17091.6 
110 50 0.78 15.5 15.5 17107.2 
111 50 0.68 13.6 13.6 17120.8 
112 50 1.64 32.8 32.8 17153.5 
113 50 1.17 23.4 23.4 17176.9 
114 50 1.82 36.4 36.4 17213.3 
115 50 0.60 11.7 11.7 17225.1 
116 50 1.03 20.6 20.6 17245.6 
117 50 0.97 19.3 19.3 17264.9 
118 50 0.95 17.1 17.1 17282.1 
119 50 0.76 15.2 15.2 17297.3 
120 50 0.61 12.2 12.2 17314,9 
121 50 0.72 14.3 14.3 17329.3 
122 50 1.29 25.8 25.8 17355,1 
123 50 0.76 15.1 15.1 17370.2 
124 50 0.97 19.3 19.3 17389.4 
125 50 0.47 9.40 9.40 17398.8 
126 50 1.20 24.1 24.1 17422.9 
127 50 0.64 12.9 12.9 17435.9 
128 50 1.25 25.1 25.1 17460.9 
129 50 0.62 12.5 12.5 17473.4 
130 50 1.29 25.9 25.9 17499.3 
131 50 0.45 8.90 8.90 17508.3 
132 50 0.88 18.7 18.7 17526.9 
133 50 0.52 10.3 10.3 17537.3 
134 50 0.85 16.8 16.8 17554.1 
135 50 0.69 13.7 13.7 17567.8 
136 50 1.20 24.0 24.0 17588.8 
137 50 0.49 9.0 9.0 17598.7 
138 50 0.89 17.6 17.6 17616.3 
139 50 0.38 7.70 7.70 17624 
140 50 1.57 31.5 31.5 17655.5 
141 50 0.67 13.3 13.3 17668.8 
142 50 1.72 34.4 34.4 17703.2 
143 50 0.44 8.90 8.90 17712.1 
144 50 1.12 22.4 22.4 17734.5 
207 
Release Volume of Tyl. Tartrate Total Release Cumulative 
Time dilution in spot drug Rate Release 
(hr) W) (Mg) (Mg) (Mg/hr) (Mg) 
145 50 0.45 9.00 9.00 17743.5 
146 50 0.71 14.1 14.1 17757.6 
147 50 0.69 13.7 13.7 17771.3 
148 50 0.66 13.1 13.1 17784.4 
149 50 0.50 9.90 9.90 17794.3 
150 50 0.46 9.2 9.2 17803.5 
151 50 0.38 7.6 7.6 17824.9 
152 50 0.69 13.8 13.8 17824.9 
153 50 0.66 13.3 13.3 17838.2 
154 50 0.74 14.7 14.7 17852.9 
155 50 0.45 9.0 9.0 17861.9 
156 50 0.88 17.6 17.6 17879.5 
157 50 0.52 10.3 10.3 17889.8 
158 50 0.84 16.8 16.8 17906.6 
159 50 0.76 15.1 15.1 17950.7 
160 50 1.45 29.0 29.0 17950.7 
161 50 0.52 10.3 10.3 17961 
162 50 0.80 15.9 15.9 17976.9 
163 50 0.69 13.7 13.7 17990.6 
164 50 0.35 7.00 7.00 17997.6 
165 50 0.45 8.90 8.90 18006.5 
166 50 1.09 21.8 21.8 18028.3 
167 50 0.45 9.00 9.00 18037.3 
®Total drug with respect to one 1 hr sample. 
